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ABSTRACT
Beryllium is a potent and unique GSK-3β inhibitor with potential to differentially regulate
glycogen synthase and β-catenin
By
Ata Ur Rahman Mohammed Abdul

Dr. Ronald K Gary
Examination Committee Chair
Associate Professor
Department of Chemistry and Biochemistry
University of Nevada, Las Vegas

Glycogen Synthase Kinase-3β (GSK-3β) is an important serine/threonine kinase that
phosphorylates/regulates diverse and metabolically important proteins. Some of the important
substrates of GSK-3β are glycogen synthase, tau, β-catenin, cyclin D1, axin, c-jun, c-myc, Heat
Shock Factor–1, BCL-3, CREB, Histone H1.5, mdm2, p21 (CIP1), pyruvate dehydrogenase and
many more. De-regulation of GSK-3β has been implicated in diseases like cancer, Alzheimer’s
disease, bipolar disorder and type 2 diabetes mellitus. Currently, GSK-3β is one of the most
widely studied proteins and there is a great interest in developing potent and efficient GSK-3βinhibitors for research as well as therapeutic purposes. We demonstrate that beryllium in the form
of BeSO4 salt is a much more potent GSK-3β-inhibitor compared to LiCl.
We observed that one of the unique properties of beryllium is its modus operandi to regulate
the inhibitory Ser-9 phosphorylation of GSK-3β in a cell type specific manner. Our study for the
first time validates the potential of beryllium to function as a biologically relevant GSK-3βiii

inhibitor. Beryllium induces a decrease in the phosphorylation of glycogen synthase in cultured
NIH/3T3 cells. This decrease in phosphorylated form of glycogen synthase demonstrates the
ability of beryllium to inhibit GSK-3β’s kinase activity in treated cells. One of the most important
substrates in relation to GSK-3β’s inhibition is β-catenin – one of the downstream effector
molecules of the Wnt signaling pathway. Our results in NIH/3T3 and A172 cells indicate that
beryllium has minimal effect on Wnt signaling/ β-catenin pathway compared to other established
GSK-3β-inhibitors. The minimal effect of beryllium at physiologically effective concentrations
on Wnt signaling/β-catenin pathway indicates that it could be a more pathway specific inhibitor.
One of the most intriguing discoveries of our study has been the lithium induced increase in the
phosphorylated form of β-catenin, which is against the “accepted dogma”. Here we propose an
alternative model explaining the regulation of the Wnt/β-catenin signaling pathway by lithium.
Use of GSK-3β-inhibitors for therapeutic purposes presents the risk of inducing cancer in
patients due to accumulation of β-catenin, an oncogene activator. The unique ability of beryllium
to repress the kinase activity of GSK-3β without inducing a heavy nuclear localization of βcatenin might provide an opportunity to develop a potentially potent, efficient, pathway-specific
and biologically active GSK-3β inhibitor with minimal adverse effects.
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CHAPTER 1

OVERVIEW
Research purpose
GSK-3β is an important Ser/Thr kinase, which is involved in various physiologically
important cellular pathways (Frame and Cohen, 2001; Doble and Woodgett, 2003; Grimes and
Jope, 2001). De-regulation of GSK-3β is directly linked to the development of different diseases
such as type 2 diabetes milletus, Alzhemier’s disease and cancer (Grimes and Jope, 2001;
Henriksen and Dokken, 2006; Smalley and Dale, 1999; Peifer and Polakis, 2000). There is great
deal of interest in understanding the precise role of GSK-3β in the signaling pathways. Inhibitors
act as an irreplacable tool to examine the role of an enzyme/protein in different signaling
networks. Different categories of GSK-3β inhibitors are available and the most important among
them is the small metal cations group. Lithium is a monovalent cation and is the most well
characterized metal cation inhibitor of GSK-3β with an IC50 value of 12 mM (Ryves et al., 2002;
Mudireddy et al., 2014). Li+ is a fairly specific GSK-3β inhibitor but is physiologically effective
only at millimolar concentrations. Be2+ is a divalent cation capable of inhibiting GSK-3β (Ryves
et al., 2002). We have used beryllium in the form of BeSO4.4H2O and documented some of the
different outcomes it induces in mammalian cell cultures in its role as a GSK-3β inhibitor.
Emphasis was laid to understand and validate the effect of beryllium on GSK-3β-substrates or
target proteins.
The present study can be summarized as follows:


Chapter 1 – Overview and research questions.



Chapter 2 - A brief introduction and information available about GSK-3β.

1



Chapter 3 - We have analyzed the effect of beryllium salt on the different mammalian cell lines.
This information was used in selecting cell lines that are most suitable for studies involving
beryllium. Cell lines that are resistant or too sensitive to beryllium salt were not used for further
studies.



Chapter 4 - The effect of BeSO4 on the kinase activity of GSK-3β was analyzed and Be2+ was
found to be a more effective GSK-3β inhibitor compared to Li+. Emphasis was laid on
understanding the effect of beryllium on the Ser-9 phosphorylation status of GSK-3β. It is also
observed that unlike lithium, beryllium cannot induce a clear increase in the Ser-9
phosphorylation of GSK-3β in certain cell lines.



Chapter 5 - In this study we demonstrate the intra cellular effects of beryllium on GSK-3β
substrates like glycogen synthase and β-catenin for the first time ever in cell culture. This study
will be helpful in validating the ability of Be2+ to function as a biologically active GSK-3β
inhibitor.



Chapter 6 - We have used RT-PCR to analyze the effect of Be2+ treatment on the expression of
certain genes. Genes which seems to be responding to beryllium were selected for this study
depending on the microarray data available in our lab.



Chapter 7 – Research summary and future directions.

Research questions
Beryllium is a known GSK-3β inhibitor, which competes for the Mg2+ and ATP binding sites
of GSK-3β (Ryves et al., 2002). There is a great dearth of information regarding the role of
beryllium as a GSK-3β inhibitor. This study is an attempt to establish whether Be2+ is an efficient
GSK-3β inhibitor. Following are few important research questions we tried to address through
this study.
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1. Is Be2+ a potent GSK-3β inhibitor and how well is it tolerated by mammalian cell lines?
Test: Inhibitory effect of Be2+ on the in vitro kinase activity of pure recombinant GSK-3β will be
analyzed using a FRET based kinase assay. The cyto toxicity of Be2+ can be examined using a
live/dead cell protease assay.
2. Is Be2+ a specific GSK-3β inhibitor?
•

Test: The effect of Be2+ on pure recombinant protein kinase A (PKA - a kinase involved
in insulin signaling pathway) can be analyzed using a FRET based kinase assay. PKA
phosphorylates GSK-3β (Fang et al., 2000; Li et al., 2000; Tanji et al., 2002) suggesting
that PKA and GSK-3β work closely to one another. Hence PKA is a suitable candidate to
analyze the specificity of beryllium towards other related kinases.

3. What is the effect of Be2+ on the Ser-9 phosphorylation of GSK-3β?
Test: Increase in the phosphorylation of Ser-9 residue on GSK-3β is closely associated with its
regulation. The impact of Be2+ on the Ser-9 phosphorylation of GSK-3β will be investigated using
western blotting. The effect of Be2+ on the Ser-9 phosphorylation of GSK-3β can be quantified by
using flow cytometry and TR-FRET based methods.
4. What is the effect of Be2+ treatment on the proteins downstream of GSK-3β (if Be2+ is a
potent GSK-3β inhibitor)?
Test: GSK-3β is an important Ser/Thr kinase, which phosphorylates its substrates and plays an
important role in their regulation. If Be2+ is a potent GSK-3β inhibitor in treated cells – then its
inhibitory effects can be validated by analyzing the phosphorylation status of the GSK-3β–
substrates. The phosphorylation status of important GSK-3β-substrates like glycogen synthase, βcatenin or tau will be investigated via western blotting.
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5. Can Be2+ regulate the Wnt signaling pathway like Li+?
Test: GSK-3β is an important constituent of the Wnt signaling pathway. Inhibition of GSK-3β
can cause nuclear localization of β-catenin, which in turn leads to activation of some oncogenes.
It is necessary to investigate the effect of a GSK-3β inhibitor on Wnt signaling pathway. The role
of Be2+ in regulating the Wnt signaling pathway will be investigated by studying the nuclear
localization pattern of β-catenin via immunofluorescence, flow analysis and western blotting.
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CHAPTER 2

GSK-3β: An important Ser/Thr kinase
Glycogen synthase kinase 3 (GSK-3) is an important serine/threonine kinase found in all
eukaryotes. GSK-3 was first isolated in its homogenous form from rabbit skeletal muscle cells
(Embi et al., 1980). The name glycogen synthase kinase refers to its ability to phosphorylate
glycogen synthase, a key regulatory element of glycogen synthesis and insulin signaling pathway.

GSK-3 family
There are two isoforms of mammalian GSK-3: GSK-3α and GSK-3β encoded by distinct
genes (Woodgett, 1990). GSK-3α is 51 kDa and GSK-3β is 47 kDa, the difference in the size of
the isoforms is due to the presence of a glycine rich extension on the N-terminus of GSK-3α. The
two isoforms of GSK-3 share only 36% identity in their last 76 residues on the C-terminal but
their kinase domains are highly identical (98%) (Woodgett, 1990). The GSK-3 homologues are
found in almost all eukaryotes and shares highly similar kinase domains (Ali et al., 2001). In spite
of their identical kinase domains GSK-3α and GSK-3β are not functionally identical. The deletion
of exon 2 of GSK-3β causes the death of mouse embryos at day 16 due to the extreme hepatocyte
apoptosis induced liver degeneration. Functional GSK-3α cannot alleviate the lethality induced in
mouse embryos due to homozygous deletions of exon 2 of GSK-3β (Hoeflich et al., 2000). The
lethality observed in GSK-3β null mouse embryos cannot be alleviated by a functional GSK-3α
indicating the importance of the protein/enzyme GSK-3β. However animal models representing
GSK-3α knock out are viable but display enhanced insulin sensitivity (MacAulay et al., 2007).
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Table 1a Important events in the field of GSK-3 research from 1963 to 1993
(Adapted from Cohen and Frame, 2001) – Reprinted by permission from Macmillan Publishers
Ltd: [nature reviews molecular cell biology] (Cohen P, Frame S. 2001). The renaissance of
GSK3. Nature reviews Molecular cell biology 2: 769-776), copyright (2001))

Year

Research related GSK-3

1963

Glycogen synthase was found to exist in active Friedman and Larner,
and inactive forms
1963.

1964

Insulin promotes the conversion of glycogen Craig
synthase to its active form
1964.

1978

Insulin could inhibit the activity of GSK-3

Cohen, 1979.

1980

GSK-3 purified

Embi et al., 1980.

1983

Insulin induced dephosphorylation of Parker et al., 1983.
glycogen synthase occurs at serine residues,
which are targets of GSK-3

1986

Li+ treatment caused duplication of dorsal Kao et al., 1986.
axis in Xenopus oocytes

1987

A “priming phosphate” is required for GSK-3 Fiol et al., 1987.
to recognize its substrates

1990

Two isoforms of GSK-3: GSK-3 α and β Woodgett, 1990.
idetified

1991

GSK-3 phosphorylates Jun family proteins in Boyle et al., 1991.
vitro and negatively regulates them

1992

1993





Refrences

Insulin inactivates GSK-3
GSK-3 phosphorylates Tau
Wingless (WNT homologue) found to
inactivate GSK-3

eIF2B identified as a GSK-3 substrate
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and

Larner,

Hughes et al., 1992.
Hanger et al., 1992.
Siegfried at al., 1992.

Welsh et al., 1993

Table 1b: Important events in the field of GSK-3 research from 1994 t0 2014
1994




1995




1996

1998

1999

2000

2001

2002

2003

2007

2014




Protein kinases activated by mitogen
leads to inactivation of GSK-3α
PI3K inhibition found to hamper
GSK-3 inhibition
Insulin induced inactivation of GSK3β through the Ser-9 phosphorylation
PKB/AKT phosphorylates GSK-3 in
vitro at appropriate sites
Li+ ions inhibit GSK-3
GSK-3 regulates sub cellular
distribution of β-catenin

Sutherland and Cohen,
1994.
Cross et al., 1994.
Cross et al., 1995.

Klein and Melton,
1996.
Stambolic et al., 1996.
Rubinfeld et al., 1996.
Axin shown to exist in a complex with GSK- Ikeda et al., 1998.
3β and β-catenin and promotes GSK-3β
dependent phosphorylation of β-catenin
FRATtide
inhibits
GSK-3
mediated Thomas et al., 1999.
phosphorylation of axin and β-catenin, but
not glycogen synthase.


Disruption of GSK-3β is lethal to
mouse embryos
 Specific small molecule inhibitors of
GSK-3β developed
 Insulin and Wnt regulates GSK-3β
differentially
 GSK-3 inhibitors shown to hamper
neuronal apoptosis
 Crystal structure of GSK-3 solved
 Li+ competes for the Mg2+ binding sites
of GSK-3β
Be2+ is a GSK-3β inhibitor and could be
competing for Mg2+ and ATP binding sites of
GSK-3β


GSK-3β interacts and positively
regulates p53 activity
 GSK-3β-TIMAP-PP1 feedback loop
plays a critical role in the regulation
of GSK-3β
Phosphorylation of TIMAP by GSK-3β
activates PP1

Hoeflich et al., 2000.
Coghlan et al., 2000.
Ding et al., 2000.

Cross et al., 2001.
Dajani et al., 2001.
Ryves and Harwood,
2001.
Ryves et al., 2002.

Watcharasit et
2003.
Zhang et al., 2003.

al.,

Li et al., 2007

Be2+ is a 1000 times more potent GSK-3β Mudireddy et al., 2014.
inhibitor compared to Li+
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GSK-3β – A brief introduction
GSK-3β is a fascinating enzyme playing a central role in extremely diverse intra cellular
signaling pathways like Wnt signaling and hedgehog pathway. GSK-3β regulates glycogen
synthesis, gene transcription, apoptosis, protein synthesis and cellular differentiation in various
cell types (Frame and Cohen, 2001; Doble and Woodgett, 2003; Grimes and Jope, 2001). The
moniker glycogen synthase kinase doesn’t justify the ability/range of GSK-3β to phosphorylate
various metabolically and structurally important proteins. There is overwhelming evidence which
establishes a plethora of different proteins as validated substrates of GSK-3β and they are tau, βcatenin, Cyclin D1, Axin, c-jun, c-myc, Heat Shock Factor–1, BCL-3, CREB, Histone H1.5,
mdm2, p21(CIP1), pyruvate dehydrogenase and many more (reviewed in Sutherland, 2011).
Phylogenetically GSK-3β is closely related to the cyclin dependent protein kinases, however a
major difference is the preference of GSK-3β for primed substrates. The GSK-3β substrates have
to be primed at n + 4 position with a phosphate moiety in order to be recognized by the enzyme
(n is the site of phosphorylation by GSK-3β) (Fiol et al., 1987). The common consensus sequence
that serves as the phosphorylation site of GSK-3β is Ser/Thr-Xaa-Xaa-Xaa-pSer/pThr (where
pSer/pThr are the primed residues, Xaa – any amino acid and Ser/Thr is the target site of GSK3β) (Fiol et al., 1987).
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Table 2a. Proposed GSK-3β substrates
(Adapted from - What are the bonafide GSK-3 substrates, Sutherland, 2011 ; open access journal,
International journal of Alzheimer’s disease, 2011, 505607)
Proposed
substrate

Target
residue(s)

Priming
residue(s)
and kinase
1505 (CK1)
1507 (CK1)

Effect of GSK-3β
induced
phosphorylation
Regulates degradation

Refrences

Adenomatous
Polyposis
Coli (APC)

1501
1503

Axin

Ser-322
Ser-326
(putative)

Ser-330

Regulates stability

Ikeda et al, 1998.
Yamamoto et al,
1999.

BCL-3

Ser-394

Ser-398
(ERK
putative)

Regulates degradation

Viatour
2004.

β-catenin

Ser-33
Ser-37
Thr-41

Ser-45
(CK1)

Regulates degradation

Ikeda et al, 1998.

Cyclin D1

Thr-286

NONE

Nuclear transport and
degradation

Diehl et al, 1998.

Glycogen
Synthase

Ser-640
Ser-644
Ser-652

Ser-658
(CKII)

Reduces activity

Rylatt et al, 1980.
Parker et al, 1983.

Heat shock
factor 1

Ser-303

Ser-307
(MAPK)

Reduces DNA binding

Chu et al, 1996.

Histone HI.5

Thr-10

NONE

Coincides
chromosome
condensation

with

Happel et al, 2009.

c-jun, Jun B,
Jun D

The-239

Thr-243

Reduces DNA binding

Boyle et al, 1991.
Nikolakaki et al,
1993.

9

Ferrarese et al,
2007.
Ikeda et al, 2000.

et

al,

Table 2b. Proposed GSK-3β substrates
Proposed
substrate

Target
residue(s)

mdm2

Ser-240
Ser-254

c-myc,
myc

L- Thr-58
Thr-62
myc)

Priming
residue(s)
and kinase
Ser-244
Ser-258
(CKI)

Ser-62
(c- (ERK1/2)

Effect of GSK-3β Refrences
induced
phosphorylation
Promotes
activity Kulikov et
towards p53, reduces 2005
activity p53 levels.
Promotes
degradation

p53

Ser33(GSK-3β
only)

Ser-37
(DNA-PK)

Increases
transcriptional
activity

p21 CIP1

Thr-57

ND

Induces degradation

Protein
Ser-38
phosphatase Ser-42
1 G-submit (human)

Ser-46
Not clear
(PKA or
p90RSK)

Protein
Thr-72
phosphatase
inhibitor 2

Ser-86
(CKII)

Tau

Thr-212
(DYRK)

Ser-208
Thr-231
Thr-235
Ser-396

Inhibits
thereby
PP1

al,

Sears et al, 2000.
Henriksson et al,
1993.
Saksela et al,
1992.
Turenne
and
Price, 2001.

Rossig
2002.

et

al,

Dent et al, 1989.

inhibitor Soutar et al,
activating 2010.
Aitken et al,
1984
DePaoli-Roach,
1984.
Some
Woods et al,
phosphorylation sites 2001.
regulate microtubule Hanger et al,
binding
1992.
Yang et al, 1993.

10

Schematic diagram 1: De-regulation of GSK-3β activity towards its substartes has serious
consequences
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GSK-3β and the Wnt signaling
Wnts are a family of cysteine-rich, glycosylated, secreted protein ligands found in a wide
variety of organisms ranging from hydra to humans (Miller, 2002). One of the pathways regulated
by Wnt ligands is known as the canonical Wnt pathway or the Wnt/β-catenin pathway (Polakis,
2000; Seidensticker and Behrens, 2000; Sharpe et al., 2001). The Wnt signaling pathway is
important for embryonic development, homeostatis, and development of central nervous system.
(McMohan and Bradley, 1990; Patapoutian and Reichardt, 2000; Woodarz and Nusse, 1998;
Moon et al., 1997; Polakis, 2000). GSK-3β is an important constituent of the Wnt signaling
pathway and also the highly homologous wingless signaling pathway of drosophila. GSK-3β
forms the β-catenin destruction complex along with APC (Adenomatous Polyposis Coli), axin,
casein kinase 1 (CK1), protein phosphatase 2A (PP2A) and E3-ubiquitin ligase β-TrCP (Zeng et
al., 1997; Behrens et al., 1998; Hart et al., 1998, Ikeda et al., 1998;Itoh et al., 1998; Salic et al.,
2000; Kikuchi, 1999). β-catenin is an important substrate of GSK-3β and the GSK-3β mediated
phosphorylation on the N-terminal region of β-catenin (Pefifer et al., 1994; Yost et al., 1996)
marks it for ubiquitin-mediated proteosomal degradation (Hart et al., 1998, 1999; Behrens et al.,
1998; Oxford et al., 1997; Winston et al., 1999; Kitagawa et al., 1999; Latres et al., 1999; Liu et
al., 1999). β-catenin is one of the most important downstream effectors’ of the Wnt signaling
pathway.
In the absence of Wnt ligands, the active GSK-3β in concert with axin and adenomatous
polyposis coli (APC) phosphorylates β-catenin targeting it for ubiquitinylation and proteasomal
degradation (Hart et al., 1998; Peifer and Polakis, 2000; Oxford et al., 1997; Aberle et al., 1997)
Wnt ligands bind to the extracellular domain of their receptor called frizzled protein thereby
activating the Wnt signaling pathway. The activation of Wnt signaling cascade destabilizes axin
which has a detrimental effect on the β-catenin destruction complex (Willert et al., 1999;
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reviewed in Kikuchi, 1999). Wnt activation also blocks the phosphorylation of β-catenin by GSK3β (Bilic et al., 2007; MacDonald et al., 2009; Metcalfe and Bienz, 2011) Thus Wnt activation
inhibits GSK-3β phosphorylation of β-catenin and causes accumulation of β-catenin. These
events ultimately lead to stabilization of β-catenin (Cook et al., 1996; Willert et al., 1999) and the
accumulated β-catenin is translocated into the nucleus where it interactes with the TCF/LEF (Tcell factor/lymphocyte enhancer factor) proteins to form a protein complex (Huber et al., 1996;
Molenar et al., 1996; Behrens et al., 1996). The β-catenin-Tcf/Lef protein complex binds to DNA
and regulates the transcription of TCF/LEF target genes (Behrens et al., 1996; Dale, 1998;
Brantjes et al., 2002). It is important to note that some of the target genes of β-catenin are proto
oncogenes (Dale, 1998; Brantjes et al., 2002).
The relationship between GSK-3β and Wnt signaling pathway can be summarized as follows
- a stable β-catenin destruction complex is required for the GSK-3β enzyme to phosphorylate βcatenin and it happens in the absence of Wnt signaling/ligands. Inhibition of GSK-3β by Wnt
ligands prevents the phosphorylation and proteasomal degradation of β-catenin.
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Schematic diagram explaining the role of GSK-3β in insulin pathway and Wnt/β-catenin
pathway

Schematic diagram 2: Dissecting the role of GSK-3β in insulin and Wnt pathway. Lithium
induced destability of the β-catenin destruction comeplex could be the possible reason for the
nuclear localization of β-catenin in Li+ treated cells. Whether beryllium can destabilize the βcatenin destruction comeplex or not is worth investigating further. It can be summarized that
probably GSK-3β occurs in two cellular forms “free GSK-3β” and “bound GSK-3β” and
beryllium seems to be mostly targeting the “free GSK-3β” for inhibition
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GSK-3β and its role in insulin signaling
One of the primary functions of GSK-3β is to phosphorylate and inactivate the enzyme
glycogen synthase (GS) (Parker et al., 1983; Roach, 1990, Zhang et al., 1993). GSK-3β is
constitutively active in cells and insulin mediated regulation/inhibiton of GSK-3β leads to the
activation of glycogen synthase. In the presence of insulin, sequential activation of Insulin
Receptor Substrate (IRS-1), PI3-kinase and Akt/PKB takes place, which eventually causes
inactivation of GSK-3β (Sutherland et al., 1993; Cross et al., 1994, 1995; Stambolic and
Woodgett, 1994). Akt/PKB mediates the GSK-3β inactivation by phosphorylating the N-terminal
Ser-9 residue (Sutherland et al., 1993; Cross et al., 1994, 1995; Stambolic and Woodgett, 1994).
Glycogen synthase and IRS-1 are important constituents of the insulin signaling pathway and
both are putative substrates of GSK-3β enzyme (Rylatt et al., 1980; Parker et al., 1983; Liberman
and Eldar-Finkelman, 2005). Like glycogen synthase; IRS-1 is phosphorylated and inactivated by
GSK-3β thus imparing the insulin signaling pathway (Eldar-Finkelman and Krebs, 1997;
Liberman and Eldar-Finkelman, 2005). GSK-3β plays a critical role at multiple steps in the
insulin signaling pathway. Various studies indicate that GSK-3β acts as a negative modulator of
insulin signaling and plays an important role in maintaining glycogen synthase in a repressed
state. Hence deregulation or hyper activation of GSK-3β has been implicated in the development
of diabetes mellitus type 2 (formerly known as non insulin dependent diabetes mellitus –
NIDDM) (Henriksen and Dokken, 2006).
GSK-3β and regulation of Hedgehog pathway
Hedgehog (Hh) signaling is involved in important cellular functions like cell division and cell
survival and its deregulation is linked to the development of different disorders (reviewed in
Murone et al., 1999; Briscoe and Pascal, 2013). Hedgehog signaling is a complex pathway and
GSK-3β plays an important role in it along with other kinases (Jia et al., 2002; Jiang et al., 1995;
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Price and Kalderon, 2002, Lum et al., 2003). The downstream effector of the Hh signaling
pathway in drosophila is called as Cubitus interruptus (Ci) and it is responsible for the regulation
of target genes in response to Hh stimulation. (Alexandre et al., 1996; Von Ohlen et al., 1997;
Methot and Basler, 2001). Ci appears in two forms called as Ci155 and Ci75 (a truncated form of
Ci155) and in relation to the regulation of Hh target genes - Ci155 is the active form and Ci75 is the
repressor form (Aza-Blanc et al., 1997). GSK-3β is involved in the conversion (truncation) of
Ci155 into its repressor form along with other kinases. In the absence of Hh stimulation or Hh
ligands, Protein Kinase A (PKA) phosphorylates Ci thus priming it for further phosphorylation by
GSK-3β and caesin Kinase 1δ (CK1δ) followed by the partial proteasomal degradation to yield
Ci75 (Jia et al., 2002; Jiang et al., 1995; Price and Kalderon, 2002). In vertebrates the final
downstream effector of the Hh pathway is called as Gli and recently it was shown that PKA is
involved in the multi site phosphorylation of Gli (Niewiadomski et al., 2014). In the presence of
Hh ligands the conversion of Ci into its repressor form i.e. Ci75 is inhibited (Methot and Basler,
1999). It can be summarized that Hh stimulation down regulates the activity of GSK-3β.

GSK-3β and diseases
Alzheimer’s disease
Since GSK-3β plays a critical role in the regulation and stability of various important
proteins, deregulation of GSK-3β has been associated with many diseases. There is enough
evidence to directly link GSK-3β with the neuropathological mechanisms associated with
Alzheimer’s disease (AD). GSK-3β induces phosphorylation of microtubule associated tau
protein, which resembles the Alzhemer’s disease-like induced tau-phosphorylation. (Hanger et
al., 1992; Yang et al., 1993; Woods et al., 2001). Increased levels of GSK-3β have been found in
AD compared to normal human brains and immunohistochemical studies have detected GSK-3β
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in the neurofibrillar tangles of the AD brain tissue (Yamaguchi et al., 1996; Imahori and Uchida,
1997; Pei et al., 1997, 1999). These studies indicate that GSK-3β has a role to play in the etiology
of Alzheimer’s disease.
Insulin resistance and diabetes mellitus type 2
Role of GSK-3β in the development of insulin resistance and diabetes mellitus type 2 has
been established in various studies (Henriksen and Dokken, 2006). Elevated GSK-3β has been
implicated in the development of insulin resistance in skeletal muscle cells. Increased levels of
GSK-3β is found in the tissues of insulin resistant obese rodent models like high fat fed mice
(Eldar-Finkelman et al., 1999), obese zucker rats (Dokken et al., 2005). Enhanced GSK-3β is also
found in type 2 diabetic humans (Nikoulina et al., 2000). At the molecular level it has been
observed that GSK-3β can hamper insulin signaling by interfering with the important components
of the insulin signaling pathway. GSK-3β can phosphorylate Ser-332 of IRS-1in vitro which
could hinder its interaction or communication with insulin receptor (Liberman and EldarFinkelman, 2005; Aguirre et al., 2002). The disruption of interactions between insulin receptor
and IRS-1 could have a detrimental effect on insulin signaling pathway and protect GSK-3β from
the inhibitory action of insulin. GSK-3β phosphorylates glycogen synthase enzyme (GS) on
multiple serine residues and leads to its inactivation (Parker et al., 1983; Roach, 1990, Zhang et
al., 1993). Inactive glycogen synthase leads to decrease in glycogenesis (glycogen synthesis),
which in turn would lead to an increase in the blood glucose levels (Cross et al., 1997; Summers
et al., 1999). These observations demonstrate that deregulation of GSK-3β could play an
important role in development of type 2 diabetes mellitus.
Cancer
GSK-3β is an important constituent of the β-catenin destruction complex along with APC
(Adenomatous Polyposis Coli), axin, casein kinase 1 (CK1), protein phosphatase 2A (PP2A) and
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E3-ubiquitin ligase β-TrCP (Zeng et al., 1997; Behrens et al., 1998; Hart et al., 1998, Ikeda et al.,
1998;Itoh et al., 1998; Salic et al., 2000; Kikuchi, 1999). The GSK-3β mediated phosphorylation
of β-catenin marks it for ubiquitin-mediated proteosomal degradation (Pefifer et al., 1994; Yost et
al., 1996; Rubinfeld et al., 1996; Hart et al., 1996; Behrens et al., 1998; Oxford et al., 1997; Farr
et al., 2000). GSK-3β and β-catenin are important members of the Wnt signaling pathway. Wnt
activation results in the inhibition of GSK-3β (Bilic et al., 2007; MacDonald et al., 2009;
Metcalfe and Bienz, 2011) leading to stabilization of β-catenin (Cook et al., 1996; Huber et al.,
1996; Willert et al., 1999). The β-catenin translocates into the nucleus where it interacts with
TCF/LEF proteins to form a complex; this complex binds to DNA and regulates the transcription
of TCF/LEF target genes (Huber et al., 1996). Abnormal or constitutive repression of GSK-3β
activity could lead to accumulation of β-catenin in the nucleus. Several studies have directly
linked the de-regulation of β-catenin with development of various cancers (Smalley and Dale,
1999; Peifer and Polakis, 2000; Thakur and Mishra, 2013).

Regulation of GSK-3β
GSK-3β controls diverse cellular processes like gene expression, apoptosis, cell viability and
development. Hence GSK-3β is regulated by complex regulatory mechanisms in order to avoid
any unwanted consequences on the normal cellular functions. It has been observed that GSK-3β
is regulated by multiple regulatory mechanisms.
Inhibitory Ser-9 phosphorylation of GSK-3β
The activity of GSK-3β is down regulated by an increase in the phosphorylation of its Ser-9
residue on the N-terminal region (reviewed in Plyte et al., 1992). Some GSK-3β inhibitors induce
an increase in the Ser-9 phosphorylation of GSK-3β thereby inhibiting it (Frame and Cohen,
2001; Grimes and Jope, 2001; Doble and Woodgett, 2003). Phosphorylated Ser-9 residue on the
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N-terminal tail of GSK-3β acts as a pseudo substrate thus blocking the access of the substrates to
GSK-3β’s catalytic site (Frame et al., 2001; Dajani et al., 2001). There are many different kinases
that can phosphorylate GSK-3β at Ser-9 position depending on specific stimuli. Some of the
kinases known to induce an increase in Ser-9 phosphorylation of GSK-3β are p70 S6 kinase
(Armstrong et al.,2001; Krause et al., 2002; Terruzzi et al., 2002), p90Rsk (also called as
MAPKAP kinase-1) (Brady et al., 1998; Saito et al., 1994), Akt (also called protein kinase B)
(Sutherland et al., 1993; Shaw, et al., 1997; Cross et al., 1994, 1995; Stambolic and Woodgett,
1994), certain isoforms of protein kinase C (Ballou et al., 2001; Fang et al., 2002), and cyclic
AMP-dependent protein kinase (protein kinase A) (Fang et al., 2000; Li et al., 2000; Tanji et al.,
2002).
Insulin is a well characterized GSK-3β’s indirect inhibitor and in response to insulin an
increase in the inhibitory phosphorylation of the Ser-9 residue on the N-terminal region of GSK3β is induced (Sutherland et al., 1993; Cross et al., 1995). The upstream kinases of the insulin
signaling pathway play an important role in the insulin induced Ser-9 phosphorylation of GSK-3β
(Sutherland et al., 1993; Welsh and Proud, 1993; Cross et al. 1995). Akt or protein kinase B is an
important component of the insulin signaling pathway and it has been observed that in response
to insulin, activation of Akt/PKB takes place. Activated Akt modulates an increase in the Ser-9
phosphorylation of GSK-3β (Sutherland et al., 1993; Shaw, et al., 1997; Cross et al., 1994, 1995;
Stambolic and Woodgett, 1994). The negative regulation of GSK-3β activity via the Ser-9
phosphorylation is a crucial step in the receptor-coupled signaling processes. Much effort has
been directed to identify the specific kinases used by different receptor coupled signaling
systems. Different kinases activated in response to different stimuli leads to the inhibitory Ser-9
phosphorylation of GSK-3β. However the Ser-9 phosphorylation of GSK-3β is reversible and its
dephosphorylation is mediated by protein phosphatase 1 (PP1) (Zhang et al., 2003).
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Regulation of GSK-3β activity by protein complex formation
Apart from the inhibitory Ser-9 phosphorylation, GSK-3β is regulated by the formation of a
protein complex mediated by GSK-3β binding proteins. Regulation of GSK-3β by protein
complex formation is a complicated mechanism which involves proteins like GSK-3β binding
protein (GBP) (Yost et al., 1998; Farr et al., 200), Axin (Ikeda et al., 1998; Yamamoto et al.,
1999) and the axin related protein named as Axil (Yamamoto et al., 1998) or Conductin (Behrens
et al., 1998). Presently FRAT1 and FRAT2 are included in the GBP family and regulate GSK-3β
by forming a protein complex with it (Jonkers et al., 1997; Li et al., 1999; Thomas et al., 1999;
Yost et al., 1998). An interesting fact about binding of GBP to GSK-3β is that it doesn’t inhibit
the catalytic activity of GSK-3β towards all its substrates (Thomas et al., 1999). According to
Thomas et al binding of FRAT1 to GSK-3β inhibits its activity towards β-catenin but not
glycogen synthase. The binding of GBP family proteins to GSK-3β produces a probable localized
inhibition of GSK-3β enzyme, partially limiting its phosphorylating activity towards certain
substrates.
As explained GSK-3β forms the β-catenin destruction complex along with axin, APC
(Adenomatous Polyposis Coli), casein kinase 1 (CK1), protein phosphatase 2A (PP2A) and E3ubiquitin ligase β-TrCP (Hart et al., 1996; Behrens et al., 1998; Oxford et al., 1997). β-catenin is
an important substrate of GSK-3β and the GSK-3β mediated phosphorylation of β-catenin marks
it for ubiquitin-mediated proteosomal degradation (Behrens et al. 1998; Oxford et al. 1997). Axin
and APC both are substrates of GSK-3β and phosphorylation of axin and play an important role
in the assembly of the β-catenin destruction complex (Rubenfeld et al., 1996; Ikeda et al., 1998).
The GSK-3β of the β-catenin destruction complex induces an increase in the rate of β-catenin
phosphorylation thus marking it for proteasomal degradation (Rubinfeld et al., 1996; Hedgepeth
et al., 1999; Farr et al., 2000). The relationship between GSK-3β and axin is mutualistic. Binding
of axin enhances the activity of GSK-3β similarly the GSK-3β induced phosphorylation of axin
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stabilizes it from degradation (Yamamoto et al., 1999). There is evidence to support that GBP and
axin may not bind to GSK-3β simultaneously but compete with one another for protein complex
formation (Farr et al., 2000). One such regulatory mechanism is elicited by Disheveled (Dsh)
proteins. Dsh is a negative regulator of GSK-3β, which can bind both to FRAT1 and axin. Dsh
facilitates the binding of FRAT1 to GSK-3β and simultaneously enhances the disassociation of
axin from GSK-3β (Li et al., 1999; Krylova et al., 2000).
The differential regulation of GSK-3β by protein complex formation indicates that there are
two populations of cellular GSK-3β, the “free GSK-3β” and the axin “bound GSK-3β”, which is
part of the β-catenin destruction complex (refer schematic diagram 2 on page 14). There is
evidence to suggest that the free and bound GSK-3β could be participating in independent and
different signaling pathways (Ding et al., 2000) (discussed in more detail in chapter 5).
Competitive inhibition
GSK-3β is a Mg2+ and ATP dependent enzyme. Any interference with the binding of Mg2+
ions and ATP to the GSK-3β enzyme will restrict its kinase activity. Some of the GSK-3β
inhibitors act either by competing with Mg2+ or ATP or both thus inhibiting the enzyme.
(explained in Table 3)

GSK-3β inhibitors
The most desired characteristics in an inhibitor are its specificity and potency towards the
target proteins. There are various classes of GSK-3β inhibitors and Table 3 provides a
comprehensive list of different GSK-3β inhibitors and their specificity towards other kinases. The
simplest among the various classes of GSK-3β inhibitors are the metal cation group.
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Lithium – an efficient GSK-3β inhibitor
Lithium (Li+) is a monovalent metal cation that acts as an efficient inhibitor of GSK-3β. Li+ is
the most well characterized metal cation inhibitor of GSK-3β and is commonly used in the form
of LiCl salt (Klein and Melton, 1996, Stambolic et al., 1996). Li+ inhibits the activity of GSK-3β
both directly and indirectly (Jope, 2003). GSK-3β is a Mg2+ dependent enzyme and Li+ inhibits
GSK-3β by directly competing with Mg2+ ions for the magnesium binding sites (Ryves and
Harwood, 2001; Ryves et al., 2002). Like insulin, Li+ too leads to an increase in the inhibitory
Ser-9 phosphorylation in a wide variety of cells thereby inhibiting GSK-3β enzyme indirectly
(Zhang et al., 2003). According to Zhang et al Li+ induces an increase in the Ser-9
phosphorylation of GSK-3β by perturbing the GSK-3β-TIMAP-PP1 feed back loop. The Li+
induced inhibition of protein phosphatase 1 (PP1) leads to a build up of pSer-9-GSK-3β thus
accounting partly for the regulation of GSK-3β.
From the inhibitory Ser-9 phosphorylation perspective, Li+ mimics insulin and has a positive
effect on glycogen metabolism (Cheng et al., 1983; Bosch et al., 1986; Woo et al., 2000). In
addition Li+ also mimics Wnt ligands and activates the Wnt signaling pathway, which in turn
leads to nuclear localization of β-catenin (Stambolic et al., 1996; Hedgepeth et al., 1997). Li+ is a
reasonably selective GSK-3β inhibitor but its inhibitory concentration range is in millimolar (Ki =
2 mM) (Klein and Melton, 1996). Beryllium (Be2+) another metal cation inhibitor of GSK-3β is
1000 times more potent compared to lithium (Mudireddy et al., 2014). But not much is known
about the role of Be2+ as a GSK-3β inhibitor.
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Table 3a. List of GSK-3β inhibitors
(Adapted from - Cell and Molecular Life Sciences, volume - 64, 2007, 1930-1944, Glycogen
synthase kinase 3: a key regulator of cellular fate, Forde J.A, Dale T,Table.1 GSK-3 inhibitors;
with kind permission from Springer Science and Business Media")
(Adapted with permission from Journal of Cell Science, Doble BW, Woodgett JR. 2003. GSK-3:
tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.)
Inhibitor

Specific
example
N/A

Inhibition Mode of action
potency
Ki = 2 Competes with
mM
Mg2+,
Mimics
Wnt signaling

Bivalent
Zinc

N/A

IC50 = 15 Undetermined;
N/A
µM
doesn’t compete
for substrate

Ilouz
et
al., 2002

Beryllium

N/A

IC50 = 6 Competes with Also inhibits cdc 2
µM
Mg2+ and ATP

Ryves et
al., 2002

Anilino
maleimides

SB216763
and
SB415286

IC50 = 10 ATP competitor
– 30 nM

Bisindole
malemides

Ro 31-8220, IC50 = 5 – ATP competitor
GF 109203x 170 nM

Lithium
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Specificity

Reference

Also
inhibits
IMPase, Fructose 1,6
biphosphate, IPPase,
BPNT,
Phosphoglucomutase
(PGM)

Ryves and
Harwood,
2001;
Klien and
Melton,
1996;
York
et
al., 2001;
Gurvich
and Klein,
2002; Ray
et
al.,
1978

Doesn’t inhibit a Couglan et
range
of
other al., 2000;
kinases
Smith et
al., 2001
Also inhibits PKC
Hers et al.,
1999

Table 3b. List of GSK-3β inhibitors

Inhibitor
Bisindole
malemides

Specific
example
Ro 31-8220,
GF 109203x

Inhibition
potency
IC50 = 5 –
170 nM

Aldisine
alkaloids

hymenialdisi
ne

IC50 = 5 – ATP
10 nM
competitor

Aloisines

aloisine A

IC50 = 0.4 ATP
– 85 µM
competitive

Indirubins

6bromoindiru
bin-3’-oxime
aka BIO
Alsterpaullo
ne

IC50 = 5 – ATP
50 nM
competitor

N/A

Ki = 0.7 Substrate
mM
competitor

Paullones

Pseudo
substrate
peptide

Mode
of Specificity
action
ATP
Also inhibits PKC
competitor

IC50 = 4 – ATP
80 nM
competitor
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References
Hers et al.,
1999

Also inhibits MEKs, Meijer et
CK1 and CDKs
al., 2000;
Tasdemir et
al., 2002
Also
inhibits Mettey et
CDK1/cyclin B and al., 2003
CDK5
Also inhibits CDKs

Meijer et
al., 2003;
Leclerc et
al., 2001
Also inhibits CDKs Knockaert
and mMDH
et al., 2002;
Leost et al.,
2002
Specific
Dajani et
al., 2001

GSK-3β: A therapeutic target
In recent times GSK-3β has emerged as an important therapeutic target because of its role in
the etiological development of different abnormalities and diseases. It is important to identify
potent inhibitors of GSK-3β so as to characterize and understand the impact of GSK-3β
deregulation. GSK-3β inhibitors could have therapeutic potential in the pathophysiological
process involving hyper active GSK-3β. For example in patients suffering from diabetes milletus
type 2 and neurological disorders; inhibitors of GSK-3β could serve the purpose of a potential
therapeutic agent. It has also been observed that inhibition of GSK-3β leads to an increase in
cellular senescence, apoptosis and sensitization of tumor cells to ionizing radiation (Thotala et al.,
2008) and chemotherapeutic agents (Miyashita et al., 2009).
It has been reported that the levels and activity of GSK-3β are elevated in diabetic and obese
mice (Elder-Finkelman et al., 1999). There is a great pharmaceutical interest in identifying
compounds which can mimic insulin and repress GSK-3β activity especially in patients suffering
from type 2 diabetes. GlaxoSmith Kline developed GSK-3β inhibitors belonging to the malemide
group and these compounds facilitated the activation of glycogen synthase in liver cells (Coghlan
et al., 2000).
Li+, another GSK-3β inhibitor, is already in use as a mood stabilizer. Li+ treatment leads to
slight stimulation of the glucose uptake as well as an increase in the translocation of glucose
transporter GLUT4 to the plasma membrane in 3T3-L1 and rat adipocytes (Chen et al., 1998;
Orena et al., 2000; Summers et al., 1999), indicating the potential therapeutic role the GSK-3β
inhibitors could play.
The use of GSK-3β inhibitor for therapeutic applications sounds exciting and promising but it
also raises serious concerns about the unwanted outcomes, which could result from the inhibition
of GSK-3β. One of the primary concerns is the specificity of GSK-3β inhibitors, majority of the
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GSK-3β inhibitors seems to be regulating other related kinases as well (explained in Table 3). A
more serious problem that could arise due to inhibition of GSK-3β is the stabilization and nuclear
localization of β-catenin. The abnormal accumulation of β-catenin due to different reasons is
associated with the development of various cancers especially colorectal cancers (Thakur and
Mishra, 2013). It has been reported that GSK-3β inhibitors developed by GlaxoSmith Kline leads
to activation of glycogen synthase but also causes dramatic increase in the levels of β-catenin
(Cross et al., 2001). Use of the GlaxoSmith Kline GSK-3β inhibitors also stimulates transcription
of genes regulated by β-catenin (Coghlan et al., 2000). However whether prolonged use of GSK3β inhibitors stimulates the formation of tumor or enhances tumorigenesis in animal models is
still under investigation. There is always a possibility that prolonged use of GSK-3β inhibitors
could be potentially oncogenic.
Taking into consideration the adverse effects elicited due to GSK-3β-inhibiton induced
nuclear localization of β-catenin, a pathway specific GSK-3β inhibitor is desired. A good GSK-3β
inhibitor, which can be used for therapeutic purpose would be the one that can inhibit the nonaxin or free GSK-3β. The selective inhibition of non-axin GSK-3β should not have any effect on
the canonical Wnt/ β-catenin pathway since it is the axin-bound GSK-3β, which is involved in the
regulation of β-catenin.

Beryllium: An unsung anti-hero
Beryllium in the form of BeSO4 salt acts as a potent GSK-3β inhibitor and is less toxic to
some cells at physiologically effective concentrations, compared to LiCl (Mudireddy et al., 2014).
Apart from the fact that Be2+ could be competing for both Mg2+ and ATP binding sites on GSK3β, not much is known about the mechanism by which Be2+ inhibits the activity of GSK-3β
(Ryves et al., 2002).
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Beryllium (Be) is an alkaline earth metal belonging to the group IIA elements. The atomic
number of beryllium is 4 and it occurs in two oxidation states, Be0 and Be2+. Beryllium has many
industrial applications, since it is lighter than aluminium yet stronger than steel. Beryllium was
discovered

by

Nicholas-Louis

Vauquelin

in

the

year

1797. The

French

chemist

AntoineAlexandre-Brutus Bussy and German chemist Friedrich Wohler isolated beryllium
independently in the year 1828 (de Laeter et al., 2003). Out of the nine known radioisotopes of
beryllium, beryllium-7 (Be-7) and beryllium-10 (Be-10) are stable with half lives of 53.29 days
and 1.51x106 years respectively (Hammond, 2000).
The cytostatic effects of beryllium were first documented in 1949, using an animal limb
regeneration model (Thornton, 1949; Chevremont and Firket, 1951). Apart from the study
published by Ryves et al, no work has been published to examine beryllium’s role as GSK-3β
inhibitor until it was demonstrated by our lab that beryllium is a 1000 times more potent GSK-3β
inhibitor (Mudireddy et al., 2014). Traditionally the aim of the research work related to beryllium
has been to analyze/establish its cytotoxic effects. Beryllium has been classified as a potent
carcinogen in humans and in rats. Various studies in rats have shown that beryllium when inhaled
caused a high incidence of lung tumors (Haley et al., 1990; Nikula et al., 1997; Finch et al.,
1998).

The route of beryllium administration plays a crucial role in inducing its toxic effects.
Acute oral toxicity
Oral toxicity of beryllium was tested in rats, where in the LD50 was found to be >2000 mg kg1
body weight (Strupp, 2011). The very high dosage of beryllium to induce its lethal effects when
administered orally suggests that ingestion of soluble form of beryllium is not very harmful.
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Inhalation toxicity
The available literature suggests that delayed toxic effects after acute inhalation of beryllium
metal has been reported in rats (Haley et al., 1990; Nikula et al., 1997; Finch et al., 1998). It has
been observed that inhalation of high doses of soluble form of beryllium is known to cause an
acute beryllium disease, which is an obstructive inflammatory lung disease (Eisenbud, 1955;
Cummings et al., 2009).
Dermal sensitization
Studies have shown that beryllium did not lead to any dermal sensitization reaction in
patients who had a history of beryllium sensitization in beryllium plants (Curtis, 1951).
Cytotoxicity and carcinogenicity
In our lab it was observed that beryllium induces cytotoxicity only when used at high
concentrations (high micromolar range). Different cell lines are fairly resistant to the low
beryllium dosage (10 – 100 µM). Majority of the research work to establish the role of beryllium
as a carcinogen has been carried out in rats. A robust carcinogenic response is observed in rats
after inhalation of beryllium metal at high concentrations. Experimental attempts to reproduce the
same results in mice and guinea pigs showed no carcinogenic response (Schepers, 1961). It has
been reported that the potential of beryllium induced lung cancer increases only when the patients
are exposed to high concentrations (Hollins et al., 2009). In an independent study it was observed
that exposure of BALB/c-3T3 cells to high concentrations of BeSO4 (100 – 200 µg/ml or 0.5 – 1
mM) caused an increase in the transformation efficiency (Keshava et al., 2001). From the
epidemiological studies it can be speculated that beryllium is hazardous when inhaled at high
dosage. The studies indicating the carcinogenic role of beryllium has been mostly centered on the
use of beryllium metal. It was observed that beryllium when inhaled in the form of beryllium
metal or beryllium oxide caused lung cancer in rodents (Gordon and Bowser, 2003). However
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there is no evidence to suggest that beryllium in form of salt could be a potentially strong
carcinogen.
The probable carcinogenic role of particulate beryllium cannot undermine the potential of
beryllium salt as a potent GSK-3β inhibitor. In our study we have used beryllium in the form of
BeSO4.4H2O and investigated the intracellular effects of beryllium treatment at molecular level in
different cell lines. The focus of this study was to investigate beryllium as a biologically relevant
GSK-3β inhibitor. We also tried to understand the inhibitory mechanisms that play an important
role in the beryllium induced inhibition of GSK-3β.

29

CHAPTER 3

Dose Response Curve – survey of different cell lines to analyze their sensitivity towards
BeSO4
Introduction
The aim of this study is to analyze and document the cytostatic/cytotoxic effects of Be2+ on
different mammalian cell lines. Cell lines selected for this study were cultured in media
supplemented with Be2+ in the form of BeSO4.4H2O. It is imperative to have prior knowledge
about the behavior of different cell lines when cultured in the presence of beryllium because cell
signaling studies could be highly cell type specific. Having a good idea about the sensitivity of
different cell line towards BeSO4 will help us in selecting the correct cell line. Some cell lines
could be highly sensitive or highly resistant to BeSO4 making them unsuitable for the present
study. It was observed that beryllium caused an increase in the cell division time or doubling time
of HFL-1 cells (human lung fibroblasts) (Absher et al., 1983). Treatment with beryllium seems to
be inducing diametrically opposite effects on cells. Beryllium is known to promote
carcinogenesis (Wagoner at al., 1980) implying that it is capable of inducing unregulated cell
proliferation. It has also been demonstrated that beryllium induces cytostatic effects in the form
of cellular senescence indicating that beryllium can effectively regulate cellular growth (Coates et
al., 2007; Gorjala and Gary, 2010).
In order to analyze the sensitivity of different cell lines towards BeSO4 a “dose response
curve” was obtained. Different mammalian cell lines are cultured in the presence of beryllium salt
over a period of nine days. The cell numbers are monitored on day3, 6 or 9. The effect of
beryllium on the survival of mammalian cells can be quantified form the cell counting experiment

30

(DRC curves). This survey includes the dose response curve data of 8 different mammalian cell
lines. This survey will provide an insight into the senstivity of mammalian cells towards BeSO4.

Materials and methods
Cell lines
Cell lines B35, C6, Caki-1, IMR 32, NIH/3T3, MCF-7, T47D were purchased from ATCC
(Manassas, VA). The SF539 cell line was purchased from National Cancer Institute.
Cell culture media
RPMI 1640 HEPES (cat#23400-021, Gibco) supplemented with 10% fetal bovine serum
(FBS) and 1x antibiotic-mycotic was used for culturing B 35, C6, Caki-1, IMR 32 and SF539 cell
lines. Only for NIH/3T3 cells, RPMI 1640 was supplemented with 10% bovine growth serum
(BGS) instead of FBS. For MCF-7 and T47D cell line the RPMI 1640 was supplemeted with
growth factors – 344.3 pM insulin and 1 nM β-estradiol.
Dose response curve - cell counting
Cells were cultured in 60 mm CELLSTAR cell culture dishes (cat 664 160) at 37 C using a
5% CO2 incubator. Cells were dosed with culture media supplemented with appropriate
concentrations of BeSO4 and the dosing day was counted as Day 0. On Day 3 the cells were
collected by trypsinization using 0.5 ml trypsin (0.05% Trypsin-EDTA). The cells were collected
by adding 2.5 ml of RPMI (3.5 ml RPMI + 0.5 ml trypsin = total 3 ml cell suspension). Cells
were counted using a cell counter .0.5 ml of the total cell suspension from day 3 was added to a
new 60 mm culture dish. The cells were allowed to grow till day 6 and were trypsinized again,
counted in a manner similar to day 3. 0.5 ml of cells from the total 3 ml cell suspension from day
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6 was added to a new 60 mm dish. The process was repeated again on Day 9 with the exception
that the cells were discarded instead of re seeding.
Note: Cells have to be seeded in the range of 1.5–2.0 x 106 cells/100 mm dish to obtain sub
confluency (50-60%) after approximately 12 hr incubation
Data analysis
The day 3, day 6 and day 9 cell counts were fitted onto a plot using non-linear regression.
The effect of BeSO4 on the different cell lines was represented as % of control (untreated cells) on
the y-axis and the log values of BeSO4 concentration on the x-axis. GraphPad Prism v6.0c (Mac
OS) was used for curve fitting and calculating IC50 values.

Results
Beryllium in the form of BeSO4.4H2O was used at concentrations ranging from 0, 0.3, 1, 3, 5,
10, 30, 100, 300, 500, 1000 or 3000 µM. The IC50 values were calculated using the day 6 data.
The day 3 and day 9 DRC data was not used for calculating the IC50 values because the beryllium
resistant cell lines may not show optimum response by day 3. The 9 day BeSO4 treatment could
be extremely stringent on the BeSO4 sensitive cell lines hence the day 6 data was used to calculate
the IC50 values.The results in Fig. 1a, Fig. 1b and Fig. 1c demonstrates that all cell lines do not
respond uniformly to BeSO4. Some of the cell lines are sensitive to beryllium while others are
resistant. The results have been summarized in table 4.
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Fig. 1a Day 3 dose response curve. Each curve represents the response of individual cell lines to
concentrations of BeSO4 ranging from 0 – 3000 µM on day 3. The day 3 data was not used for
calculating the IC50 values because the cyto toxic effect of BeSO4 may not manifest correctly at a
short exposure time i.e. day 3, especially for BeSO4 resistant cells lines.

33

Fig. 1b Day 6 dose response curve. Each curve represents the response of individual cell lines to
concentrations of BeSO4 ranging from 0 – 3000 µM on day 6. The day 6 data was used to
calculate the IC50 values. Day 6 data was selected because by day 6 the cells are not under
exposed nor over exposed to the inhibitory cytotoxic/cytostatic effects of BeSO4.
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Fig. 1c Day 9 dose response curve. Each curve represents the response individual cell lines to
concentrations of BeSO4 ranging from 0 – 3000 µM on day 9. The possibility of cells being over
exposed to BeSO4 might interfere with the correct IC50 calculation. The day 9 data was not used to
calculate the IC50 values.
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Table 4. IC50 values of BeSO4 for different cell lines

Cell Line

IC50
value
(µM BeSO4)

1

B 35

34.50

2

C6

5.27

3

Caki-1

4.93

4

IMR 32

37.94

5

MCF-7

136.1

6

NIH/3T3

7.59

7

T47D

190.9

8

SF 539

2.9
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Discussion
The DRC analysis clearly shows that not all cell lines respond uniformly to BeSO4. In this
study the T47D cell line was found to be the most resistant to BeSO4 followed by MCF-7, IMR
32 and B35. SF539 was found to be the most sensitive towards BeSO4 followed by C6, Caki-1
and NIH/3T3. In order to investigate the intra cellular effects of beryllium on mammalian cells it
is essential to choose a cell line that is not too resistant to the beryllium salt. If a cell line is too
resistant to beryllium treatment then it could be possible that the particular cell type may not be a
good system to study the beryllium induced intra cellular effects. If a cell line is too sensitive to
beryllium salt treatment then it would be difficult to recover sufficient number of viable cells
after Be2+ treatment for further processing (for example – generating western samples). Hence cell
lines that can fairly tolerate beryllium treatment are usually selected for further studies.
We have included cell lines of different lineages in our survey Table 4 & 5. It is observed that
cell lines of mammary lineage (MCF-7&T47D) seems to be resistant to higher concentration of
beryllium salt with an IC50 value range of approximately 150 µM (Table 4). In an independent
study it was observed that RKO cells (human colon carcinoma) were found to be resistant to
higher concentrations of beryllium with an IC50 value of 440 µM (Gorjala, 2012).
GSK-3β plays an important role in the regulation of microtubule associated neuronal protein
tau. Tau protein is involved in several functions associated with neurons (Liu et al., 1999; Avila
et al., 2004; Fuster-Matanzo et al., 2009) GSK-3β induces phosphorylation of tau protein that
resembles the Alzhemer’s disease-like induced tau-phosphorylation (Hanger et al., 1992; Yang et
al., 1993; Woods et al., 2001). Tau protein seems to be playing an important role in cell lines that
are of neuronal lineage. Hence we included neuronal cell lines like B35, C6, IMR-32 and SF-539
in our study for potential use in future work related to GSK-3β-tau protein. It was observed that
the neuronal cell lines can tolerate optimum concentration of BeSO4 (IC50 values 3 – 30 µM).
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Independently it was also observed that additional neuronal cell lines A172 and U87MG (Gorjala,
2012) also showed a similar trend in their response to beryllium treatment as observed in our
study.
It can be summarized that cell lines of mammary and colorectal lineage included in our study
seems to be resistant to concentrations higher than 100 µM of BeSO4. The lone cell line
representing the human kidney cells were found to be sensitive to BeSO4 (IC50 = 4.93 µM).
However cell lines representing neuronal lineage seem to be respond to a range of different
concentrations of BeSO4 For example SF-539 was found to be very sensitive to Be2+ treatment
(IC50 = 2.9 µM). However, most of the other neuronal cell lines like C6, A172 and U87MG were
found to be responsive to optimum concentrations of BeSO4 (approx 10 µM).
The rate of BeSO4 uptake by these cell lines could be one of the possible reasons for their
differential sensitivity towards BeSO4. ICP MS analysis could provide an idea as to which cell
lines fail to uptake BeSO4 from the surrounding media.
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Table 5 General information about cell lines used in this study (www.atcc.org)

S.
No
1

Cell
Line
B35

ATCC info

Species

Origin, Type

TP53 status

Refrences

CRL-2754

Rattus
norvegicus

Neuronal,
neuroblast

NA

NA

2

Caki-1

HTB-46

Homo
sapiens

Kidney, clear Wild type
cell carcinoma

Jia et
1997.

3

C6

CCL-107

Rattus
norvegicus

Neuronal,
glioma

Wild type

Asai et al.,
1994.

4

IMR-32

CCL-127

Homo
sapiens

Neuronal,
neuroblast

Wild type

NA

5

MCF-7

HTB-22

Homo
sapiens

Breast,
Wild type
adenocarcinoma

Wasielewski
et al., 2006.

6

T-47D

HTB-133

Homo
sapiens

Mutated

Nigro et al.,
1989.

7

NIH/3T3

CRL-1658

Mus
musculus

Breast,
Ductal
carcinoma
Embryo,
fibroblast

8

SF539

NCI-60
line*

cell Homo
sapiens

Neuronal,
Glioma

Mutated

Forbes
et
al., 2010.

9

A172

CRL-1620

Homo
sapiens

Neuronal,
Glioma

Wild type

Mirzayans et
al., 2005

10

U87MG

HTB-14

Homo
sapiens

Neuronal,
Glioma

Wild type

Van Meir et
al., 1994.

11

HFL-1

CCL-153

Homo
sapiens

Fetus lung,
fibroblast

NA

NA
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CHAPTER 4

Beryllium a potent GSK-3β inhibitor
Introduction
Beryllium (Be2+) is a metal cation inhibitor of GSK-3β. The other metal ions which are
included under this group are lithium (Li+) and zinc (Zn2+). Lithium is the most well characterized
metal cation inhibitor of GSK-3β, which mimics both insulin (Cheng et al., 1983; Bosch et al.,
1986; Woo et al., 2000) and Wnt ligands (Stambolic et al., 1996; Klein and Melton, 1996;
Hedgepeth et al., 1997). The effects of lithium treatment on GSK-3β at molecular level and the
underlying inhibitory mechanisms have been studied by different research groups. Some of the
important points related to lithium’s role as GSK-3β inhibitor can be summarized as follows:


Li+ treatment leads to an increase in the inhibitory Ser-9 phosphorylation of GSK-3β (Zhang et
al., 2003).



Li+ mimics Wnt ligands and activates the Wnt signaling pathway (Stambolic et al., 1996;
Hedgepeth et al., 1997).



Ryves and Hartwood reported that Li+ competes with Mg2+ ions for the Mg2+- binding sites of
GSK-3β enzyme.



Li+ mimics the GSK-3β-inhibitory action of both insulin and Wnt ligands (Cheng et al. 1983;
Bosch et al. 1986; Woo et al. 2000; Stambolic et al., 1996)
Li+ is a well characterized GSK-3β inhibitor with a Ki value of 2 mM (Klein and Melton,
1996). Li+ is a fairly specific inhibitor of GSK-3β but it also inhibits other kinases (explained in
Table. 3). Be2+ is a GSK-3β inhibitor eliciting its GSK-3β - inhibitory action at a much lower
concentration compared to the Ki value of Li+ (Mudireddy et al., 2014). The IC50 value of Be2+ is 6
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µM, which is much lower than the IC50 value of Li+ required for GSK-3β inhibition (Ryves et al.,
2002). This preliminary study is to investigate whether Be2+ is a better and potent GSK-3β
inhibitor compared to the other metal ion Li+.
There is a great deal of information explaining the role/mechanism of Li + as a GSK-3β
inhibitor but not much is known about Be2+. Except for the information that Be2+ competes for
both Mg2+ and ATP binding sites on GSK-3β nothing much is known about its inhibitory effects
on GSK-3β. There are many unanswered questions about beryllium’s role as a potent GSK-3β
inhibitor.


Can beryllium inhibit the activity of GSK-3β?



How potent/efficient is beryllium compared to lithium in terms of GSK-3β inhibition?



Is beryllium a specific GSK-3β inhibitor?



What could be the underlying inhibitory mechanism behind beryllium induced inhibition
of GSK-3β?

In this study we investigated the effect of Be2+ on the kinase activity of pure recombinant
GSK-3β enzyme in vitro. In this study we also analyzed the effect of Be2+ on treated cells and
emphasis was laid to investigate the effect of Be2+ on the viability of cells compared to Li+.
As explained in the Chapter 2, Ser-9 phosphorylation of GSK-3β plays an important role in
its regulation. We investigated whether Be2+ can regulate the Ser-9 phosphorylation of GSK-3β.
Independently, the effect of Be2+ on endogenous GSK-3β was also analyzed as part of this
research project (Mudireddy et al., 2014) but is not part of the thesis.
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Materials and methods
Cell culture
HFL-1 (human lung fibroblast) and A172 (human glioblastoma) cells were obtained from
ATCC (Manassas VA). Cells were grown in RPMI 1640 supplemented with 25 mM HEPES,
10

FBS, and 1x antibiotic-antimycotic (Invitrogen-Gibco) at 37 C in 5% CO2. HEPES was

included as an auxiliary buffering agent.
Cell viability assay
ApoToxGlo Triplex assay (Promega-cat#G6321, lot# 32439) was used to assess the cellular
protease activity in cultured cells. This assay simultaneously measures the activity of two cellular
proteases generically called as the live cell protease and the dead cell protease. The live cell
protease activity is present only in the intact viable cells and is measured using a fluorogenic,
cell-permeant, peptide substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC). The cellpermeant substrate enters the live intact cells where it is acted upon and cleaved by the live cell
protease. The cleaved cell-permeant substrate generates a fluorescent signal proportional to the
number of live cells. The other substrate in the assay is a fluorogenic cell-impermeant peptide
substrate (bis-alanylalanyl-rhodamine 110; bis-AAF-R110). This cell-impermeant substrate is
inaccessible to the live cell protease. The live cell protease becomes inactive upon loss of
membrane integrity and leaks into the culture medium. The dead cell protease acts upon the
second fluorogenic substrate and generates a fluorescent signal, which is different from the live
cell signal. The live cell and dead cell proteases produce different fluorogenic products, AFC and
R110 respectively. These products have different excitation and emission spectra allowing them
to be detected simultaneously (Niles et al., 2007). A172 cells were cultured in the presence of
different concentrations of beryllium and lithium for 24, 48 and 72 hr. The cells were initially
cultured in 60 mm culture dishes and were trypsinized, counted and reseeded into 384 well plates
42

at 5000 cell/well. Proper care was taken to ensure that cells are under the influence of appropriate
concentrations of the inhibitors for the above mentioned treatment periods. After the conclusion
of the treatment time i.e at 24, 48 or 72 hr, the substrates from the ApoToxGlo Triplex (Promega)
was added to the cells in the 384 well plates. The plate was then incubated for 30 min at 37 C.
The live cell (ex 400 nm, em 505 nm) and dead cell fluorescence (ex 485 nm, em 520 nm) was
measured using a Tecan M1000 plate reader.
FRET based assay for analyzing in vitro kinase activity of enzymes
The z-Lyte is a FRET based biochemical assay that can be used to analyze the kinase activity
of different enzymes. The assay kit provides customized substrate peptides that can be
phoshorylated by the candidate enzyme whose kinase activity is to be tested. The z-lyte assay will
be used to analyze the effect of BeSO4 and LiCl on the activity of pure recombinant proteins GSK-3β and PKA.
z-Lyte FRET assay principle:
The z-Lyte Ser/Thr peptide #9 (#PV3324) {sequence derived from glycogen synthase I
(PRPASVPP(pS)P(pS) and the z-Lyte Ser/Thr peptide #1 (#PV3174) {sequence derived from
porcine pyruvate liver kinase (LRRASLG)} were used as substrates for GSK-3β and PKA
respectively. The peptide substrates are labeled with two fluorophores one at each end, which act
as a FRET pair. In this case the peptide substrates are labeled with methyl coumarin (FRET
donor) at one end and fluorescein (FRET acceptor) on the other end. The substrate peptides
phosphorylated at the designated Ser residues will be immune to the peptide-cleavage activity of
site-specific protease used in this assay. The substrate peptides phosphorylated at the designated
Ser residues will not be cleaved and maintain the FRET pair thereby emitting a detectable
fluorescence signal. Conversely the un-phosphorylated peptide substrate will be cleaved resulting
in the loss of the FRET pair (loss of fluorescence signal as well)
43

Pure recombinant GSK-3β and PKA were used in the kinase assay at a final concentration of
1 ng/reaction in order to maintain the final or over all phosphorylation capacity of the enzyme at
50% rather than 100% (this was done avoid the saturation of enzyme activity). It is important to
prepare the inhibitors in the kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA,
0.01% BRIJ-35, 100 µM ATP) only. The enzyme (1 ng/reaction) and the substrate peptides (2
µM – final concentration) were incubated for 60 min at 25 C in a reaction volume of 20 µL. The
kinase reaction was terminated by adding the development reagent A (site specific protease) and
incubating the reaction mix for 60 min at 25 C, followed by the addition of the stop solution. The
reaction mix is then transferred to a 96 well plate and the fluorescence is measured using Tecan
M1000 platereader (coumarin fluorescence - ex 400 nm, em 445 nm) and fluorescein florescence
- ex 400 nm, em 520 nm).
In the control samples (no inhibitors) the FRET pair will be intact because of the ability of the
enzyme to phosphorylate the peptide substrates and shield them from the proteolytic activity of
development solution A. The fluorescence values are expected to be higher for the control
samples. If the inhibitors (BeSO4 and LiCl) are successful in inhibiting the kinase activity of the
candidate enzyme then the phosphorylation of the substrate peptide will be hampered. The
unphosphorylated or under phosphorylated substrate peptides will be cleaved by the development
reagent A. The cleavage of the substrate peptides results in the loss of the FRET pair that will
eventually be translated in the form of low fluorescence signal values.
To validate the FRET-kinase assay, the effect of H-89 a PKA specific inhibitor was analyzed
on purified recombinant GSK-3β and PKA enzymes.
Important precautions for z-Lyte assay:
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In order to maintain the phosphorylation levels at 50% the final enzyme concentration
has to be approximately 1ng/reaction. (enzyme efficiency keeps decreasing with multiple
thawing cycles).



The BeSO4 and LiCl stocks should always be prepared in the kinase buffer instead of any
other solvent for best results.

/

Emission ratio = Coumarin Emission (445 nm) Fluorescein Emission (520 nm)

The % of phosphorylation was calculated by using the formula provided in the assay kit protocol
(Invitrogen #PV3324).

/

% Phosphorylation = 1- {(Emission Ratio * F100%) – C100%} {(C0% - C100%) + [Emission Ratio
*(F100% - F0%)]}

Emission Ratio =

Coumarin/Fluorescein ratio of sample wells

C100%

=

Average Coumarin emission signal of the 100% Phos. Control

C0%

=

Average Coumarin emission signal of the 0% Phos. Control

F100%

=

Average Fluorescein emission signal of the 100% Phos. Control

F0%

=

Average Fluorescein emission signal of the 0% Phos. Control

Western blotting
Cells were cultured in 100 mm CELLSTAR cell culture dishes (cat#664 160). Total cell
lysates were prepared from A172 and HFL-1 cells treated with BeSO4.4H2O (lot&filling code:
413015/1 22001, Fluka) and LiCl (L-8895, Lot#22K0184, sigma) for 24 and 48 hr. MPER buffer
(Prod#78501, thermo scientific) was used for protein extraction. The MPER buffer was
supplemented with protease inhibitor (halt protease inhibitor cocktail kit, Pierce cat#78442) and
phosphatase inhibitors (sodium fluoride - 20 mM, beta glycerol phosphate - 10 mM, sodium ortho
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vanadate - 0.1 mM, paranitro phenyl phosphate - 20 mM and 1X EDTA). Protein concentration
was measured by BCA assay (Thermo scientific, #23227) and the protein samples were
normalized. Samples were run either on 10% SDS PAGE gel or 4-12% gradient SDS-PAGE gels
(ref#WG1402BX10 from Novex-life technologies) and transferred onto a PVDF membrane 0.2
µm pore size (Millipore cat#IPFL20200; Bio-Rad. cat#162-0255). Post transfer the membranes
were blocked in 10% milk or starting block TBS (Prod#37543, thermo scientific - when probing
with phospho antibodies). The post transfer and blocked PVDF membranes were probed with the
following primary antibodies separately: anti GSK-3α/β mouse monoclonal (cat#368662, clone
1H8, EMD Calbiochem), phospho-GSK-3β (Ser-9) affinity purified rabbit polyclonal antibody
(cat#9336, Cell Signaling Technologies), phospho-GSK-3β (Ser-9) affinity purified mouse
monoclonal antibody (cat#361527, clone 2D3, EMD-Calbiochem), p53 mouse monoclonal
(cat#sc-126, clone DO1, Santa Cruz Biotechnology, actin goat polyclonal (cat#1615, Santa Cruz
Biotechnology). Blots were incubated with the appropriate HRP conjugated secondary antibodies,
developed with ECL-Plus (GE Healthcare Life Sciences), and imaged using a GE Typhoon 9410
Variable Mode Imager.
Antibody information
phospho GSK-3β (2D3) (Ser-9): Mouse monoclonal (#361527, EMD-Calbiochem) and goat
anti-mouse IgG peroxidase (cat#A9917 Sigma Aldrich)
Total GSK-3α/β (1H8): Mouse monoclonal IgG2b (cat#sc-368662, EMB – Calbiochem) and
goat anti-mouse IgG peroxidase (cat#A9917, Sigma Aldrich)
p53 DO1: Mouse monoclonal IgG2b (cat#sc-126 Santa Cruz Biotechnology, inc) and goat
anti-mouse IgG peroxidase (cat#A9917, Sigma Aldrich)
Actin: Goat monoclonal IgG2b (cat#sc-1615 Santa Cruz Biotechnology, inc) and bovine antigoat IgG-HRP (cat#sc-2350, Santa Cruz Biotechnology, inc)
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TR-FRET assay for quantifying the pSer-9 of GSK-3β
BacMam-enabled lantha screen cellular assay is an efficient tool to analyze the post
translational modification of proteins. The LanthaScreen BacMam assay system (Invitrogen - life
technologies) combines two powerful techniques to generate reliable fluorescence data with
minimized background. It consists of different components - a modified baculo virus capable of
infecting mammalian cells and a terbium (Tb) labeled antibody system. The modified bacculo
virus acts a vector to accomplish the successful expression of a fusion protein (Green Fluorescent
Protein + protein of interest) in the host cells. After the successful transduction of the host cells
they are treated with the inhibitors or stimulators for a specific period of time. After the treatment
cells are lysed and fresh cell lysates are probed with the Tb antibody specific for the post
translational modification of the candidate protein (fusion protein).
In this study the LanthaScreen BacMam reagent (part#PM4355A0, lot#E0272-43882,
Invitrogen - life technologies) was used to introduce a GFP-GSK-3β fusion protein (Green
Fluorescent Protein–GSK-3β) into A172 cells. The fusion protein contains the GFP on the Nterminus, and the full length GSK-3β on the C-terminal side. The GFP and the GSK-3β are
connected by a short linker. The successful transduction of the A172 cells with the BacMam virus
can be confirmed by the expression of GFP. The transformed A172 cells numbering 40,000 each
were then transferred to each well in a 384 well plate and cultured in the RPMI supplemented
with BeSO4 or LiCl for 24 hr. After the completion of the treatment time, cells were lysed using
the LanthaScreen cellular assay lysis buffer (PM4355X, lot#MSN1143-086) supplemented with
3 nM of the Tb-conjugated anti-pSer9 GSK-3β antibody (PM4312AV, lot#MSN1023-183-3).
Tecan M1000 plate reader was used to record the Tb fluorescence (ex 332 nm, em 485) and GFP
fluorescence (ex 395 nm, em 515 nm). Phosphorylation was reported as ((515 nm/485 nm)/GFP
Fluorescence)*100000.
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In the BacMam-enabled lantha screen cellular assay the GFP-GSK-3β fusion protein acts as
the substrate for the action of BesO4 or LiCl. The Ser-9 phosphorylation of the GSK-3β in the
fusion protein is assessed by using a Tb-conjugated anti-pSer9 GSK-3β antibody. The binding of
the terbium labeled anti- pSer9GSK-3β antibody to the substrate (fusion protein) brings the
terbium close enough to the GFP to support the formation of a successful TR-FRET pair (Time
Resolved Fluorescence Energy Resonance Transfer). Terbium and GFP forms an effective TRFRET pair (David Comley, 2006) which has the added advantage of minimizing the background
fluorescence interference. In this assay the increase in the Ser-9 phosphorylation of the GFPGSK-3β fusion protein will in turn lead to the formation of abundant TR-FRET pairs. More the
number of successful TR-FRET pairs the higher would be the fluorescence signal and it indicates
that in the presence of a specific inhibitor at a particular concentration an increase in the pSer9GSK-3β is observed.
Flow cytometry
Cells were treated with BeSO4 and LiCl for 24 hr. After the treatment period, cells were
collected by trypsinization, washed with PBS and fixed with 4% formal dehyde. Cells were then
permeabilized with methanol. Cells were blocked with starting block TBS (prod#37543, thermo
scientific), supplemented with halt protease and phosphatase inhibitor cocktail (Pierce
cat#78442). Fixed and blocked cells were then incubated with pSer9-GSK-3β rabbit monoclonal
antibody (clone D85E12, cat#5558, Cell Signaling Technology) over night at 4 C, followed by
FITC conjugated goat anti-rabbit secondary antibody (cat#sc-2012, Santa Cruz Biotechnology) at
0.5 µg/1 x 106 cells. Cells were run on a BD FACSCalibur flow cytometer collecting 20,000
events per sample each time. Post data collection the FITC channel fluorescence intensity was
analyzed using CellQuest Pro Software.
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Microscopy
Nikon Inverted Microscope Eclipse TE2000-U (dia-illuminator 100W) was used to capture
bright field images of A172 cells treated with different concentrations of BeSO4 and LiCl.
Data analysis
GraphPad Prism v6 (Mac OS) was used for curve fitting, calculating IC50, performing twotailed t-test (unpaired) with P < 0.05 considered as significant. For data sets involving two or
more groups per treatment; the data was analyzed using one-way ANOVA (P < 0.05 considered
significant) with post Tukey’s multiple comparision test.

Results
BeSO4 inhibits the kinase activity of purified recombinant GSK-3β in vitro
The Z-Lyte assay, which is a FRET-based kinase assay was used to assess the activity of
GSK-3β. Purified recombinant GSK-3β enzyme was used in the assay along with the appropriate
assay buffers. A synthetic peptide was used as the substrate, which has the coumarin and
fluorescein labels conjugated to its ends. The reaction mix was spiked with different
concentrations of BeSO4 (µM) or LiCl (mM). The effect of the inhibitors on the kinase activity of
GSK-3β was analyzed by monitoring the FRET signal intensity. The activity of the pure
recombinant GSK-3β is directly correlated to the FRET signal. Inhibition of GSK-3β leads to
decrease in the FRET signal as well. It is observed that with increasing concentration of Be 2+ and
Li+, the activity of pure recombinant GSK-3β is decreasing (Fig. 2a&2b) and it is translated in the
form of lower fluorescence signal. It is also observed that Be2+ is a much more potent GSK-3β
inhibitor compared to Li+. BeSO4 being effective in micromolar concentrations range compared to
the effective range of LiCl which is in millimolars. From the in vitro FRET kinase assay the IC50
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values were calculated as follows; BeSO4 IC50 = 2 µM, LiCl IC50 = 12 mM. The in vitro FRET
kinase assay demonstrates that Be2+ inhibits the activity of purified recombinant GSK-3β enzyme
and is much more effective than the other established GSK-3β inhibitor Li+.
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Fig. 2a Effect of beryllium on the in vitro kinase activity of GSK-3β. Pure recombinant GSK3β enzyme activity was measured using the FRET-based fluorescence assay. The activity of pure
recombinant GSK-3β in the absence of inhibitors (control) or in the presence of 0.3, 1, 3, 10, 30,
100, 300 µM BeSO4 was measured. Enzyme activity is measured as formation of the
phosphorylated peptide product (mean +/- SD). Data was analyzed using one-way ANOVA (P <
0.05 considered significant compared to control) by Tukey’s multiple comparison test. GraphPad
Prism trial version 6.0 for Mac OS X, GraphPad Software, La Jolla California USA,
www.graphpad.com. (ns = non significant compared to the control, * = P ≤ 0.05, ** = P ≤ 0.01,
*** = P ≤ 0.001, **** = P ≤ 0.0001). For Be2+ the IC50 = 2 µM.
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Fig. 2b Effect of lithium on the in vitro kinase activity of GSK-3β. Pure recombinant GSK-3β
enzyme activity was measured using the FRET-based fluorescence assay. The activity of pure
recombinant GSK-3β in the absence of inhibitors (control) or in the presence of 1, 3, 10, 30, 100,
300 mM LiCl was measured. Enzyme activity is measured as formation of the phosphorylated
peptide product (mean +/- SD). Data was analyzed using one-way ANOVA (P < 0.05 considered
significant compared to control) by Tukey’s multiple comparison test. GraphPad Prism trial
version 6.0 for Mac OS X, GraphPad Software, La Jolla California USA, www.graphpad.com
was used. (ns = non significant compared to control, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤
0.001, **** = P ≤ 0.0001). For Li+, IC50 = 12 mM.
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Specificity of Be2+ towards other kinases
To analyze whether Be2+ is a specific GSK-3β inhibitor, another kinase i.e. protein kinase A
(PKA) was chosen for the FRET-based kinase assay. Li+ is a fairly specific GSK-3β inhibitor,
which supposedly has no inhibitory effect towards PKA enzyme (Klein and Melton, 1996). In the
presence of BeSO4 a decrease in the in vitro kinase activity of PKA is observed (Fig. 3a). On the
other hand the kinase activity of PKA remains fairly constant in the presence of LiCl at lower
concentrations 1-30 mM (Fig. 3b).
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Fig. 3a Effect of Be2+ on the in vitro kinase activity of protein kinsae A (PKA). In vitro PKA
activity was measured by the FRET-based kinase assay in the absence (control) presence of 0.3,
1, 3, 10, 30, 100 or 300 µM of BeSO4. Data was analyzed using one-way ANOVA (P < 0.05
considered significant) by Tukey’s multiple comparison test. GraphPad Prism trial version 6.0 for
Mac OS X, GraphPad Software, La Jolla California USA, www.graphpad.com was used. (ns =
non significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
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Fig. 3b Effect of Li+ on the in vitro kinase activity of protein kinsae A (PKA). In vitro PKA
activity was measured by the FRET-based kinase assay in the absence (control) presence of 1, 3,
10, 30, 100 or 300 mM of LiCl. Data was analyzed using one-way ANOVA (P < 0.05 considered
significant) by Tukey’s multiple comparison test. GraphPad Prism trial version 6.0 for Mac OS
X, GraphPad Software, La Jolla California USA, www.graphpad.com was used. (ns = non
significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
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Effect of Be2+ and Li+ on the viability of cells
Use of BeSO4 and LiCl in culture media is bound to produce physiological and morphological
effects on mammalian cells especially at higher concentrations. An important observation has
been the induction of cellular senescence by BeSO4 at concentrations as low as 10 µM (Gorjala
and Gary, 2010) We wished to investigate the effect of BeSO4 and LiCl on the viability and
growth of cells. In order to analyze the effect of Be2+ - Li+ treatment on the viability of cells, A172
cells were cultured in the presence of BeSO4 and LiCl for 24, 48 or 72 hr. The effect of inhibitors
on the viability of cells was analyzed using a live cell protease based fluorescence assay. The
viability assay shows that beryllium does not have any major impact on the viability of A172 cells
even at concentrations higher than its IC50 of GSK-3β (Fig. 4). Lithium caused a significant
decrease in the number of viable cells at 24 hr; when used at a concentration of 30 mM or
more.When treated with 10-100 µM BesO4 for 24 hr no major morphological changes were
observed in A172 cells (appendix II, Fig. 2.1). For LiCl treatment, a concentration above 20 mM
produced a marked decrease in the number of viable cells (Fig. 4). Morphologically as well A172
cells treated with 20 mM or higher concentrations of LiCl look very unhealthy (appendix II, Fig.
2.2)
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Fig. 4a Effect of BeSO4 and LiCl treatment on cells viability at 24 hr. A172 cells were treated
with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 24 hr. Cell viability was
assessed using a fluorogenic substrate that can be cleaved by a protease associated with intact
viable cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using oneway ANOVA (P < 0.05 considered significantly different from control) by Tukey’s multiple
comparison test. GraphPad Prism trial version 6.0 for Mac OS X, GraphPad Software, La Jolla
California USA, www.graphpad.com was used. (ns = non significant compared to the control, * =
P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
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Fig. 4b Effect of BeSO4 and LiCl treatment on cells viability at 48 hr. A172 cells were treated
with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 48 hr. Cell viability was
assessed using a fluorogenic substrate that can be cleaved by a protease associated with intact
viable cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using oneway ANOVA (P < 0.05 considered significantly different from control) by Tukey’s multiple
comparison test. GraphPad Prism trial version 6.0 for Mac OS X, GraphPad Software, La Jolla
California USA, www.graphpad.com was used. (ns = non significant compared to the control, * =
P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
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Fig. 4c Effect of BeSO4 and LiCl treatment on cells viability at 72 hr. A172 cells were treated
with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 72 hr. Cell viability was
assessed using a fluorogenic substrate that can be cleaved by a protease associated with intact
viable cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using oneway ANOVA (P < 0.05 considered significantly different from control) by Tukey’s multiple
comparison test. GraphPad Prism trial version 6.0 for Mac OS X, GraphPad Software, La Jolla
California USA, www.graphpad.com was used. (ns = non significant compared to the control, * =
P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
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Beryllium has little effect on the Ser-9 phosphorylation of GSK-3β
Autoregulation of GSK-3β by the inhibitory Ser-9 phosphorylation is an important
mechanism by which it is regulated (Frame et al., 2001; Dajani et al., 2001). Lithium treatment
leads to an increase in the Ser-9 phosphorylation of GSK-3β (Zhang et al., 2003). In order to
investigate the effect of beryllium on the Ser-9 phosphorylation of GSK-3β A172 and HFL cells
were cultured in different concentrations of BeSO4 and LiCl for 24 or 48 hr. Phosphorylation of
GSK-3β at Ser-9 was assessed by western blotting using a phosphospecific affinity-purified
rabbit polyclonal and a phosphospecific mouse monoclonal antibody. Li+ treatment caused an
increase in the Ser-9 phosphorylation of GSK-3β in both A172 (Fig. 5a, b; lane–6, 7, 8) and HFL
cells (Fig. 5c, d; lane-6, 7, 8). Fig. 5a, b The Li+ treatment induced increase in the Ser-9
phosphorylation was observed in the 24 & 48 hr samples. However, Be2+ treatment did not elicit
any drastic change in the Ser-9 phosphorylation of GSK-3β in A172 (Fig. 5a, b; lane–2, 3,4) or
HFL cells (Fig. 5c, d; lane-3, 4, 5) at 24 or 48 hr. To rule out the possibility that the lack of
increase in the Ser-9 phosphorylation of GSK-3β is not due to the failure of Be2+ treatment, the
levels of p53 were assessed in the same samples. Beryllium treatment is known to cause an
increase in the levels of p53 (Coates et al., 2007; Gorjala and Gary, 2010). As expected Be2+
treatment caused an increase in the level of p53 (Fig. 5a-d), thus the p53 western serves as a
positive control for Be2+ induced upregulation of protein expression. The total GSK-3α and GSK3β levels remained constant in the A172 and HFL cells indicating that the Li+ induced increase in
the Ser-9 phosphorylation of GSK-3β is not due to the increase in the total GSK-3β levels (Fig.
5a-d). Actin serves as a loading control (Fig. 5a-d).
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Fig. 5 Li+ treatment caused an increase in the Ser-9 phosphorylation of GSK-3β and Be2+
does not. The protein levels of total GSK-3α/β, GSK-3β phosphorylated at Ser-9 (using two
different antibodies), p53 and actin were assessed via western blotting. A172 cells were treated
with 0, 10, 30, or 100 µM BeSO4 or 0, 10, 20 or 30 mM LiCl. A172 cells - (a) 24 hr or (b) 48 hr;
HFL cells – (c) hr or (d) 48 hr.
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Quantitative analysis of the Ser-9 phosphorylation of GSK-3β
Li+ is a monovalent metal cation inhibitor of GSK-3β competing for its Mg2+ binding site
(Ryves and Harwood, 2001) and also leads to an increase in the inhibitory Ser-9 phosphorylation
at physiologically relevant concentrations. Be2+ too is a metal cation inhibitor of GSK-3β and we
expected it to have similar effect on the Ser-9 phosphorylation of GSK-3β. On the contrary Be2+
when used at physiologically relevant concentrations did not induce any appreciable change
(increase) in the Ser-9 phosphorylation of GSK-3β as observed in the western blotting
experiments (Fig. 5). As an alternate approach a TR-FRET based assay and flow cytometry
analysis was used to study the effect of Be2+ and Li+ on the Ser-9 phosphorylation of GSK-3β.
The quantification of the Ser-9 phosphorylation signal from GSK-3β was done via flow
cytometry. A172 cells were fixed using 4% fomalin solution followed by permeabilization and
probed with a flow cytometry specific pSer9-GSK3β antibody. It was observed that Li+ treatment
of A172 cells caused a dose dependent increase in the Ser-9 phosphorylation of GSK-3β. Be2+
treatment had little effect on the Ser-9 phosphorylation of GSK-3β in comparision to Li+ (Fig. 6).
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Fig. 6a Analyzing the effect of Be2+ treatment on the Ser-9 phosphorylation of GSK-3β using
flow cytometry. A172 cells were treated with 0, 10, 30, 100 BeSO4 for 24 hr. The change in the
pSer-9 status of GSK-3β was assessed using a pSer9-GSK3β primary antibody and FITC
conjugated secondary antibody. Each flow cytometry histograms represents the mean
fluorescence per cell value obtained from independent replicates for each inhibitor used at
different concentrations.
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Fig. 6b Analyzing the effect of Li+ treatment on the Ser-9 phosphorylation of GSK-3β using
flow cytometry. A172 cells were treated with 0, 10, 20, 30 mM LiCl for 24 hr. The change in
the pSer-9 status of GSK-3β was assessed using a pSer9-GSK3β primary antibody and FITC
conjugated secondary antibody. Each flow cytometry histograms represents the mean
fluorescence per cell value obtained from independent replicates for each inhibitor used at
different concentrations.
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Table 6. Analysis of mean fluorescence/cell (Ser-9 phosphorylation) at 24 hr

Treatment

Duration

Mean
Fluorescence/Cell
(% of control +/- std dev)

Control

24 hr

100 (+/- 2)

10 µM BeSO4

24 hr

98.9 (+/- 1)

30 µM BeSO4

24 hr

108 (+/- 5)

100 µM BeSO4

24 hr

120 (+/- 8)

10 mM LiCl

24 hr

185 (+/- 12)

20 mM LiCl

24 hr

221 (+/- 8)

30 mM LiCl

24 hr

245 (+/- 25)

Control

48 hr

100 (+/- 2)

10 µM BeSO4

48 hr

102 (+/- 4)

30 µM BeSO4

48 hr

110 (+/- 5)

100 µM BeSO4

48 hr

105(+/- 2)

10 mM LiCl

48 hr

200 (+/- 15)

20 mM LiCl

48 hr

247 (+/- 19)

30 mM LiCl

48 hr

282 (+/- 3)

65

As a final verification the TR-FRET lantha screen based assay was used to quantify the effect
of Be2+ and Li+ on the Ser-9 phosphorylation of GSK-3β. The BacMam virus based transfection
system was used to introduce the GFP-GSK-3β fusion protein into A172 cells. The transfected
cells were treated with BeSO4 and LiCl for 24 hr. Cell lysates obtained from the Be2+ or Li+
treated A172 cells were probed with Tb-conjugated antibody that binds to the GFP-GSK-3β
fusion protein phosphorylated at Ser-9. It leads to the formation of a successful FRET pair with
Tb serving as the FRET donor and GFP acting as the FRET acceptor. The FRET donor and
acceptor are brought together to generate a successful FRET signal because of the binding of Tbconjugated antibody to the pSer9 of GSK-3β. Increase in the Ser-9 phosphorylation of the GSK3β is translated in the form of increase in the FRET signal. Be2+ has no significant effect on the
Ser-9 phosphorylation of GSK-3β (Fig. 7a). Li+ on the other hand caused a concentration
dependent increase in the Ser-9 phosphorylation of GSK-3β (Fig. 7b).
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Fig. 7a Be2+ treatment has no effect on the Ser-9 phosphorylation of GFP-GSK-3β fusion
protein. A172 cells expressing GFP-GSK3β fusion protein were treated with 0, 10, 30 or 100 µM
BeSO4 for 24 hr. The Ser-9 phosphorylation of the GFP-GSK-3β was measured using the TRFRET assay (mean +/- SD). One-way ANOVA with Sidak’s multiple comparisons test was used
to obtain P values comparing the each dosage group with its corresponding control group (P
<0.05 considered as significant; ns - not significant; * - significant).
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Fig. 7b Li+ treatment induces an increase in the Ser-9 phosphorylation of GFP-GSK-3β
fusion protein. A172 cells expressing GFP-GSK3β fusion protein were treated with 0, 10, 20 or
30 mM LiCl for 24 hr. The Ser-9 phosphorylation of the GFP-GSK-3β was measured using the
TR-FRET assay (mean +/- SD). One-way ANOVA with Sidak’s multiple comparisons test was
used to obtain P values comparing the each dosage group with its corresponding control group (P
<0.05 considered as significant; ns - not significant; * - significant).
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Discussion
GSK-3β is an important kinase regulating various signaling pathways. GSK-3β plays a
critical role in cell divison, cell adhesion and apoptosis (Frame and Cohen, 2001; Doble and
Woodgett, 2003; Grimes and Jope, 2001). Many important proteins that are part of the cell cycle
regulation apparatus are putative targets of GSK-3β. p53, p21 CIP1, mdm 2, cyclin D1 are some
of the important GSK-3β-substrates, which plays an important role in cell cycle regulation and
are in turn regulated by GSK-3β (reviewed in Sutherland, 2011). De regulation of GSK-3β has
been associated with many diseases (Grimes and Jope, 2001; Henriksen and Dokken, 2006;
Smalley and Dale, 1999; Peifer and Polakis, 2000). There is considerable interest towards the
development of simple and effective GSK-3β inhibitors for therapeutic purpose and also to
understand the precise role of GSK-β in different signaling pathways.
Be2+ is a cytostatic agent and its cytostatic effects were documented for the first time in an
animal limb regeneration model (Thornton, 1949; Chevremont and Firket, 1951). BeSO4 is known
to elicit cellular senescence at concentrations as low as 10 µM (Coates et al., 2007; Gorjala and
Gary, 2010). Work from our lab shows that Be2+ treatment leads to an increase in the level of p53
and p21 CIP1 (Coates et al., 2007; Gorjala and Gary, 2010; Mudireddy et al., 2014). There is a
strong possibility that the cytostatic effects of Be2+ could be due to the up regulation of cell cycle
regulators like p53 and p21 CIP1. It has been reported that proteins involved in cell cycle
regulation such as p53, p21 CIP1, cyclin D1 and mdm2 are important substrates of GSK-3β
(reviewed in Sutherland, 2011). It could be possible that the cytostatic effects elicited by
beryllium could be partly because of the ability of beryllium to regulate GSK-3β’s activity
towards its putative substrates (cell cycle regulators). GSK-3β is a Mg2+ and ATP dependent
enzyme and it has been reported by Ryves et al that Be2+ could inhibit GSK-3β enzyme by
competing for both the Mg2+ and ATP binding sites (Ryves et al., 2002). The available
information suggests that beryllium could possibly function as an effective GSK-3β inhibitor.
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Historically majority of the research work related to beryllium has been directed towards
establishing its propensity to act as a carcinogen. Beryllium at high concentrations and when
administered via the nasal route could act as a potential carcinogen (Haley et al., 1990; Nikula et
al., 1997; Finch et al., 1998). Moreover beryllium seems to be effective as a carcinogen in rats but
not in other mammalian models such as mice and guinea pigs (Schepers, 1961). The question
whether Be2+ could act as a potential GSK-3β inhibitor was ignored till it was shown that Be2+ in
the form of BeCl2 can inhibit the in vitro kinase activity of GSK-3β (Ryves et al., 2002). We have
used Be2+ in the form of BeSO4.4H2O and demonstrated that it can inhibit the in vitro kinase
activity of the pure recombinant GSK-3β protein (Fig. 2a). In our study we found the IC50 of Be2+
to be ~ 2 µM, which is quite close to the IC50 = 6 µM value reported by Ryves et al. Be2+ was
found to be a potent GSK-3β inhibitor acting at a much lower concentration compared to Li +.
Be2+ was also found to be inhibiting the activity of endogenous GSK-3β activity in A172 and
HFL cells (Mudireddy et al., 2014). The ability of Be2+ to inhibit the activity of GSK-3β at low
concentrations has the added advantage of Be2+ being much less toxic to the cells compared to Li+
at physiologically relevant concentrations (Fig. 4). The low IC50 value of Be2+ combined by its
low cytotoxicity, points to the fact that Be2+ could act as a much more potent and effective GSK3β inhibitor compared to Li+.
To investigate whether Be2+ can inhibit the activity of other related kinases, protein kinase A
(PKA) was selected as a negative control. PKA is closely associated with regulation of GSK-3β
and is known to phosphorylate GSK-3β at the Ser-9 residue (Fang et al., 2000; Li et al., 2000;
Tanji et al., 2002). Hence PKA could serve as a good candidate to investigate the specificity of
beryllium towards other kinases. The effect of Be2+ on the kinase activity of pure recombinant
PKA was analyzed using the FRET- based kinase assay (Fig. 3a). Be2+ seems to be inhibiting the
in vitro kinase activity of purified recombinant PKA protein. Li+ supposedly has no effect on the
kinase activity of PKA (Fig. 3b) at a concentration that is within the range of its GSK-3β-IC50.
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However at high concentrations i.e 100 – 300 mM, Li+ seems to be inhibiting the in vitro kinase
activity of pure recombinant PKA protein (Fig. 3b). To address the specificity of Be2+ towards
other kinases it is necessary to analyze the effect of Be2+ treatment on other closely related
kinases. To provide a comprehensive answer whether Be2+ is an indiscriminate kinase inhibitor or
a specific GSK-3β inhibitor it would be prudent to include as many kinases in this study.
The most surprising aspect of this study is the lack of prominent increase in the Ser-9
phosphorylation of GSK-3β (Fig. 5, 6, 7a). Unlike Li+, Be2+ has minimal effect on the Ser-9
phosphorylation status of GSK-3β. The Ser-9 residue on the N-terminal tail of the GSK-3β
protein plays an important role in its regulation. The N-terminal Ser-9 residue when
phosphorylated acts a pseudo substrate thus blocking the actual substrate-GSK-3β interaction.
The inhibition of GSK-3β induced by the Ser-9 phosphorylation is reversible and the GSK-3βTIMAP-PP1 feedback loop plays a critical role in it (refer schematic diagram 3 on page 73).
TIMAP serves as a substrate/target of GSK-3β and is an important regulatory subunit of protein
phosphatase 1 (PP1). GSK-3β mediated phosphorylation of TIMAP, up regulates the phosphatase
activity of PP1 (Li et al., 2007). The phosphatase activity of PP1 facilitates a decrease in the
phosphorylation at Ser-9 of GSK-3β, there by having a positive effect on the GSK-3β-activity.
The activation of GSK-3β has an enhancing effect on the activity of PP1 via the GSK-3β
mediated TIMAP phosphorylation. Activated PP1 in turn leads to decrease in the pSer-9 of GSK3β. Hence GSK-3β and PP1 regulate each other via a positive feedback loop. Activated GSK-3β
leads to enhanced phosphatase activity of PP1; PP1 in turn works towards decreasing the pSer-9
of GSK-3β. Li+ inhibits the activity of GSK-3β by inducing Ser-9 phosphorylation, which in turn
negatively regulates the phosphatase activity of PP1. The Li+ induced inhibition of GSK-3β has a
compounding effect on the pSer9-GSK-β status because of the perturbation in the GSK-3βTIMAP-PP1 feedback loop (Zhang et al., 2003). It is quite plausible that the lack of appreciable
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increase in the Ser-9 phosphorylation of GSK-3β in the presence of Be2+ could be because of its
inability to upset the GSK-3β-TIMAP-PP1feedback loop.
However the GSK-3β-TIMAP-PP1feedback loop may not be the only mechanism by which
Li+ regulates the Ser-9 phosphorylation of GSK-3β. It has been observed that Li+ treatment leads
to activation and phosphorylation of phosphotidylinositol 3-kinase (PI3K) and the
threonine/serine kinase Akt/PKB respectively (Chalecka-Franaszek and Chuang, 1999). PI3K and
Akt/PKB are important constituents of the insulin signaling pathway, which ultimately leads to
activation of glycogen synthase via the inhibition of GSK-3β. Akt/PKB is known to
phosphorylate GSK-3β at Ser-9 and inactivate it (Sutherland et al., 1993; Cross et al., 1994, 1995;
Stambolic and Woodgett, 1994). Li+ is an insulin mimetic agent (Cheng et al., 1983; Bosch et al.,
1986; Woo et al., 2000). It is possible that like insulin, Li+ too caused an increase in the Ser-9
phosphorylation of GSK-3β via the activation/phosphorylation of Akt/PKB. However according
to some reports Li+ has no effect on the phosphorylation of Akt/PKB (De Sarno et al., 2002).
Another possible explanation for the minimal increase in the Ser-9 phosphorylation of GSK-3β in
response to Be2+ could possibly be because of its in ability to interact/affect a critical component
of the insulin signaling pathway.
This study adds valuable information to establish Be2+ as a metal cation that elicits strong
inhibition of GSK-3β and demonstrates that Be2+ is a potent and efficient GSK-3β inhibitor
compared to Li+.
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Schematic diagram 3: GSK-3β-TIMAP-PP1 positive feedback loop model proposed by Zhang et
al. (Zhang et al., 2003)
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CHAPTER 5
Differential regulation of glycogen synthase and β-catenin by beryllium: a unique inhibitor
of GSK-3β

Introduction
Glycogen synthase kinase 3 (GSK-3) is an important serine/threonine kinase found in all
eukaryotes. GSK-3 was first isolated in its homogenous form from rabbit skeletal muscle cells
(Embi et al., 1980). The name glycogen synthase kinase refers to its ability to phosphorylate
glycogen synthase, a key regulatory element of glycogen synthesis pathway. There are two
isoforms of mammalian GSK-3: GSK-3α and GSK-3β, which are not functionally
interchangeable in spite of sharing 95% sequence identity in their kinase domains (Woodgett,
1990). Functional GSK-3α cannot alleviate the lethality induced in mouse embryos due the
homozygous deletions of exon 2 of GSK-3β (Hoeflich et al., 2000).
GSK-3β is a fascinating enzyme playing a central role in extremely diverse intra cellular
signaling pathways like Wnt signaling pathway and hedgehog pathway. GSK-3β regulates
glycogen synthesis, gene transcription, apoptosis, protein synthesis and cellular differentiation in
various cell types (Frame and Cohen, 2001; Doble and Woodgett, 2003; Grimes and Jope, 2001).
The moniker glycogen synthase kinase doesn’t justify the ability of GSK-3β to phosphorylate
various metabolically and structurally important proteins. There is overwhelming evidence that
establishes a plethora of different proteins as validated substrates of GSK-3β like tau, β-catenin,
cyclin D1, axin, c-jun, c-myc, Heat Shock Factor – 1, BCL-3, CREB, Histone H1.5, mdm2,
p21(CIP1), pyruvate dehydrogenase and many more (reviewed in Sutherland, 2011). Since GSK3β plays a critical role in the regulation and stability of various important proteins, de-regulation
of GSK-3β has been associated with many diseases. Hyper phosphorylation of tau protein by
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GSK-3β is one of the primary causes for the development of Alzheimer’s disease (Hooper et al.,
2008). Role of GSK-3β in the development of insulin resistance and type 2 diabetes has been
established in various studies (Henriksen and Dokken, 2006).
GSK-3β is an important constituent of the β-catenin destruction complex along with APC
(Adenomatous Polyposis Coli), axin, casein kinase 1 (CK1), protein phosphatase 2A (PP2A) and
E3-ubiquitin ligase β-TrCP (Zeng et al., 1997; Behrens et al., 1998; Hart et al., 1998, Ikeda et al.,
1998; Itoh et al., 1998; Salic et al., 2000; Kikuchi, 1999). The β-catenin destruction complex is
involved in regulating β-catenin turn over and GSK-3β plays a central role in it (refer schematic
diagram 2 on page 14) Wnt activation results in the repression of GSK-3β activity (Bilic et al.,
2007; MacDonald et al., 2009; Metcalfe and Bienz, 2011) leading to stabilization and nuclear
translocation of β-catenin (Cook et al., 1996; Huber et al., 1996; Willert et al., 1999). In nucleus
β-catenin interacts with TCF/LEF proteins to form a complex that regulates the transcription of
TCF/LEF target genes (Huber et al., 1996). The inhibition of GSK-3β associated or bound to the
components of β-catenin destruction complex has to be tightly regulated because some of the
target genes of β-catenin are proto oncogenes (Dale, 1998; Brantjes et al., 2002).
Apart from the Wnt ligands, insulin is another well characterized inhibitor of GSK-3β
(Sutherland et al., 1993; Cross et al., 1995; Shaw et al., 1997). Insulin regulates GSK-3β by
inducing an increase in the phosphorylation of its N-terminal Ser-9 residue (Sutherland et al.,
1993; Welsh and Proud, 1993; Cross et al., 1995). The phosphorylated Ser-9 residue on the Nterminal region of GSK-3β acts as a pseudo substrate thus blocking the access of putative
substrates to GSK-3β’s catalytic site (Frame et al., 2001; Dajani et al., 2001). The upstream
kinases of the insulin signaling pathway especially Akt/PKB (protein kinase B) plays an
important role in the insulin induced inhibition of GSK-3β (Cross et al., 1994, 1995; Stambolic
and Woodgett, 1994). Akt/PKB has been found to phosphorylate GSK-3β at the N-terminal Ser-9
residue thus inhibiting it (Shaw et al., 1997; Cross et al., 1994, 1995; Stambolic and Woodgett,
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1994). There are other inhibitors of GSK-3β that are also known to induce the inhibitory Ser-9
phosphorylation of GSK-3β (discussed later). The available information suggests that
phosphorylation of Ser-9 residue on the N-terminal region of GSK-3β plays an important role in
its regulation.
Even though Wnt ligands and insulin have been established as negative regulators of GSK-3β
their mode of action seems to be different (Ding et al., 2000). Ding et al showed that insulin
seems to be inhibiting GSK-3β activity via the inhibitory Ser-9 phosphorylation route and Wnt
ligands could not mediate such an affect. The differential regulation of GSK-3β by insulin and
Wnt ligands was supported by the observation that Wnt ligands could not induce the Ser-9
phosphorylation of GSK-3β and insulin failed to induce nuclear localization of β-catenin (Ding et
al., 2000). This study demonstrates that the Wnt pathway cannot inhibit the GSK-3β-enzyme
fraction involved in the insulin signaling and vice versa. The hypothesis that the GSK-3β fraction
involved in the insulin signaling pathway is insulated from the inhibitory effect of Wnt ligands
and vice versa is contradicted by reports which suggests the possibility of a cross talk between
insulin and Wnt signaling pathways (Desbois-Mouthon et al., 2001; Yi et al., 2008).
Apart from insulin and Wnt, another well characterized inhibitor of GSK-3β is FRAT1. It
was observed that FRAT1 selectively inhibits GSK-3β mediated phosphorylation of axin and βcatenin (Thomas et al., 1999). Nonetheless FRAT1 did not interfere with the GSK-3β mediated
phosphorylation of glycogen synthase (Thomas et al., 1999). It implies that FRAT1 is able to
selectively target the Wnt signaling pathway, while the insulin signaling pathway is insulated
from FRAT1’s inhibitory effects.
The available data suggests that few GSK-3β inhibitors are able to selectively regulate the
activity of GSK-3β depending upon the pathway in which it is involved. This information raises
the possibility of GSK-3β existing in two different fractions – the “free GSK-3β” associated with
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the insulin signaling pathway and the “bound GSK-3β” involved with the β-catenin destruction
complex of Wnt signaling (refer schematic diagram 2 on page 14). It can be hypothesized that
the ability of GSK-3β-inhibitors to inhibit a specific pathway depends on whether they are
inhibiting the “free GSK-3β” or the “bound GSK-3β” or both. Alternatively it is also possible that
the pathway selectivity of the GSK-3β-inhibitors depends on their effect on the other components
of the signaling pathways (apart from GSK-3β). It would be interesting to investigate the effect of
GSK-3β-inhibitors on the other members of the insulin signaling pathway such as Akt/PKB or
IRS-1. Additionally analyzing the effect of GSK-3β-inhibitors on the proteins involved in the βcatenin destruction complex (axin, APC, PP2A) could provide us with an insight into the
underlying mechanism behind the differential regulation of GSK-3β.
As discussed earlier inhibition of GSK-3β activity leads to stabilization and nuclear
localization of β-catenin in the nucleus (Cook et al., 1996; Willert et al., 1999; Behrens et al.,
1996; Huber et al., 1996). Several studies have directly linked the abnormal accumulation of βcatenin with development of various cancers (Smalley and Dale, 1999; Peifer and Polakis, 2000;
Thakur and Mishra, 2013). It can be speculated that de-regulation of the “bound GSK-3β” could
be playing an important role in the nuclear localization of β-catenin.
In recent times GSK-3β has emerged as an important therapeutic target because of its role in
the etiological development of different abnormalities and diseases. It is important to identify
potent inhibitors of GSK-3β in order to characterize and understand the impact of GSK-3β deregulation. There are various classes of GSK-3β inhibitors and the simplest among them is the
group containing metal cations. Lithium (Li+) is a monovalent metal cation that acts as a potent
inhibitor of GSK-3β and is commonly used in the form of LiCl salt (Klein and Melton, 1996;
Stambolic et al., 1996). Li+ inhibits the activity of GSK-3β both directly and indirectly (Jope,
2003). GSK-3β is a Mg2+ dependent enzyme and Li+ inhibits GSK-3β by directly competing with
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Mg2+ ions for the magnesium binding sites on the protein (Ryves and Harwood, 2001; Ryves et
al., 2002).
The post translational modification that leads to an increase in the phosphorylation of Ser-9
on GSK-3β is the indirect mode of action for some GSK-3β inhibitors. Like insulin, Li+ too leads
to an increase in the inhibitory Ser-9 phosphorylation in a wide variety of cells thereby inhibiting
GSK-3β enzyme indirectly (Zhang et al., 2003). From the inhibitory Ser-9 phosphorylation
perspective, Li+ mimics insulin and has a positive effect on glycogen metabolism (Cheng et al.,
1983; Bosch et al., 1986; Choi et al., 2000). In addition Li+ also mimics Wnt ligands and activates
the Wnt signaling pathway, which in turn causes nuclear localization of β-catenin (Stambolic et
al., 1996; Hedgepeth et al., 1997). Li+ is a reasonably selective GSK-3β inhibitor but its inhibitory
concentration range is in millimolars (Ki = 2 mM) (Klein and Melton, 1996). Beryllium (Be 2+)
another metal cation acts as an efficient inhibitor of GSK-3β and is 1000 times more potent
compared to lithium (Mudireddy et al., 2014).
Beryllium in the form of BeSO4 salt acts as a potent GSK-3β inhibitor and is also tolerated
well by mammalian cells at concentrations up to 100 µM (Mudireddy et al., 2014). Apart from
the fact that Be2+ could be competing for both Mg2+ and ATP binding sites on GSK-3β not much
is known about the mechanism by which Be2+ inhibits the activity of GSK-3β (Ryves et al.,
2002). Be2+ fails to induce an increase in the Ser-9 phosphorylation of GSK-3β in A172 cells
(Mudireddy et. al., 2014), indicating that it might be inhibiting GSK-3β by an unknown
mechanism. In this study we investigated whether the lack of increase in Ser-9 phosphorylation of
GSK-3β in the beryllium treated cells is a universal phenomenon or a cell type specific event. Our
results for the first time demonstrates the intra cellular effects of Be 2+ on important substrates of
GSK-3β like glycogen synthase and β-Catenin. This study validates the efficacy of beryllium as a
cell culture reagent for GSK-3β inhibition. Our results also suggests that unlike Li+, which shows
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an unrestricted inhibitory action on GSK-3β activity, Be2+ could be a more pathway-selective
GSK-3β inhibitor.

Materials and methods
Cell culture
A172 (human glioblastoma), U87MG (human glioblastoma/astrocytoma), Caki-1 (human
kidney carcinoma) and NIH/3T3 (murine embryo fibroblasts) were obtained from American Type
Culture Collection (Manassas, VA). RKO E6 human colon carcinoma, A172 E6 and U87MG E6
cells are RKO, A172 and U87MG transfected with pCMV-E6 plasmid expressing the human
papillomavirus 16 E6 gene. A172 E6 cells are established and well characterized clones as
described in (Xu et al., 2005). The E6 cell lines were a kind gift of Dr. J. Gregory Cairncross
(University of Calgary, Calgary, Alberta, Canada). Cells were grown in RPMI 1640
supplemented with 10% Fetal Bovine Serum, (10% Bovine Growth Serum for NIH/3T3 cells),
25 mM Hepes and 1x antibiotic-antimycotic (Invitrogen-Gibco) at 37 C in 5% CO2.
Serum starvation
NIH/3T3 cells were grown to 50-60% confluency in 5% BGS RPMI 1640. Cells were washed
with serum-less RPMI 1640 and incubated in 2% BGS RPMI for 24 Hr. Cells were then serum
starved for 2 Hr after being washed twice with serum-less RPMI 1640. Cells were then stimulated
with 100 nM Insulin (Bovine pancreas insulin, sigma #I0516) for 30-60 min before harvesting the
cells.
Salt treatment
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BeSO4.4H2O (Fluka - lot & filling code 413015/1) was used to prepare a 10 mM stock in
nanopure H2O and sterile filtered. The stock solution was used to prepare the appropriate
concentrations of beryllium-RPMI 1640 for dosing cells. A 4M LiCl (sigma#L-8895,
lot#22K0184) stock was prepared in nanopure H2O. 1 M stocks of other salts like CaCl2 (sigma
#C-5080, lot #10K0197), MgCl2 (sigma #M-2670, lot #91K0108), NaCl (Amresco#0241-500G,
lot #0452C125), KCL (sigma#P-3911, lot#91K0142) and Na2SO4.5H20 (#SX0760 E-3) were
prepared using nanopure H2O and sterile filtered.
Cells used for all experiments were obtained from a common pool and seeded in appropriate
numbers (usually 1.5 – 2.0*106) to obtain sub confluency (50 – 70%). Cells were grown
overnight but not more than 24 Hr before dosing them with freshly prepared RPMI 1640 +
inhibitors (beryllium or lithium). The untreated/control cells would receive normal (fresh) RPMI
1640 without any beryllium or lithium.
Small molecule inhibitors of GSK-3β
SB216763 (sc-200646A, lot #D2711) and Rottlerin (sc-3550, lot #K1313) were prepared in
DMSO.
Western blotting
Cells were grown in 100 mm CELLSTAR polysterene cell culture dishes (cat#664 160) and
harvested by trypsinization. Cells were washed twice with phosphate-buffered saline and total
cell lysates were prepared using M-PER (cat#78501, Thermo Scientific) supplemented with
protease and phosphatase inhibitors (Halt protease inhibitor cocktail kit, Thermo Scientific
cat#78442) and phosphatase inhibitors (sodium fluoride - 20 mM, beta glycerol phosphate - 10
mM, sodium ortho vanadate - 0.1 mM, paranitro phenyl phosphate - 20 mM and 1x EDTA) and
the cell suspension was gently vortexed for 10 sec. The lysed cell suspension was incubated on
ice for 10 min and followed by gentle vortexing for 5 sec and centrifuged at 14,000 RPM for 30
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min. Appropriate amount of cell supernatant was added to 5x laemmli SDS sample buffer and
boiled immediately for 5 min. Total protein concentration in the supernatant was measured by
using BCA assay (Thermo Scientific #23227). Normalized protein samples were loaded onto 8%
SDS-PAGE gels for probing with total glycogen synthase, β-catenin and phospho-β-catenin
proteins. For probing p53, actin, GSK-3β (Ser-9), total GSK-3β, p53 (1C12), total GSK-3α/β, αTubulin, lamin-B and lamin A/C 10% SDS-PAGE gels were used. For the phospho glycogen
synthase samples 4-12% bis-tris gradient gels (ref#WG1402BX10 from Novex-Life
Technologies) were used. After electrophoresis the proteins were transferred to polyvinylidine
difluoride membrane (Millipore cat#IPFL20200, Biorad cat#162-0255). Post transfer the
membranes were blocked in 10% milk or starting block TBS (Prod#37543, Thermo Scientific)
when probing with phospho antibodies. Primary antibody labeled blots were incubated with the
respective HRP-conjugated secondary antibodies and developed with ECL-Plus (GE Healthcare
Life Sciences) or clarity western ECL substrate (Bio-Rad cat#170-5061).
Fractionation of cytoplasmic and nuclei proteins
For the preparation of cytoplasmic and nuclear extracts from mammalian cells (A172,
U87MG, Caki-1, NIH/3T3, RKO E6, A172 E6 and U87MG E6), NE-PER nuclei and cytoplasmic
extraction kit from thermo scientific was used (#78833, Thermo Scientific).


Cells were grown as explained in the cell culture section above.



To analyze the effect of beryllium on different cell lines, they were grown in RPMI 1640
supplemented with appropriate concentration of BeSO4 (10 – 100 μM).



Cells were harvested by trypsinization. Phosphate buffered saline was used to wash the cells
twice to remove traces of serum and trypsin. (soyabean trypsin inhibitor was used to nullify
the adverse effects of trypsin on the cells).



250 μL of CER-I buffer was added to each dry cell pellet and vortexed vigorously for 15 sec.



The cell suspension in CER-I buffer was incubated on ice for 20 min.
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13.75 μL of CER-II buffer was added to the cell suspension and vortexed vigorously for 15
sec followed by incubation on ice for 10 min.



Cell suspension was vortexed again vigorously for 5 sec. Followed by centrifugation at
14,000 RPM for 30 min.



After centrifugation the supernatant (cytoplasmic proteins) was removed and added to a pre
chilled 1.5 ml tube.



Extra supernatant present on top of the nuclei pellet was discarded. Nuclei pellets were then
washed with 400 µL of phosphate buffered saline (to prevent any cross contamination of
nuclear fraction with cytoplasmic proteins).



110 µL of NER buffer was added to each pellet. Nuclei suspension was mixed well.



The nuclei suspension was vortexed vigorously for 15 sec followed by incubation on ice for
15 min.



Nuclei suspension was subjected to 4 cycles of vigorous vortexing followed by 15 min of
incubation on ice.



The nuclei suspension was then centrifuged at 14,000 RPM for 30 min.



The supernatant containing the nuclear proteins was added to pre chilled 1.5 ml tubes.



Appropriate amount of cytoplasmic and nuclear supernatants were mixed with 5x laemmli’s
buffer and boiled for 5 min.

Note: All the steps were carried out at 4 C.
Total protein concentration in the supernatant was measured by using BCA assay (Thermo
Scientific # 23227). Normalized protein samples were loaded onto SDS-PAGE gels for probing.

Antibodies
p53 DO1: Mouse monoclonal IgG2b (cat#sc-126, Santa Cruz Biotechnology, inc) and goat
anti-mouse IgG peroxidase (cat#A9917 Sigma Aldrich)
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Actin: Goat monoclonal IgG2b (cat#sc-1615, Santa Cruz Biotechnology, inc) and bovine antigoat IgG-HRP (cat# SC-2350 Santa Cruz Biotechnology, inc)
phospho GSK-3β (Ser-9): Rabbit antibody (#9336S, Cell Signaling Technology) and antirabbit IgG-HRP (cat#31460 Thermo Scientific)
phospho GSK-3β D85E12 (Ser-9): Rabbit antibody(#5558, Cell Signaling Technology) and
goat anti-rabbit IgG- FITC (cat#2012, Santa Cruz Biotechnology, inc) (for nuclei flow
experiment)
Total GSK-3β (H-76): Rabbit polyclonal IgG2b (cat#sc-9166, Santa Cruz Biotechnology, inc)
and anti-rabbit IgG-HRP (cat#31460, Thermo Scientific)
Total

GSK-3α/β

(0011-A):

Mouse

monoclonal

IgG2b

(cat#sc-7291,

Santa

Cruz

Biotechnology, inc) and goat anti-mouse IgG peroxidase (cat#A9917 Sigma Aldrich)
β-catenin (E5): Mouse monoclonal IgG1 (cat#sc-7963, Santa Cruz Biotechnology, inc) and
goat anti-mouse IgG peroxidase (cat#A9917 Sigma Aldrich)
Phospho β-catenin (Ser-33) – R: Rabbit polyclonal IgG (cat#sc-16743-R, Santa Cruz
Biotechnology, inc) and anti-rabbit IgG-HRP (cat#31460, Thermo Scientific)
α -Tubulin (B-7): Mouse monoclonal IgG2a (cat#sc-5286, Santa Cruz Biotechnology, inc) and
goat anti-mouse IgG peroxidase (cat#A9917, Sigma Aldrich)
Lamin – B (C12): Mouse monoclonal IgG2b (cat#sc-365214, Santa Cruz Biotechnology, inc)
and goat anti-mouse IgG peroxidase (cat#A9917, Sigma Aldrich)
p53(1C12): Mouse monoclonal IgG1(#2524, Cell Signaling Technology) goat anti-mouse IgG
peroxidase (cat#A9917, Sigma Aldrich) (for mouse cell lines)
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Lamin A/C (4C11): Mouse monoclonal IgG2a (#4777S, Cell Signaling Technology) goat antimouse IgG peroxidase (cat#A9917, Sigma Aldrich)
α-Tubulin: Rabbit polyclonal (#2144S, Cell Signaling Technology) and anti-rabbit IgG-HRP
(cat#31460, Thermo Scientific)
phospho-Glycogen synthase (Ser641/Ser645): Rabbit polyclonal (#07-817, EMD Millipore)
and anti-rabbit IgG-HRP (cat#31460, Thermo Scientific)
Total Glycogen synthase: Rabbit polyclonal (#3893S, Cell Signaling Technology) and antirabbit IgG-HRP (cat#31460, Thermo Scientific)
Lamin-B (C-20): Goat polyclonal IgG (cat#sc-6216, Santa Cruz Biotechnology, inc) (used
mostly for nuclei flow experiments)
Secondary antibodies for flow cytometry and immunoflorescence experiments
Anti Mouse IgG (H+L), F(ab’)2 Fragment (Alexa Fluor 647 Conjugate: (#4410, Cell
Signaling Technology)
Donkey anti goat IgG-FITC (cat#sc-2024, Santa Cruz Biotechnology, inc)
Stable nuclei isolation from mammalian cells for flow analysis
A minimum of 5x106 cells are required for stable nuclei isolation.


A172 Cells were grown in 100 mm dishes and harvested by trypsinization.



Post trypsinization cells were washed twice with phosphate buffered saline (soyabean trypsin
inhibitor was used to nullify the adverse effects of trypsin on the cells).



Washed cells were resuspended in 500µL of cold nuclei extraction buffer (320mM sucrose,
5mM MgCl2, 10mM HEPES, 2% Triton X-100 at pH 7.4) at approximately 1 mL/1 million
cells.
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Cells were vortexed gently for 10 sec and incubated on ice for 10 min.



Cell suspension was centrifuged at 3,500 RPM for 20 min.



Isolated nuclei were washed twice with nuclei wash buffer (320mM sucrose, 5mM MgCl 2, 10
mM HEPES at pH 7.4, no Triton X-100).



Isolated nuclei were resuspended in 100 µL of primary antibody solution. Antibody
incubation buffer (320mM sucrose, 5mM MgCl2, 10mM HEPES, 1% BSA and 0.1% sodium
azide at pH 7.4, no Triton X-100). Recommended primary antibody concentration is 1 µg/
nuclei pellet.



Isolated nuclei were incubated with the primary antibody solution

4 C overnight (isolated

nuclei can remain stable for 24 Hr in the nuclei wash buffer).


Post primary antibody incubation, the nuclei were washed twice with nuclei wash buffer.



Nuclei were resuspended in 100 µL of secondary antibody (FITC or Alexa 647 tag) solution
at a concentration of 0.5 – 0.75µg/nuclei pellet and incubated at room temperature for 2 Hr
(post secondary antibody steps under dark conditions).



Post secondary antibody incubation the nuclei were washed twice with nuclei wash buffer.



Nuclei were resuspended in 500 µL of nuclei wash buffer in flow cytometry tubes for
analysis.

Immunofluorescence Microscopy
Cells were grown in Matek glass bottom dishes - cover slip # 1.5 (thickness – 0.16-0.19 mm).
After the treatment with inhibitors cells were washed twice with phosphate-buffered saline
supplemented with 1 mM CaCl2 and 0.5 mM MgCl2. Cells were fixed with freshly prepared 4%
paraformaldehyde – PBS (Ca2+&Mg2+) at 37 C for 10 min. Fixed cells were washed twice with
PBS (Ca2+&Mg2+) and permeabilized with 0.2% Tween20 - PBS (Ca2+&Mg2+) at room
temperature for 15 min. Cells were blocked in antibody incubation buffer (1% BSA + 0.2%
Tween20 - PBS (Ca2+&Mg2+) for 30 min at room temperature. Cells were incubated in β-catenin
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(E5): Mouse monoclonal IgG1 (cat#sc-7963 Santa Cruz Biotechnology, inc) and Lamin-B (C20): Goat polyclonal IgG (cat sc-6216 Santa Cruz Biotechnology, inc) overnight at 4 C.
Secondary antibodies used were anti mouse IgG (H+L), F(ab’)2 fragment (Alexa Fluor 647
conjugate: (#4410, Cell Signaling Technology), donkey anti goat IgG-FITC (cat#sc-2024 Santa
Cruz Biotechnology, inc) and Hoechst dye to stain chromatin (1 µg/ml, Sigma-Aldrich). Images
were collected using Nikon A1R BX40 confocal laser scanning microscopy system. The images
were processed using ImageJ.
p53 knock down using stealth RNAi in A172 cells
TP53 validated stealth RNAi (Cat No. 45-1492) from Invitrogen was used to knock down p53
expression transiently in A172 cells.1.2x106 A172 cells were seeded in 100 mm dishes to obtain
50 – 60% confluency after 12 Hr. The 10% FBS RPMI 1640 was removed and cells were washed
once with phosphate-buffered saline, later OptiMem reduced serum media (#11058, Gibco) was
added to each dish. 20 nM of the Stealth p53 RNAi oligo II duplex was used since it was less
toxic to cells compared to the RNAi Oligo I Duplex. Stealth p53 RNAi oligo II duplex and
lipofectamine 2000 (ref #11668-030, Invitrogen/Life Technologies) were diluted in OptiMem
individually in such a way that the final volume is equal to 250 µL. The lipofectamine 2000 +
OptiMem mix was incubated at room temperature for 5 min. The Stealth p53 RNAi oligo duplex
II + OptiMem solution was mixed with lipofectamine 2000 + OptiMem so that the final ratio
between the oligo and lipofectamine 2000 is 1:5 (5 µL of Oligo and 25 µL of lipofectamine 2000.
The Oligo + Lipofectamine 2000 + OptiMem mix (transfection mix) was incubated at room
temperature for 20 min. The Oligo + Lipofectamine 2000 + OptiMem mix was added to A172
cells growing in the OptiMem media. The dishes were incubated at 37 C for 8 Hr 30 min. The
OptiMem media containing the transfection mix was replaced with normal RPMI 1640 (10% FBS
+ 1% PSF) and RPMI 1640 supplemented with 100 µM BeSO4 or 20 mM LiCl after the 8.5 Hr
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incubation time. Cells were harvested (either total cell lysates or cytoplasmic and nuclear
fractionations) after culturing them under the influence of beryllium and lithium for 24 Hr.
p53 knock down using shRNA(h) lenti viral particles in A172 cells
Integration of specific short hairpin RNA (shRNA) constructs into genomic DNA of A172
cells can lead to the generation of A172 clones with constitutively down regulated p53
expression. Stable A172 p53 KO or control A172 cell lines were generated by Dr. Priyatham
Gorjala using a lentiviral shRNA expression vector. Detailed methods describing the production
of these cells are available in Dr. Gorjala's dissertation (Gorjala, 2012).
Addgene clone transfection
The following addgene plasmids were obtained from addgene plasmid repository
plasmid#14753–HA GSK-3β wt pcDNA3, plasmid 14754–HA GSK-3β S9A pcDNA3,
plasmid#14755–HA GSK-3β K85A pcDNA3. A172 cells were transfected with the above
mentioned plasmids to generate stable clones over expressing wt GSK-3β and its mutants. A172
cells were grown to sub confluence in a 24 well plate. 1 µg of plasmid DNA was diluted in 25 µL
of plain RPMI 1640 lacking serum and antibiotics. 4 µL of Plus TM was added to the plasmid mix
and incubated at room temperature for 15 min. 1 µL of LipofectamineTM reagent was diluted in 25
µL of plain RPMI 1640 lacking serum and antibiotics. The pre complexed plasmid DNA was
mixed with diluted LipofectamineTM and incubated at room temperature for 15 min. The cells in
the 24 well plate was supplemented with 200 µL of serum less RPMI 1640 containing plasmid
DNA + PlusTM + LipofectamineTM reagent and incubated at 37 C for 6 Hr. The RPMI containing
the transfection mix was replaced with normal RPMI 1640 (10

FBS + 1

PSF) and cells were

grown for 24 Hr at 37 C (cells were grown in normal RPMI initially to provide cells with proper
growth conditions). Transfected A172 cells were grown in RPMI 1640 supplemented with 400
µg/ml of G418 (cat#1811-23, lot#1213491, Gibco) for first 48 Hr followed by a lower
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concentration of 200 µg/ml with G418 acting as selective pressure for isolating and propagating
transfection positive A172 cells. Single cell colonies of transfectants were selected via serial
dilution in a 96 well plate. The obtained clones were tested for the expression of the respective
proteins by analyzing the presence of the HA tag in the lysate samples via western blotting.

Results
A cell type specific event: Be2+ induces either an increase or no change in the Ser-9
phosphorylation of GSK-3β depending on the cell type
A. Beryllium does not cause an increase in the Ser-9 phosphorylation of GSK-3β in A172
(Human glioblastoma) and U87MG cells (Human glioblastoma astrocytoma)
Increase in the Ser-9 phosphorylation of GSK-3β is one of the hallmarks of Li+ induced
inhibition of GSK-3β (Chalecka-Franaszek and Chuang 1999; Lochhead et al., 2001; Zhang et al.,
2003). We have shown previously that beryllium unlike lithium does not lead to substantial
increase in Ser-9 phosphorylation of GSK-3β in A172 and HFL cells (Mudireddy et al., 2014).
This was an unexpected result, so we wished to extend this analysis to include additional cell
types to see whether the initial observation was a general result or whether it might be cell-typespecific. The Ser-9 phosphorylation status of GSK-3β in A172 and U87MG cells was analyzed
using western blotting (#9336S rabbit polyclonal anyibody, Cell Signaling inc.) (Fig. 8) Li +
served as a positive control. In A172, Li+ treatment (20 mM) caused an increase in the Ser-9
phosphorylation of GSK-3β at 24 hr, an observation that is consistent with our prior results
(Mudireddy et al., 2014). Treating A172 with increasing concentrations of Be 2+ did not elicit any
appreciable change in the Ser-9 phosphorylation of GSK-3β. Treating U87MG cells with Be2+
(100 µM) at 0, 6, 12 and 24 hr did not induce any increase in the Ser-9 phosphorylation of GSK3β or total GSK-3β (sc 9166, Santa Cruz Biotechnology, inc) (Fig. 9a). U87MG cells when
88

treated with Be2+ (10, 100 µM) or Li+ (20 mM) at 24 hr in an independent experiment did not
cause any increase in the Ser-9 phosphorylation of GSK-3β (Fig. 9b).
An established effect of Be2+ treatment at molecular level is the increase of p53 protein levels
in mammalian cells (Lehnert et al., 2001; Coates et al., 2007; Gorjala and Gary, 2010). The
increase in the p53 protein level in the A172 (Fig. 8) and U87MG (Fig. 9a&9b) validates the
effect of Be2+ treatment on the mentioned cell lines. Thus, the p53 westerns serve as a positive
control for Be2+- induced change in protein expression, which strengthens the conclusion that
Be2+ does not cause any substantial increase in the Ser-9 phosphorylation of GSK-3β in A172 and
U87MG cells at 24 hr.
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Fig. 8 Beryllium does not cause induction of GSK-3β Ser-9 phosphorylation in A172 cells at
24 hr. A172 cells were treated with 0, 5, 10, 25, 50 or 100 µM BeSO4 or 10 or 20 mM LiCl for 24
hr. Ser-9 phosphorylation of GSK-3β (GSK-3β-pS9) was detected by western blotting using
phospho-GSK-3β (Ser-9) antibody. Total GSK-3β and actin protein levels are shown as loading
control. Li+ treatment caused a prominent increase in the Ser-9 phosphorylation of GSK-3β but
not in Be2+ treated A172 cells.
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Fig. 9 Beryllium does not cause induction of GSK-3β Ser-9 phosphorylation in U87MG
cells. a U87MG cells treated with 100 µM BeSO4 did not show any increase in the Ser-9
phosphorylation of GSK-3β at 0, 6, 12 or 24 hr. b U87MG cells treated with 0 or 20 mM LiCl or
10 or 100 µM BeSO4 in an independent experiment again show the lack of increase in the Ser-9
phosphorylation of GSK-3β in the presence of Be2+.
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B. Beryllium induces an increase in the Ser-9 phosphorylation of GSK-3β in NIH/3T3
(murine embryo fibroblast) and Caki-1(human kidney carcinoma) cells
To analyze, whether the inability of Be2+ to induce Ser-9 phosphorylation of GSK-3β is a cell
type specific event or a universal phenomenon, two additional cell systems were included in this
study. The Ser-9 phosphorylation status of GSK-3β in these cell lines was investigated post Be2+
treatment.
To investigate the effect of Be2+ on the Ser-9 phosphorylation of GSK-3β in NIH/3T3 cells
(murine fibroblasts), cells were treated with increasing concentration of BeSO4 for 24 hr. A
prominent increase in the Ser-9 phosphorylation of GSK-3β was observed in the Be2+ treated
NIH/3T3 cells (Fig. 10a). The p53 westerns demonstrate that 25-100 µM BeSO4 represents a
sufficient dose to effect physiological change in this cell type. The p53 (1C12) antibody used here
is specific for mouse cell lines and produces much weaker bands compared to the p53 DO1
(sc#126, Santa Cruz Biotechnology, Inc) used for human cell lines. In our study the p53 DO1
antibody did not yield any visible p53 bands in mouse samples hence the p53 (1C12) mouse
specific antibody was used, even though it produces weak bands. However the p53 (1C12) results
confirmed the expected results in mouse cell lines.
Caki-1 cells (human kidney carcinoma) were treated with 0, 5, 10, 25, 50 µM BeSO4 or 5, 15
mM LiCl for 24 hr. Caki-1 cells (from the DRC data) are more sensitive to BeSO4 and LiCl,
hence the maximum concentrations of beryllium and lithium was limited to 50 µM and 15 mM
respectively. The cell lysates were analyzed for the Ser-9 phosphorylation of GSK-3β through
western blotting (#9336S, rabbit polyclonal antibody). Increase in the Ser-9 phosphorylation of
GSK-3β after treating the cells with increasing concentration of Be2+ was observed (Fig. 10b). Li+
also caused an increase in the Ser-9 phosphorylation of GSK-3β.
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Fig. 10 Be2+ induces an increase in the Ser-9 phosphorylation of GSK-3β in NIH/3T3 and
Caki-1 cells. a-b, western blots showing the Ser-9 phosphorylation of GSK-3β (GSK-3β-pS9)
was detected by western blotting using phospho-GSK-3β (Ser-9) antibody. Total GSK-3β and
actin protein levels are shown as loading control. p53 has been used to validate the effect of Be 2+
on the cells. a NIH/3T3 cells treated with 0, 1, 2.5, 5, 10, 25, 50 or 100 µM BeSO4 for 24 hr. b
Caki-1 cells treated with 0, 5, 10, 25 or 50 µM BeSO4 or 5, 15 mM LiCL for 24 hr.
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To verify the results of pSer9-GSK-3β in NIH/3T3 cells, an alternate analytical method flow
cytometry was used to quantify the Ser-9 phosphorylation of GSK-3β in situ (Fig. 11). Be2+ (a)
and Li+ (b) treatment of NIH/3T3 cells at 24 hr produced a concentration dependent increase in
the Ser-9 phosphorylation of GSK-3β corroborating the western results. These flow results
suggests that in NIH/3T3 cells Be2+ is imitating Li+ by inducing an increase in the inhibitory post
translational modification of GSK-3β i.e. Ser-9 phosphorylation of GSK-3β.
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Fig. 11 Be2+ treatment induces an increase in the Ser-9 phosphorylation of GSK-3β in
NIH/3T3 cells – a flow cytometric approach. The increase in the Ser-9 phosphorylation of
GSK-3β in NIH/3T3 cells in the presence of beryllium and lithium was measured by flow
cytometry. a flow cytometry histograms of NIH/3T3 cells treated with 0, 30 or 100 µM BeSO4 for
24 hr. b flow cytometry histograms of NIH/3T3 cells treated with 0 or 20 mM LiCl for 24 hr.
GSK-3β-pS9 (#5558 (D85E12), rabbit polyclonal) and FITC conjugated secondary antibody was
used. For each beryllium and lithium treatment, mean fluorescence per cell was determined. Data
shown here is representative of at least two independent experiments done in triplicates with
similar results.
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Different GSK-3β inhibitors induce an identical or matching effect on the phosphorylation
status of GSK-3β, whereas beryllium’s effect on Ser-9 phosphorylation of GSK-3β is cell
type specific
Post translational modification of GSK-3β (Ser-9 phosphorylation of GSK-3β) plays an
important role in its regulation. An increase in the Ser-9 phosphorylation of GSK-3β in beryllium
treated NIH/3T3 and Caki-1 cells was observed in our study. On the other hand A172, HFL and
U87MG cells seem to be immune to the beryllium induced Ser-9 phosphorylation of GSK-3β. It
is important to investigate whether any other GSK-3β inhibitor can induce Be2+ like cell type
specific effect on the Ser-9 phosphorylation of GSK-3β. The effect of Be2+ was compared against
lithium, SB216763, rottlerin, CaCl2 and insulin in A172, NIH3T3, and Caki-1 cells.
Insulin is a negative regulator of GSK-3β and it induces an increase in its inhibitory Ser-9
phosphorylation. It is possible that only certain cell lines would be able to respond to insulin
treatment. The insulin receptor is widely distributed in mammalian tissues, and it was anticipated
that each of these cell types might be suitable for such a comparison. A172 cells are derived from
human glioma, and human glioma cells are known to express insulin receptors (Grunbereger et
al., 1986) Normal untransfected serum-starved NIH3T3 cells have been shown to respond to
insulin (Bossenmaier et al., 2000). The Caki-1 are renal carcinoma cells and kidney is a major
organ for glycogen storage that is highly responsive to insulin. It can be expected that these three
cell lines should be able to respond to insulin.
Rottlerin is known to cause an increase in the Ser-9 phosphorylation of GSK-3β (Gschwendt
et al., 1994; Zhang et al., 2003). Zhang et al have used rottlerin at 5 µM to analyze its effect on
the Ser-9 phosphorylation of GSK-3β in Neuro2A cells. We decided to use rottlerin at 10 µM for
A172 cells (to maximize the effect) and considering the fact that Caki-1 cells are sensitive to
GSK-3β inhibitors the rottlerin concentration was fixed at 5 µM for this study. Another small
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molecule inhibitor of GSK-3β is SB216763 - an anilino malemide (Coghlan et al., 2000) was also
selected for this study. Dose response curve of A172, NIH/3T3 and Caki-1 cells with SB21673
was used to decide the SB216763 dosage to be used for the given cell lines 10 µM for Caki-1 and
20 µM for both A172 and NIH/3T3 (Appendix-VI). In addition the effect of insulin, LiCl and
CaCl2 on the Ser-9 phosphorylation of GSK-3β was compared parallely with BeSO4 in NIH/3T3,
Caki-1 and A172 cells. In our studies insulin was found to be effective within a range of 100-200
nM.
As observed previously BeSO4 at 24 hr did not induce any increase in the Ser-9
phosphorylation of GSK-3β in A172 cells (Fig. 12, panel c) conversely an increase in the Ser-9
phosphorylation of GSK-3β in NIH/3T3 (panel a) and Caki-1 cells (panel b) is observed. Lithium
– LiCl at 24 hr induced an increase in the Ser-9 phosphorylation of GSK-3β in all the three cell
lines, A172 (panel c), NIH/3T3 (panel a) and Caki-1 (panel b). To analyze the effect of insulin on
phosphorylation status of GSK-3β, cells were serum starved as mentioned in the materials and
methods section. After inducing cells with 200 nM of Insulin for 30-60 min, an increase in the
Ser-9 phosphorylation of GSK-3β is observed in NIH/3T3 (panel a) and a slight increase in A172
(panel c) is observed. The effect of insulin on Caki-1 cells is not clear (panel b). Like lithium,
insulin too produces an identical effect i. e. increase in Ser-9 phosphorylation of GSK-3β in
NIH/3T3 and A172 cell lines. Rottlerin at 10 µM and 5 µM for 24 hr produced inconsistent
results in A172 (panel c) and Caki-1 (panel b) cells respectively. Rottlerin at 10 µM seems to be
causing a slight increase in Ser-9 phosphorylation in NIH/3T3 cells (panel a). Overall the effect
of rottlerin on the Ser-9 phosphorylation is inconclusive. SB216763 at a concentration of 10-20
µM caused a drastic decrease in Ser-9 phosphorylation of GSK-3β in NIH/3T3 (panel a), Caki-1
(panel b) and A172 (panel c). SB216763 induced decrease in the Ser-9 phosphorylation of GSK3β is an unexpected result, which is quite different from the “inhibitory effects” of other GSK-3β
inhibitors. In all the three cell lines the total Gsk-3β levels are stable indicating that SB216763 is
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inducing a decrease only in the phosphorylation status of GSK-3β. A possible explanation for
SB216763 induced decrease in pSer9-GSK-3β could be because of its failure to deactivate
phosphatases that in turn could be causing a drastic decrease in the pSer9-GSK-3β. Li+ affects an
increase in the Ser-9 phosphorylation of GSK-3β by modulating the activity of protein
phosphatase 1 (PP1) (Zhang et al., 2003). SB216763 is a specific GSK-3β inhibitor with no
known inhibitory activity against other related kinases (Coghlan et al., 2000). It can be speculated
that SB216763 because of its specific activity towards GSK-3β only may not be able to inhibit
the activity of PP1. The active PP1 could be inducing a drastic decrease in the Ser-9
phosphorylation of GSK-3β as observed in the SB216763 samples.

However SB216763

produced identical results in three different cell lines (in relation to pSer9-GSK-3β); adding
confidence in its ability to function as a reliable control. CaCl 2 at 100 µM did not induce any
noticeable change in the Ser-9 phosphorylation of GSK-3β. It indicates that the up regulation of
pSer9-GSK-3β is a property limited to specific GSK-3β inhibitors.
A comparison of the effect of different GSK-3β inhibitors on the Ser-9 phosphorylation of
GSK-3β clearly shows that among the 5 different GSK-3β inhibitors used in this study i.e.

BeSO4, LiCl, Insulin and SB216763; only Be2+ elicits a clear cell type specific effect on
the Ser-9 phosphorylation of GSK-3β (Table 5). Other GSK-3β inhibitors listed below elucidates
their inhibitory effects either by inducing a definitive/identical increase (LiCl and insulin) or
decrease (SB216763) in the Ser-9 phosphorylation of GSK-3β in the mentioned cell lines. These
results suggest that Be2+ could be modulating its effect on the Ser-9 phosphorylation of GSK3β via a unique and cell type specific mechanism.
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Fig. 12 Unique effect of beryllium on the Ser-9 phosphorylation status of GSK-3β compared
to other established GSK-3β inhibitors and CaCl2 salt. a-c, western blots showing the Ser-9
phosphorylation of GSK-3β (GSK-3β-pS9) was detected by western blotting using phosphoGSK-3β (Ser-9) antibody. Total GSK-3β and actin protein levels are shown as loading control. a,
c NIH/3T3 and A172 cells were treated with 0, 100 µM BeSO4, 20 µM SB216763, 20 mM LiCl,
100 µM CaCl2 or 10 µM rottlerin (only for A172 cells) for 24 hr or 200 nM Insulin for 30-60 min.
b, Caki-1 cells were treated with 0, 60 µM BeSO4, 10 µM SB216763, 15 mM LiCl, 100 µM
CaCl2 or 5 µM rottlerin for 24 hr or 200 nM Insulin for 30-60 min.
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Table 7. Effect of GSK-3β inhibitors and CaCl2 salt on the Ser-9 phosphorylation status of
GSK-3β

A172

BeSO4

LiCl

Insulin

SB216763

Rottlerin CaCl2

No

Increase

Increase

Decrease

Inconclu

No

-sive*

change

Inconclu

No

-sive

change

Inconclu

No

-sive*

change

change
NIH/3T3

Caki-1

Increase

Increase

Increase

Increase

Increase

Increase

Decrease

Decrease

* Effect of rottlerin on the pSer9-GSK-3β was inconsistent; hence it was difficult to ascertain the
role played by it in relation to the inhibitory Ser-9 phosphorylation of GSK-3β.
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Induction of Ser-9 phosphorylation on GSK-3β by BeSO4 is not random salt effect
To establish that the Be2+ induced increase in Ser-9 phosphorylation of GSK-3β in NIH/3T3
cells is not a random salt effect, NIH/3T3 cells were treated with 0 or 100 µM BeSO 4, KCl,
MgCl2 or Na2SO4 for 24 hr (Fig. 13). The lack of increase in the Ser-9 phosphorylation of GSK3β in the 100 µM KCl, MgCl2 or Na2SO4 treated samples confirms the Be2+ induced increase in
Ser-9 phosphorylation is not a random salt effect.
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Fig. 13 Beryllium induced Ser-9 phosphorylation in NIH/3T3 is not random salt effect. .
NIH/3T3 cells were treated with 0 or 100 µM BeSO4, KCl, MgCl2 or Na2SO4 for 24 hr.Western
blots showing the Ser-9 phosphorylation of GSK-3β (GSK-3β-pS9) was detected by using
phospho-GSK-3β (Ser-9) antibody. Total GSK-3β and actin protein levels are shown as loading
control. p53 has been used to validate the effect of Be2+ on the NIH/3T3 cells
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Investigating the credentials of beryllium as a biologically active GSK-3β inhibitor
Be

2+

induced down regulation in the phosphorylated form of glycogen synthase enzyme

validates its intra cellular effect
Glycogen synthase (GS) enzyme plays a central role in glycogen metabolism. There are
several kinases that regulate the activity of GS by modulating its phosphorylation. The moniker
“glycogen synthase kinase – 3” was coined because of the ability of GSK-3 to phosphorylate
glycogen synthase enzyme. GSK-3β phosphorylates GS and plays an important role in repressing
its activity (Lawerence and Roach, 1997). There is enough evidence to demonstrate the important
role played by GSK-3β in glycogen metabolism because of its ability to regulate GS. The
phosphorylation sites which play an important role in the activation or de-activation of the GS are
target sites of GSK-3β (Rylatt et al., 1980; Parker et al., 1983).
Since the activity of GS is regulated by GSK-3β any event or inhibitor, which can regulate
the activity of GSK-3β is expected to have an affect on GS as well. The positive effect of Li + - an
established GSK-3β inhibitor on the stimulation of glycogen synthase and glycogen synthesis has
been proved in various studies (Cheng et al., 1983; Tabata et al., 1994; Orena et al., 2000;
Furnsinn et al., 1997; Chen et al., 1998). MacAulay et al demonstrated that exposure of L6
muscle cells and 3T3-L1 adipocytes to Li+ leads to accumulation of de-phosphorylated GS (active
form of GS) (MacAulay et al., 2003).
Be2+ is a potent GSK-3β inhibitor, but the inhibitory effect of Be2+ on the ability of GSK-3β
to phosphorylate its bonafide substrates has not been demonstrated yet. Be2+ seems to be inducing
an increase in the Ser-9 phosphorylation of GSK-3β in NIH/3T3 and Caki-1 cells (Fig. 12). The
phosphorylated Ser-9 residue on the N-terminal region acts as pseudo-substrate of GSK-3β
thereby blocking its active site (Dajani et al., 2001). It can be hypothesized that the inactivated
GSK-3β (blocked active site) will not be able to phosporylate its substrate i.e. the GS enzyme
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hence a decrease in the pGS levels may be observed. In this study the effect of Be 2+ on glycogen
synthase (GS) an important GSK-3β substrate was investigated in cell culture.
Selecting the best cell line for glycogen synthase studies
In order to select a cell line with optimum expression of glycogen synthase (GS); A172,
Caki-1 and NIH/3T3 were cultured in the presence of 0 or 20 mM LiCl for 24 hr. Total cell
lysates of these cells lines were probed for the expression of pGS. Caki-1 and A172 samples
seems to be having no visible pGS bands indicating that these two cell lines may not be suitable
for GS studies (Fig. 14). NIH/3T3 cells show optimum expression of GS and also seem to be
responsive to inhibitory effects of LiCl. Hence NIH/3T3 cells were selected for further pGS
studies.
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Fig 14: Murine fibroblasts are responsive to LiCl induced GS dephosphorylation.Total cell
lysates extracted from A172 , Caki-1and NIH/3T3 treated with 0 or 20 mM LiCl for 24 hr were
analysed using western blotting for the pGS levels. The pGS (Ser641/Ser645) antibody #07-817
from millipore was used.
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Effect of Be2+ on pGS in murine fibroblasts (NIH/3T3 cells)
NIH/3T3 cells were treated with 0, 30 or 100 µM BeSO4 or 20 mM KCl or 20 mM LICl or 20
µM SB216763 for 24 hr or serum starved NIH/3T3 cells were induced with 100 nM insulin for
15–60 min. The phosphorylation state of glycogen synthase (GS) in the total cell lysates was
analyzed by western blotting using a phospho specific affinity purified rabbit antibody from
Millipore (#07-817). The GSK-3β inhibitors Be2+, Li+ and SB216763 caused a decrease in the
phospho-glycogen synthase levels. As expected no decrease in the pGS levels was observed in
the KCl treated samples (KCl was intended to serve as a negative control) (Fig. 15a).
This data suggests that Be2+ treatment elicits a decrease in the pGS levels of NIH/3T3 cells,
demonstrating the ability of beryllium to inhibit the intra cellular kinase activity of GSK-3β in
cell culture.
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Fig. 15a GSK-3β inhibitors and beryllium induce a decrease in the phospho-GS. NIH/3T3
cells were cultured in the presence of 0 or 30 or 100 µM BeSO4 or 20 mM LiCl or 20 µM
SB216763 or 20 mM KCL. For insulin treatment cells were grown in RPMI media supplemented
with 10% bovine growth serum for 24 hr. Post 2X washing with serum less RPMI cells were
serum starved by growing them in 0% BGS RPMI for 2 - 2.5 hrs. Cells were induced with 100
nM insulin for 15 or 30 or 60 min. Total cell lysates were analyzed for phospho-GS using a
affinity purified rabbit polyclonal antibody. The non specific low molecular weight back ground
band in the pGS panel serves as an internal loading control. Total GS, actin and total GSK-3β
were used as loading controls.
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Fig 15b phospho-GS band intensity quantification. The phospho-GS bands intensity was
quantified using Licor ImageStudio 5.0. The band intensity was plotted as percentage of control.
(Additional information about band quantification is available in Appendix VII)
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Closely spaced pGS bands in murine fibroblast samples
An interesting observation in the phospho-GS westerns has been the appearance of a cluster
of three closely spaced bands as seen on the pGS blots at molecular weight close to that of
glycogen synthase i.e. ~80-90 kDa. These bands have been generically designated as band 1,
band 2 and band 3 (Fig. 16a). GSK-3 phosphorylates glycogen synthase (GS) on different serine
residues designated as Ser-640, 644, 648 and 652 (Rylatt et al., 1980; Parker et al., 1983). GS is
primed at Ser-656 by casein kinase II (CKII) (Picton et al., 1982) and is then sequentially
phosphorylated at Ser-652 followed by Ser-648 and so on (Fiol et al., 2000). According to Fiol et
al the phosphorylation of GS by GSK-3β is not random, phoshorylation of Ser-652 leads to
phoshorylation of Ser-648, phosphorylation of Ser-648 leads to phosphorylation of Ser-644 and
so on.
The consensus sequence for the phosphorylation sites of GSK-3β in rabbit skeletal muscle
cells is -P-R-P-A-S(Ser-640/641)-V-P-P-S(Ser-644/645)-P-S-L-S(Ser-648)-R-H-S-S(Ser-652)P-H-Q-S(Ser-656)-E-D-E-E-P (Ryllat et al., 1980). The amino acids of GS mentioned in bold are
the target sites of GSK-3β. Majority of the initial work related to GS was carried out in rabbit
muscle cells and the amino acid numbers were designated based on biochemical studies. The
work on mouse and human GS is more recent and follows the HUGO recommendations; that
begin with the translation start site. Hence the amino acid numbers between rabbit GS and
mouse/human GS differ by one i.e the Ser-640 of rabbit GS (in the consensus sequence)
corresponds to the Ser-641 of mouse GS (explained in Roach et al., 2012).
For western blots, an affinity-purified rabbit polyclonal antibody specific for mouse or human
GS was used. The immunogen used for raising the phospho-GS-antibody is a synthetic peptide
containing phosphor-serines at residues 641 and 645 in the human GS sequence. A cluster of
closely spaced bands is apparent in the phospho-GS western blot (Fig. 16a). Among the three
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bands, band 2’s intensity is decreasing in response to GSK-3β inhibitors as indicated by the line
label. Band 2 was interpreted as representing the main product of GSK3 phosphorylation, because
it was sensitive to treatment with GSK3 inhibitors. It is unclear whether the flanking bands
represent background bands, or alternative forms of phospho-GS arising from the availability of
multiple phosphorylation sites. Fortuitously, phospho-GS western blots also contain a
background band that runs in a different region of the gel, at much lower MW – indicated by an
arrow. This band was included in the western images to demonstrate the sharp resolution attained
during electrophoresis, and also so that it could serve as an extra loading control to document
equivalent total protein per lane.
Alternatively it is also possible that the closely spaced bands are representing the different
isoforms of glycogen synthase protein. In mammals two isoforms of glycogen synthase are
expressed: glycogen synthase -1 (GYS1) and glycogen synthase-2 (GYS2). GYS1 is expressed
mostly in skeletal muscle and most other cell types and GYS2 is restricted to liver (Browner et
al., 1989; Nuttall et al., 1994). It has been observed that NIH/3T3 cells could possibly be
expressing both the isoforms of glycogen synthase because of its embryonic lineage. There is no
direct evidence to suggest that NIH/3T3 cells indeed express both the isoforms of glycogen
synthase. However phospho-glycogen synthase antibodies from different sources seem to be
identifying both the isoforms of glycogen synthase in NIH/3T3 total cell lysates (Appendix IX).
Depending upon the information available from the use of antibodies from different sources in
NIH/3T3 cells it can be speculated that indeed NIH/3T3 cells could possibly be expressing both
the isoforms of glycogen synthase. It is observed that lithium, beryllium and SB216763 seem to
induce a decrease in the phosphorylation status of band 2. From the molecular weight difference
between the two isoforms of glycogen synthase it can be speculated that band 2 is representing
glycogen synthase-1 (Fig. 16a). The effect of insulin on the pGS is not clear, possibly because of
the failure of serum starvation or partly because NIH/3T3 cells may not be the perfect system to
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analyze the insulin-pGS dynamics. However the GSK-3β inhibitors included in this study seem
to have little effect on the phosphorylation status of glycogen synthase-2 (band 3).
The GSK-3β inhibitors Be2+, Li+, insulin (* effect on band 2 not clear) and SB216763 caused
a decrease in the pGS levels (Fig 16b). Correspondingly an increase in the pSer-9 of GSK-3β
induced by all the GSK-3β inhibitors except for SB216763 was observed. SB216763 induced a
decrease in the pGS but did not induce an increase in the pSer9-GSK-3β. KCL at 20 mM
concentration did not induce any major change in the pSer9-GSK-3β signal or decrease in the
pGS levels. This data supports the observation that Be2+ treatment elicits a decrease in the pGS
levels of NIH/3T3 cells.
These results demonstrate the ability of beryllium to inhibit intra cellular kinase activity of
GSK-3β in cell culture. This is first time ever the effect of beryllium on a GSK-3β substrate has
been documented in cell culture.

.
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Fig. 16a Identification of the correct pGS band in the multiple pGS bands cluster.Cell
lysates extracted from NIH/3T3 cells treated with 0, 30 or 100 µM BeSO4 or 20 mM KCL or 20
mM LICl or 20 µM SB216763 for 24 hr or serum starved NIH/3T3 cells induced with 100 nM
insulin for 30 – 60 min were assessed for the effect of different GSK-3β inhibitors on the pGS
levels. Western blots showing the protein levels of pGS.
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Fig 16b Effect of different GSK-3β inhibitors on phospho-GS. Cell lysates extracted from
NIH/3T3 cells treated with 0, 30 or 100 µM BeSO4, 20 mM KCL, 20 mM LICl, 20 µM
SB216763 for 24 hr or serum starved NIH/3T3 cells induced with 100 nM insulin for 30 – 60 min
were assessed for the effect of different GSK-3β inhibitors on the pGS levels. Western blots
showing the protein levels of pGS. Note: The total GSK-3α/β and pSer9—GSK-3β bands were
re-arranged to match the lane sequence of the accompanying blots.
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Beryllium has little effect on the Wnt signaling pathway compared to other GSK-3β
inhibitors
β-catenin is an important substrate of GSK-3β wherein GSK-3β-mediated phosphorylation of
β-catenin leads to its ubiquitin-mediated proteosomal degradation (Miller and Moon, 1996;
Aberle et al., 1997; Ikeda et al., 1998). GSK-3β and β-catenin play a central role in the Wnt
signaling pathway; inactivation of GSK-3β is known to stabilize β-catenin and lead to its
accumulation in the nucleus (Polakis, 2000; Lustig and Behrens, 2003). Li+ treatment induces an
increase in the N-terminal dephosphorylation of β-catenin which is then translocated to the
nucleus (van Noort et al., 2002; Staal et al., 2002; Hagen et al., 2002). In order to understand the
effect of Be2+ on the Wnt signaling pathway, we investigated whether Be2+ treatment can cause an
increase in the nuclear pool of β-Catenin.
Compared to Li+, Be2+- treatment induces negligible nuclear localization of β-Catenin in
NIH/3T3 cells
We optimized confocal microscopy to study the effect of BeSO4 on the nuclear localization of
β-catenin. The effect of BeSO4 along with other GSK-3β inhibitors like insulin, LiCl or
SB216763 was analyzed in NIH/3T3 cells (Fig. 17a). The control NIH/3T3 cells show that the βcatenin is predominantly present in the cytoplasm (Fig 17a, lane 1). 20 mM LiCl led to nuclear
accumulation of β-catenin in NIH/3T3cells as indicated by the arrows (Fig 17a, lane 2). Li+
mimics the effect of Wnt ligands (Stambolic et al., 1996; Hedgepeth et al., 1997) and leads to
accumulation of β-catenin in the nucleus. 20 µM SB216763 also caused nuclear localization of βcatenin (Fig 17A, lane 4). For stimulation with insulin, NIH/3T3 cells were serum starved and
stimulated with 200 nM insulin for 30 – 60 min. The nuclear localization pattern of β-catenin in
NIH/3T3 cells treated with 200 nM insulin and 100 µM BeSO4 is comparable to the control cells.
The lack of much nuclear localization of β-catenin is a hallmark of the control cells. Insulin is a
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GSK-3β inhibitor which doesn’t affect the Wnt signaling pathway (Ding et al., 2000). The
morphology and nuclear β-catenin localization pattern of NIH/3T3 cells treated with BeSO4 and
insulin are similar to the control cells indicating that Be 2+ could be mimicking insulin’s mode of
inhibitory action on GSK-3β.
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(Note: Refer supplementary figures I on page-186 for individual images)

Fig. 17a Effect of Be2+ on the nuclear localization of β-catenin in NIH/3T3 cells.
Immunofluorescence microscopy images of NIH/3T3 cells treated with 0, 100 μM BeSO4, 20
mM LiCl, 20 µM SB216763 for 24 hr or stimulated with 200 nM insulin for 30 – 60 min after
serum starvation. The cells were fixed with 4% formalin and double labeled with a mouse
monoclonal antibody specific for β-catenin and a goat polyclonal anytibody specific for lamin-B
followed by anti mouse Alexa-647/anti goat-FITC secondary antibodies. Nuclear localization of
β-catenin in the LiCl and SB216763 treated NIH/3T3 cells is seen (lane 2, 4 respectively)
whereas not much accumulation of nuclear β-catenin is observed in the insulin and BeSO4 treated
cells (lane 3, 5). All the images are shown at x40 magnification. Scale bar set at 50 µm.
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Be2+ induces minimal nuclear localization of β-catenin in A172 and A172 cells over
expressing wt GSK-3β
A172 cells were treated with 0, 100 μM BeSO4 or 20 mM LiCl or 20 µM SB216763 for 24
hr. Control A172 cells show a conspicuous hollow nucleus (indicated by arrows) indicating the
cytoplasmic localization of β-catenin (Fig. 17b). Li+ and SB216763 induced a clear localization of
β-catenin in the nucleus (lane 2, 4). Be2+ did not elicit any drastic change in the nuclear
localization of β-catenin and the Be

2+

treated cells are similar to the control cells in terms of

nuclear localization of β-catenin (lane 3). These results indicate that Be2+ has minimal effect on
nuclear localization of β-catenin in A172 cells when compared to other GSK-3β inhibitors.
A172 over expressing wt GSK-3β can act as a valuable system to analyze the effects of GSK3β-inhibition. The abundant amount of GSK-3β could be helpful in demonstrating the after
effects of GSK-3β-inhibition compared to untransfected A172 cells expressing native/normal
levels of GSK-3β. A172 cells were transfected with the addgene clone 14753 to over express wt
GSK-3β. Single cell clones of transfected A172 cells over expressing wt GSK-3β were selected.
A172 clone over expressing wt GSK-3β named as P1 (Appendix V) was selected for the immuno
fluorescence imaging. P1B cells (A172 cells over expressing wt GSK-3β) were treated with 0,
100 μM BeSO4 or 20 mM LiCl for 24 hr. Control cells show conspicuous empty nucleus (arrows)
indicating the cytoplasmic localization of β-catenin (Fig. 17c, lane 1). Li+ treatment induced a
clear localization of β-catenin in the nucleus (lane 2). Be2+ did not elicit any drastic change in the
nuclear localization of β-catenin and the Be2+ treated cells are somewhat similar to the control
cells in terms of nuclear localization of β-catenin (lane 3). These results coupled with the data
from untransfected A172 (Fig. 17b) cells indicate that Be2+ has minimal inhibitory effects on Wnt
signaling pathway in A172 cells compared to other established GSK-3β inhibitors. The confocal
data from NIH/3T3, A172 and A172 cells over expressing wt GSK-3β (P1B) shows that probably
Be2+ has nil to minimal effect on the Wnt signaling pathway.
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(Note: Refer supplementary figures II on page-191 for individual images)

Fig. 17b The effect of Be2+ on nuclear localization of β-catenin in A172 cells.
Immunoflorescence microscopy images of A172 cells treated with 0, 100 μM BeSO4, 20 mM
LiCl or 20 µM SB216763 for 24 hr. The cells were fixed with 4% formalin and double labeled
with a mouse monoclonal antibody specific for β-catenin and a goat polyclonal anytibody specific
for lamin-B followed by anti mouse Alexa-647/anti goat-FITC secondary antibodies. Scale bar
set at 50 µm.
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(Note: Refer summplementary figures III on page–195 for individual images)

Fig. 17c Effect of Be2+ on the nuclear localization of β-catenin in A172 cells over expressing
wt GSK-3β. Immunoflorescence microscopy images of A172 cells wt GSK-3β treated with 0,
100 μM BeSO4 or 20 mM LiCl for 24 hr. The cells were fixed with 4% formalin and double
labeled with a mouse monoclonal antibody specific for β-catenin and a goat polyclonal antibody
specific for lamin-B followed by anti mouse Alexa-647/anti goat-FITC secondary antibodies.
Scale bar set at 50 µm.
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Nuclear localization of β-catenin in stable nuclei isolated from A172 cells – A flow
cytometric approach
The immuno fluorescence imaging experiments showed that Be2+ had minimal effect on the
nuclear localization of β-catenin whereas other types of GSK-3β inhibitors such as Li+ and
SB216763 were effective. Assessing nuclear localization of β-catenin in the stable nuclei isolated
from A172 cells was used as an alternative approach to analyze the effect of Be 2+ on Wnt
signaling pathway. A172 cells were treated with 100 µM BeSO4 or 20 mM LiCl and nuclei were
isolated from the cells (Fig 18). The isolated nuclei are stable for more than 24 hr at 4 C as
(explained in the materials and methods section).
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Fig. 18 FSC analysis of stable nuclei and formalin fixed A172 cells. A clear size difference
between nuclei and cells is observed. The position of the peak (red) representing A172 cells on
the x-axis demonstrates the fact that the isolated nuclei are smaller than the cells.
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Be2+ treatment did not have a profound effect like Li+ on the nuclear localization of βcatenin
A172 cells treated with BeSO4 or LiCl for 24 hr were used for isolating stable nuclei.
Concentration dependent increase in the localization of β-catenin was observed in the nuclei
isolated from Li+ treated A172 cells (Fig. 19b). A slight increase in the nuclear β-catenin is
observed between the control nuclei and the Be2+ treated nuclei (Fig 19a). The effect of Be2+ on
the nuclear localization of β-catenin in A172 cells is quite subdued in comparison to the results
produced by Li+ treatment (Fig 19b).
The flow cytometry results along with the confocal imaging results indicate that Be2+ has
minimal effect on the Wnt signaling pathway in NIH/3T3 and A172 cells, compared to other
GSK-3β inhibitors like Li+ or SB216763.
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Fig. 19a The effect of Be 2+ on nuclear localization of β-catenin is minimal compared to Li+.
A172 cells were treated with 0, 10, 30 or 100 µM BeSO4 for 24 hr. Stable nuclei were extracted
from the Be 2+ treated cells. The effect of Be 2+ on the nuclear localization of β-catenin was
assessed using a mouse mono clonal β-catenin primary antibody and an Alexa647 – conjugated
secondary antibody. For each treatment, mean fluorescence per cell was determined from
independent replicates and representative peak for each treatment is shown here. The x-axis
values are represented in log scale.
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Fig. 19b Li+ has a profound effect on the nuclear localization of β-catenin. A172 cells were
treated with 0, 10, 20 or 30 mM LiCl for 24 hr. Stable nuclei were extracted from the Li + treated
cells. The effect of Li+ on the nuclear localization of β-catenin was assessed using a mouse mono
clonal β-catenin primary antibody and an Alexa647 – conjugated secondary antibody. For each
treatment, mean fluorescence per cell was determined from independent replicates and
representative peak for each treatment is shown here. The x-axis values are represented in log
scale.
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Be+ treatment failed to induce clear nuclear translocation of β-catenin in A172, U87MG,
Caki-1 and NIH/3T3 cells
The immunofluorescence data from NIH/3T3, A172 and A172 P1B cells indicates that
beryllium is not able to induce prominent nuclear localization of β-Catenin. The
immunofluorescence data was supported by the flow analysis of stable nuclei isolated from A172
cells after Be2+ and Li+ treatment. Traditionally it has been observed that majority of the work
related to nuclear translocation of β-Catenin is based on immunofluorescence experiments. We
thought it would be logical to analyze the nuclear localization of β-catenin using westerns. We
decided to culture cells under the influence of appropriate concentration of GSK-3β inhibitors and
then fractionate the cytoplasmic and nuclear proteins separately. A clean biochemically
fractionated cytoplasmic and nuclear protein samples lacking cross contamination might work as
a good additional system to analyze the nuclear localization of β-catenin. Be2+ treatment of A172,
Caki-1 and NIH/3T3 cell lines for 24 hr caused an increase in the p53 levels, which is seen
localized predominantly in the nuclear fraction. The up regulation of p53 in the Be2+ treated
samples validates the success of inhibitor effect and acts as a positive control for beryllium
induced up regulation of protein expression.
NIH/3T3 – 10 µM BeSO4 has no effect on the p53 expression but 100 µM BeSO4 leads to
elevated levels of p53 (Fig. 20a, lane 6) as seen in the nuclear fraction. The β-catenin levels both
in the cytoplasmic and nuclear fractions stay fairly constant indicating that probably Be 2+
treatement failed to induce any detectable up regulation of β-catenin.
Caki-1 - 50 µM BeSO4 treatment lead to elevated levels of p53 as observed in the cytoplasmic
and nuclear fraction (Fig. 20b, lane 3&6). A slight increase in the cytoplasmic levels of β-catenin
in the presence of Be2+ is observed but the nuclear β-catenin levels stay fairly constant (b, lane
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5&6) indicating that probably beryllium failed to induce detectable up regulation of β-catenin in
the nuclear fractions of Caki-1 cells.
A172 - 10 µM BeSO4 has no effect on the p53 upregulation but 100 µM BeSO4 caused an
increase in p53 levels as seen in the nuclear fraction and to an extent in the cytoplasmic fraction
as well (Fig. 20c, lane 3&6). The β-catenin level both in the cytoplasmic and nuclear fractions
stays fairly constant (C, lane 2, 3 & 5, 6). 100 µM CaCl2 was used as a negative control and was
expected not induce any change either on p53 or β-catenin. These results indicate that probably
beryllium failed to induce detectable up regulation of β-catenin in the nuclear fractions of A172
cells.
In U87MG the Be2+ induced p53 up regulation data of U87MG cells is not available but Be2+
treatment of U87MG cells causes up regulation of p53 as observed in Fig. 9. There is no effect of
Be2+ treatment on the cytoplasmic and nuclear β-catenin levels in U87MG cells (Fig. 20d). 100
µM CaCl2 was used as a negative control and was expected not induce any change either on p53
or β-catenin. It is possible that probably beryllium failed to induce detectable up regulation of βcatenin in the nuclear fractions of U87MG cells.
The strongest support for the minimal increase in the nuclear localization of β-catenin in the
presence of beryllium comes from the immunofluorescence and flow analysis of stable nuclei
experiments. These results suggest that probably Be2+ has minimal effect on the nuclear
localization of β-catenin.

126

Fig. 20 Be2+ treatment seems to have minimal effect on the nuclear translocation of βcatenin. (a-b)NIH/3T3 and Caki-1 cells were treated with 0, 10 or 100 µM BeSO4 for 24 hr and
the cytoplasmic/nuclear proteins were fractionated. (c-d) A172 and U87MG cells were treated
with 0, 100 µM CaCl2 or 100 µM BeSO4 for 24 hr and the cytoplasmic/nuclear proteins were
extracted out separately as explained in the materials and methods section. The levels of total βcatenin, p53, lamin and tubulin were assessed by western blot analysis. The endogenous lamin
and tubulin serve as loading control. The presence of tubulin or lamin in the cytoplasmic or
nuclear fractions only shows the lack of cross contamination and the good quality of sample
preparation
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Beryllium has no effect on the stability of axin – a possible mechanism for the in ability of
beryllium to induce nuclear localization of β-catenin
Beryllium treatment seems to be having minimal effect on the nuclear localization of βcatenin. Unlike Li+, the inability of Be2+ to induce a major change in the nuclear localization of βcatenin is a surprising observation. In relation to beryllium’s role as a GSK-3β inhibitor, two
contrasting results are observed i.e. the lack of appreciable nuclear localization of β-catenin and
decrease in the phosphorylation of glycogen synthase. These results indicate that Be 2+ is able to
inhibit the activity of GSK-3β fraction involved in the insulin signaling pathway. Contrarily it is
observed that the GSK-3β enzyme fraction regulating the Wnt signaling pathway is fairly
insulated from the inhibitory effects of Be2+. Axin is an important substrate of GSK-3β and
phosphorylation of axin by GSK-3β leads to its stabilization (Yamamoto et al., 1999). Axin,
GSK-3β, APC (Adenomatous Polyposis Coli), casein kinase 1 (CK1), protein phosphatase 2A
(PP2A) and E3-ubiquitin ligase β-TrCP are constituents of β-catenin destruction complex. Wnt
ligands induced inhibition of GSK-3β is known to cause destabilization of axin (Willert et al.,
1999). Inhibition of GSK-3β associated with the β-catenin destruction complex leads to
dephosphorylation/destabilization of axin. The de phosphorylated form of axin cannot interact
efficiently with β-catenin, which in turn leads to destabilization of the β-catenin destruction
complex (Willert et. al., 1999). LiCl treatment caused a decrease in the levels of axin (Yamamoto
et al., 1999) and it could be the possible reason behind the Li+ induced nuclear localization of βcatenin.
We hypothesized that the failure of beryllium treatment to induce any major changes in the
nuclear localization of β-catenin could be due to its inability to perturb the stability of the βcatenin destruction complex. We investigated the effect of beryllium on the stability of axin - an
important constituent of the β-catenin destruction complex.
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In our study we demonstrated that Be2+ has no effect on the stability of axin in A172 and
NIH/3T3 cells (Fig. 21a) Li+ caused a decrease in the total axin levels in A172 (human
glioblastoma) (panel a, lane 7&8), however Be2+ seems to be having little effect on the stability of
axin (panel a, lane 2-6). Fig. 21b Li+ caused a decrease in the total axin levels in NIH/3T3 cells
(murine fibroblasts) (panel b, lane 3), however the total amount of axin in Be 2+ treated sample is
almost same as the control (panel 1, lane 2). Fig. 21c In NIH/3T3 (murine fibroblasts) beryllium
at different concentrations did not induce any change in the total axin levels. These results
indicate that the difference in the effect of Be2+ and Li+ on the nuclear localization of β-catenin
could be because of their inability and ability respectively to disturb the β-catenin destruction
complex respectively (refer schematic diagram 4 on page 131).
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Fig. 21 Be2+ had no effect on the stability of the important β-catenin destruction complex
constituent protein – axin. a A172 (human gliblastoma) treated with 0, 5, 10, 25, 50 or 100 µM
BeSO4 or 10 or 20 mM LiCl for 24 hr. b NIH/3T3 (murine fibroblasts) treated with 0, 100 µM
BeSO4 or 20 mM LiCl for 24 hr. c NIH/3T3 (murine fibroblasts) treated with 0, 1, 2.5, 5, 10, 25,
50 or 100 µM BeSO4 for 24 hr. The effect of beryllium and lithium on the total axin levels was
assessed using western blotting. The endogenous actin serving as loading control.
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Schematic diagram comparing the GSK-3β inhibitory action of beryllium with other GSK3β inhibitors

Schematic diagram 4: Differential regulation/inhibition of GSK-3β by beryllium. The
inability of beryllium to destabilize axin indicates that probably Be2+ is not able to destabilize the
β-catenin destruction complex. Hence beryllium may not be able to strongly inhibit the activity of
“bound GSK-3β”. However the other GSK-3β inhibitors like lithium and SB216763 seems to be
inhgibiting both the fractions of GSK-3β. In this regard beryllium seems to be mimicking insulin
because it has been demonstrated that insulin has no inhibitory effect towards the Wnt/β-catenin
pathway (Ding et al., 2000).
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Activation of p53 could be responsible for down regulating nuclear localization of β-catenin
The possibility of a cross talk between β-catenin and p53 in the progression of human cancers
especially colorectal cancer has been suggested previously (Kinzler and Vogelstein, 1996). Later
studies established a more direct interaction between p53 and β-catenin, wherein it was observed
that deregulated β-catenin can lead to stabilization of p53 and vice versa (Damalas et al., 1999;
Levina et al., 2004). The elevated p53 expression in response to various stimuli is an anti
proliferative mechanism adopted by the human body for protection against the development of
cancer (Oren, 2003; Oren et al., 2002). Deregulation of β-catenin has been implicated in the
development of various cancers, pre dominantly colorectal cancer (Morin , 1999; Polakis, 2000;
Patel et al.,, 2004; Wang et al., 2005; Thakur and Mishra, 2013). Elevated p53 elicits its anti
proliferative effects in relation to β-catenin, firstly by blocking the pro-proliferative action of βcatenin and secondly by down regulating β-catenin expression (Sadot et al., 2001). (refer
schematic diagram 5 on next page)
To eliminate the possibility of aberrant or mutant p53 interfering with the p53 mediated down
regulation of β-catenin, cell lines expressing wt p53 were identified (Table 5).In our study we
observed that A172, U87MG, Caki-1 and NIH/3T3 cells do not show any nuclear localization of
β-catenin in the presence of Be2+ (Fig 20). Be2+ treatment caused up regulation of p53 expression
(Lehnert et al., 2001; Coates et al., 2007; Gorjala and Gary, 2010) and it could be responsible for
regulating the nuclear localization of β-catenin as explained in Sadot et al.
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Schematic diagram explaining the role of p53 in regulating β-catenin

Schematic diagram 5: Upregulation of p53 leads to down regulation of β-catenin via
miRNA-34. (Sadot et al., 2001; Cha et al., 2012)
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Down regulation of p53 expression up regulates nuclear localization of β-catenin
We have used three different methods to “knock down” the p53 protein expression either post
transcription or post translation.
p53 “knock down” using RNAi and its effect on the nuclear localization of β-catenin
Short interfering RNA (siRNA) is commercially available to induce an efficient p53 knock
down. The p53 siRNA is a 20 nucleotide long synthetic double stranded RNA molecule, which
will silence the p53 gene post transcriptionaly. Using siRNA to knock down p53 is the quickest
and easiest way to obtain cells with down regulated p53 expression. The down regulation of p53
using siRNA is transient with the effect lasting until 48 – 72 hr. The p53 siRNA was transfected
into A172 cells as explained in the materials and methods section. Post transfection A172 cells
were allowed to grow in normal RPMI 1640 for 6 hr followed by treatment with BeSO4 for 24 hr.
A172 cells transfected with a non specific universal control siRNA served as the negative control.
After Be2+ treatment the cytoplasmic/nuclear proteins were extracted out separately.
It was observed that in the presence of endogenous wt p53 there is no nuclear localization of
β-catenin after Be2+ treatment (Fig. 20). Fig. 22 A prominent p53 band was observed in the
nuclear samples isolated from A172 cells transfected with the universal control siRNA (Fig. 22,
lane 4). The band corresponding to p53 disappears in the nuclear samples isolated from A172
cells transfected with p53 siRNA, indicating that p53 siRNA was successful in down regulating
p53 expression (Fig. 22, lane 5). In A172 cells the successful knock down of p53 induced nuclear
localization of β-catenin (lane 5) compared to the cells transfected with control siRNA (Fig. 22,
lane 4). A more prominent increase in the nuclear β-catenin is observed when p53 knock down is
coupled with Be2+ treatment (Fig. 22, lane 6).
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The decrease of cytoplasmic β-catenin in the samples generated after p53 knockdown (panel
1, lane 2, 3) is complemented by the increase of nuclear β-catenin (panel 1, lane 5,6) indicating
that the nuclear translocation of β-catenin could be induced by down regulation of p53.
This result demonstrates that, down regulation of p53 causes nuclear localization of β-catenin
and the nuclear localization of β-catenin is amplified in the presence of Be2+.
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Fig. 22 Down regulation of p53 expression using RNAi causes nuclear localization of βcatenin. Cytoplasmic and nuclear proteins were extracted separately from A172 cells transfected
with the control siRNA and p53 siRNA. The transfected cells were treated with 0 or 100 µM
BeSO4 for 24 hr. Western blots showing the protein levels of β-catenin, p53, lamin-A/C and
tubulin. Lamin-A/C and tubulin acting as the loading control.
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p53 knock down using shRNA – Lentiviral vector system
Short hairpin RNA (shRNA) is a sequence inserted into a lentivirus vector plasmid.
Successful insertion of the shRNA sequence into the genome and its subsequent expression will
induce silencing of the target gene expression. The advantage of this method is the development
of stable cell lines with p53 knock down.
The successful transfection of the lentivirus vector plasmid and down regulation of p53
protein via the shRNA was confirmed using western blotting (Fig. 23). A172 cells were
transfected with the p53 shRNA Lentivirus vector plasmid (as explained in the materials and
methods section). As a negative control A172 cells were transfected with an empty Lentivirus
vector plasmid called as A172 p53 control. Successful transfection and expression of the p53
shRNA induced a down regulation of p53 expression (Fig. 23, lane 2). The p53 expression is not
disturbed in the A172 p53 control cells and the p53 levels are comparable to the untransfected
A172 cells (Fig. 23, lane 1, 3). Be2+ treatment at 10 µM for 24 hr did not induce any increase in
the p53 protein levels in the p53 KO cells (Fig. 23, lane 4). Conversely a Be 2+ induced increase in
p53 expression is observed in the untransfected and p53 control A172 cells (Fig. 23, lane 4, 6).
This experiment validates the successful down regulation of p53 expression by the shRNA lenti
virus vector system.
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Fig. 23 Down regulation of p53 by the shRNA lentivirus vector. The untransfected A172 cells,
A172 p53 KO and A172 p53 control cells were treated with 0 or 10 µM BeSO4 for 24 hr. Total
cell lysates were analyzed for p53 and actin after the Be2+ treatment using western blotting.
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p53 knock down using shRNA and its effect on the nuclear localization of β-catenin
The A172 cells carrying the lentivirus vector plasmid were designated as A172 p53 KO cells
(Fig. 24). The cytoplasmic and nuclear protein fractions isolated from A172 p53 KO treated with
BeSO4 show nuclear accumulation of β-catenin (Fig. 24, lane 5&6). The nuclear localization of βcatenin in BeSO4 treated A172 p53 KO is quite evident in comparison to the control (untreated)
A172 p53 KO (Fig. 24, lane 4).
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Fig. 24 Down regulation of p53 protein via the shRNA lentivirus vector aids Be 2+ in
inducing nuclear localization of β-catenin. Cytoplasmic and nuclear proteins were extracted
separately from A172 p53 KO cell treated with 0, 10 or 100 µM BeSO 4 for 24 hr. Western blots
showing the protein levels of β-catenin, p53, lamin-B and tubulin. Be2+ induced nuclear
localization of β-catenin is observed in the nuclear samples (panel 1, lane 5, 6). Lamin-B and
tubulin acting as the loading control.
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Down regulation of endogenous p53 using the HPV E6 protein
The down regulation of endogenous p53 using the HPV gene 6 product provides a good
system to analyze the cellular effects elicited by down regulation of p53. A172 and U87MG cells
transfected with pCMV-E6 plasmid and expressing the human papillomavirus 16 E6 gene were
obtained as a gift from Dr. Cairncross, University of Calgary. The HPV E6 genes can be
transfected into mammalian cells to create cell lines with down regulated p53 expression (Xu et
al., 2005). The successful translation of HPV E6 genes leads to synthesis of the E6 protein, which
can bind to wt p53 and induce ubiquitin mediated degradation of wt p53 (Werness et al., 1990;
Crook et al., 1991). The cell lines expressing HPV E6 protein known as the A172 E6 and U87MG
E6 have down regulated p53 expression as explained in Xu et al (2005). A172 E6 and U87MG E6
cells were treated with BeSO4 and the effect of p53 down regulation on β-catenin was analyzed in
the presence of Be2+.
The total cell lysates of U87MG E6 show minimal p53 expression and a subsequent increase
in the total β-catenin is observed in a concentration dependent manner. Compared to the cells
treated with 0 or 10 µM BeSO4 (Fig. 25, lane-1&2) a marked increase in the total β-catenin
amount is observed in the U87MG E6 cells treated with 30 or 100 µM BeSO4 (lane-3&4).
The total cells lysates of Be2+ treated A172 E6 cells show p53 bands because in E6 cell lines
the p53 expression is not knocked out completely (Fig. 26). The total β-catenin levels in A172 E6
cells are almost constant in the presence of increasing concentrations of BeSO4.
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Fig. 25 Effect of down regulated p53 on the β-catenin levels in total cell lysates of U87MG
E6. U87MG E6 were treated with 0, 10, 30 or 100 µM with BeSO4 for 24 hr. After total cell
lysate extraction from the Be2+ treated cells, western blotting was used to analyze the protein
levels of β-catenin, p53 with actin acting as the loading control.
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Fig. 26 Effect of down regulated p53 on the β-catenin levels in total cell lysates of A172 E6.
A172 E6 were treated with 0, 10, 30 or 100 µM with BeSO4 for 24 hr. After total cell lysate
extraction from the Be2+ treated cells, western blotting was used to analyze the protein levels of βcatenin, p53 with actin acting as the loading control.
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In order to analyze the effect of p53 down regulation on the nuclear localization of β-catenin
A172 E6 and U87MG E6 cells were treated with BeSO4 for 24 hr. The cytoplasmic and nuclear
proteins were fractionated out separately.
Be2+ treatment does not seem to be having any effect on the expression/up regulation of p53
in U87MG E6 cells. Be2+ treatment at 30 µM or 100 µM concentration leads to nuclear
accumulation of β-catenin (Fig. 27, lane 5-6) and increase in the cytoplasmic levels of β-catenin
is also observed (lane 2, 3).
In A172 E6 cells, Be2+ treatment caused an optimum increase in the p53 expression (Fig. 28,
lane 2, 3 or 5, 6). An increase in the nuclear β-catenin is observed in the nuclear fraction of the
A172 E6 treated with 100 µM BeSO4 (lane 6).
The analysis of the β-catenin accumulation/localization in the E6 cell lines shows that down
regulation of p53 leads to stabilization and nuclear localization of β-catenin.
The down regulation of p53 expression was achieved by three independent techniques “p53
RNAi knockdown”, “shRNA Lentivirus vector” and “E6 cell lines expressing HPV E6 protein”.
The results from these three independent experiments demonstrate that down regulation of p53
leads to nuclear localization of β-catenin. It is also observed that the nuclear localization of βcatenin induced by the down regulation of p53 is amplified in the presence of Be2+.
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Fig. 27 Effect of down regulated p53 on the nuclear localization of β-catenin in U87MG E6.
U87MG E6 cells were treated with 0, 30 or 100 µM with BeSO4 for 24 hr. The
cytoplasmic/nuclear proteins were extracted out separately from the Be 2+ treated cells, western
blotting was used to analyze the protein levels of β-catenin and p53. Tubulin and lamin acting as
the loading controls.
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Fig. 28 Effect of down regulated p53 on the nuclear localization of β-catenin in A172 E6.
A172 E6 cells were treated with 0, 30 or 100 µM with BeSO4 for 24 hr. The cytoplasmic/nuclear
proteins were extracted out separately from the Be2+ treated cells, western blotting was used to
analyze the protein levels of β-catenin and p53. Tubulin and lamin acting as the loading controls
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Beryllium and lithium have contrasting effects on the phosphorylation status of β-catenin
β-catenin is phosphorylated on Ser-33, Ser–37 and Thr-41 by GSK-3β (Ikeda et al., 1998;
Sadot et al., 2002; Sutherland, 2011). The phosphorylated β-catenin is then ubiquitinated
followed by proteasomal degradation. As an aftermath of Li+ mediated GSK-3β inhibition, a
decrease in phospho β-catenin level is observed in 293T cells (Sadot et al., 2002). The assessment
of decrease/increase in the phospho β-catenin levels, in the presence of GSK-3β inhibitors can act
as a direct and indisputable method of establishing the effect of GSK-3β inhibitors on Wnt/βcatenin signaling pathway.
We investigated the effect of Be2+ treatment on the phospho β-catenin levels in A172 cells.
Be2+ treatment did not induce any increase or decrease in the phospho β-catenin level (Fig. 29,
lane 2, 3, 4, 5&6) and correspondingly the total β-catenin levels too stayed fairly constant (lane 2,
3, 4, 5&6). These results suggest that probably Be2+ has nil to minimal inhibitory effect on the
Wnt signaling pathway. The analysis of the phospho β-catenin level in Li+ treated samples
showed that Li+ induces an increase in the phospho β-catenin (lane 7&8), which was unexpected.
The lack of increase in the total β-catenin levels indicates that Li+ treatment is primarily
modulating the phosphorylation status of β-catenin only (lane 7, 8). The increase in the p53
protein levels in the presence of BeSO4 and LiCl validates the effectiveness of Be2+ and Li+
treatment on A172 cells.
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Fig. 29 Be2+ has no effect on the phosphorylation status of β-catenin. A172 cells were treated
with 0, 5, 10, 25, 50 or 100 µM BeSO4 or 0, 10 or 20 mM LiCl for 24 hr. The phospho β-catenin
(Ser–33), total β-catenin, p53 and actin protein levels were assessed using western blotting with
actin serving as the loading control.
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MG132 - a proteasome inhibitor, leads to accumulation of phospho β-catenin in A172 cells
MG132 (sc-201270) is a strong proteasome inhibitor (Lee and Goldberg, 1998). Inhibition of
the proteasome machinery using MG132 should have a positive effect on β-catenin turn over.
A172 cells were treated with 100 µM BeSO4 or 20 mM LiCl for 18 hr and then the Be2+- Li+
RPMI was replaced with Be2+- Li+ RPMI supplemented with 10 µM MG132 and the cells were
cultured under the effect of MG132 for 6 hr.
In the presence of MG132 a slight increase in the phospho β-catenin was observed in the
control samples (Fig. 30, lane 4) compared to the control samples lacking MG132 (lane 1). A
profound increase in the p53 protein level is observed in the MG132 control cells (lane 4). The
increase in p53 protein levels in the MG132 samples proves the effective inhibitory effect of
MG132 on proteasome machinery. In the absence of MG132 the phospho β-catenin levels of the
Be2+ treated samples are comparable to the control phospho β-catenin level (lane 1&2). In the
presence of MG132 as well the phospho β-catenin levels of the Be2+ treated samples are
comparable to the control phospho β-catenin level (lane 4&5). These results indicate that may be
Be2+ has no role in inducing the increase in phospho β-catenin in the MG132 + Be2+ treated
samples. The slight increase in the phospho β-catenin levels in the MG132 + Be2+ treated samples
compared to the Be2+ treated samples could be because of the inhibitory effect of MG132 on the
proteasome machinery (lane 2&4). The phospho β-catenin levels of the Li+ treated samples both
in the presence and absence of MG132 are almost the same (lane 3&6). It indicates that probably
Li+-induced increase in the phospho β-catenin is an intrinsic property of Li+, which could be
independent of the effects of MG132.
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Fig. 30 Proteasome inhibitor (MG132) leads to an increase in the phospho β-catenin level in
Be2+ treated samples but not in the Li+ samples. Western blots showing the protein levels of
phospho β-catenin (Ser -33), total β-catenin, p53 and actin. A172 cells were cultured either in the
absence (Fig 30 left) or presence (Fig 30 right) of 10 µM MG132. A172 cells were treated with 0,
100 µM Be SO4 or 20 mM LiCl for 24 hr.
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Down regulation of p53 has no effect on phospho-β-catenin
The observation that Li+ caused an increase in phospho β-catenin in A172 cells was
unexpected, because β-catenin is a substrate for phosphorylation by GSK-3β and Li+ acts as an
inhibitor of GSK-3β kinase activity. Moreover, Sadot et al. observed that Li+ causes a decrease in
phospho-β-catenin when 293T cells are used (Sadot et al., 2002). The A172 cells shown in Fig.
29 and 30 have wild type p53. 293T cells are human embryonic kidney cells that have been
transformed with SV40 large T antigen, which inactivates p53. Considering the potential for
complicated interactions between p53 signaling and the Wnt/β-catenin network, we wondered
whether p53 status could account for the divergent effects of lithium on phospho-β-catenin when
comparing our results to those of Sadot et al. Therefore, we repeated this experiment using the
p53 shRNA-expressing A172 cells (p53 KO A172 cells) (Fig. 31). In p53 KO A172 the p53
expression is down regulated (Fig. 23). However, our results with p53 KO A172 reproduced our
earlier results when A172 cells expressing wild type p53 were used: In p53 KO A172 cells as
well Li+ caused an increase in the phospho-β-catenin but beryllium did not at 24 hr. These results
were reproduced after 48 hr treatment time as well. Our results from p53 KO A172 cells (Fig. 31)
indicate that probably p53 has no role to play in the lithium induced increase of phospho βcatenin.
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Fig. 31 Down regulation of p53 has no effect on the phospho-β-catenin levels. A172 p53 KO
cells were treated with 0 , 10 or 100 µM BeSO4 or 20 mM LiCl for 24 or 48 hr. Western blots
showing the protein levels of phospho β-catenin (Ser -33), total β-catenin, p53 and actin.
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Beryllium in combination with MG132 (a proteasome inhibitor) induces an increase in the
phospho-β-catenin levels in A172 p53 KO cells
In the presence of a proteasome inhibitor an increase in the phosphor-β-catenin levels was
observed (Fig. 30). We wondered what would be the effect of MG132 on shRNA-expressing p53
KO A172 cells. A172 cells were treated with 100 µM BeSO4 or 20 mM LiCl for 18 hr and then
the Be2+-Li+ RPMI was replaced with Be2+-Li+ RPMI supplemented with 10 µM MG132 and the
cells were cultured under the effect of MG132 for 6 hr.
In p53 KO A172 cells the use of MG132 caused phospho β-catenin to accumulate at higher
levels(Fig. 32). There is a marked increase in the phospho β-catenin levels in the untreated
(MG132) samples compared to the untreated samples lacking the proteasome inhibitor MG132.
The beryllium treated samples seems to be following the pattern of untreated cells in terms of
phospho β-catenin accumulation (appreciable amount of phospho-β-catenin accumulation in the
presence of proteasome inhibitor). The p53 KO A172 cells seems to be imitating the normal
A172 cells in showing a little difference in the phospho β-catenin levels in the presence or
absence of proteasome inhibitor. The results from A172 cells (Fig. 30) and p53 KO A172 cells
(Fig. 32) indicate and reiterate the point that probably p53 has no role in the lithium induced
increase of phospho β-catenin .
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Fig. 32 Down regulation of p53 coupled with proteasome inhibiton causes accumulation of
phospho-β-catenin in p53 KO A172 cells. p53 KO A172 cells were treated with 0 or 100 µM
BeSO4 or 20 mM LiCl for 24 hr. Western blots showing the protein levels of phospho β-catenin
(Ser -33), total β-catenin, p53 and actin. p53 KO A172 cells were cultured either in the absence or
presence of 10 µM MG132.
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Discussion
In our previous study we established that Be2+ is a potent GSK-3β inhibitor and it doesn’t
elicits any increase in the Ser-9 phosphorylation of GSK-3β in A172 and HFL cells (Mudireddy
et al., 2014). Analysis of the Ser-9 phosphorylation of GSK-3β in NIH/3T3 and Caki-1 cells
treated with BeSO4 for 24 hr shows that Be2+ treatment caused an increase in Ser-9
phosphorylation of GSK-3β (Fig. 9 & 10). The ability of Be2+ to induce Ser-9 phosphorylation of
GSK-3β seems to be a cell type specific action. In our present study Be2+ did not elicit any change
in the Ser-9 phosphorylation status of GSK-3β in A172 and U87MG cells (Fig. 8&9).
Surprisingly Li+ too did not induce any change in the Ser-9 phosphorylation of GSK-3β in
U87MG cells; this is in contrast to the results reported in Atkins et al (2012). (Fig. 9b, lane 4).
The comparison of beryllium’s effect on the Ser-9 phosphorylation of GSK-3β with other GSK3β inhibitors like Li+, SB216763, insulin or rottlerin shows that it is only Be2+ which elicits a cell
type specific response in A172, NIH/3T3 and Caki-1 cells (Fig. 12 & Table 5). Li+ influences the
GSK-3β to TIMAP to PP1 positive feedback loop eliciting an increase in the Ser-9
phosphorylation of GSK-3β (Zhang et al., 2003). It is possible that in some cell types Be2+ may
not be able to regulate the GSK-3β to TIMAP to PP1 feedback loop because of which no increase
in the Ser-9 phosphorylation of GSK-3β is observed. The uniqueness of beryllium’s role as a
GSK-3β inhibitor lies in its ability to regulate Ser-9 phosphorylation of GSK-3β differentially
depending upon the specific cell lines. In our comparative study here Be2+ is the only GSK-3β
inhibitor among Li+, SB216763 and insulin, which has a cell type specific effect on the Ser-9
phosphorylation of GSK-3β.
Be2+ caused a decrease in the phosphorylation of glycogen synthase (GS) in NIH/3T3 cells
(Fig. 15&16). This is the first time ever the inhibitory effect of Be 2+ on GSK-3β is demonstrated
by assessing the effect of Be2+ on the endogenous target proteins that are downstream of GSK-3β.
Be2+ caused an increase in the Ser-9 phosphorylation of GSK-3β and it could lead to its
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inactivation in NIH/3T3 cells. The increase in the Ser-9 phosphorylation of GSK-3β in the Be2+
treated samples is complemented well by the decrease in phosphorylation of glycogen synthase. It
has been demonstrated that Li+ causes a decrease in pGS levels in L6 muscle cells and 3T3-L1
adipocytes (MacAualy et al., 2003). An intriguing aspect related to the effect of GSK-3β
inhibitors on the phosphorylation status of glycogen synthase has been the selective
dephosphorylation of glycogen synthase isoform-1 only. The expression of glycogen synthase
isoforms is tissue specific (Browner et al., 1989; Nuttall et al., 1994). It has been reported that
unicellular organisms like synechocystis (cyanobacteria) and yeast express both the isoforms of
glycogen synthase (Frakas et al., 1991; Yoo et al., 2014). As explained in the results section
NIH/3T3 could possibly be expressing both the isoforms of glycogen synthase. It is not clear why
lithium, beryllium or SB216763 are able to induce a decrease in the phosphorylation status of
glycogen synthase-1 only. The regulation of glycogen synthase is a complicated phenomenon
which is not clearly understood yet. It has been reported that in yeast the expression of the
glycogen synthase isoforms is differentially regulated (Frakas et al., 1991). Phosphorylation and
dephosphorylation of glycogen synthase plays an important role in its regulation. It could be
possible that the phosphorylation status of glycogen synthase could be differentially regulated as
well. It has been observed that kinases are closely associated with phosphatases and they work in
tandem in regulating the phosphorylation status of substrates. A good example of a
kinase/phosphatase pair working in tandem would be the regulation of Ser-9 phosphorylation of
GSK-3β as explained in the Zhang’s model (schematic diagram 3). Along with different kinases
certain phosphatases like PP1G has been implicated in regulating the phosphorylation status of
glycogen synthase (Smith et al., 1983; Aschenbach et al., 2001). There is a possibility that there
might be a phosphatase that is specific for the isoforms of glycogen synthase and the GSK-3β
inhibitors could be interfering with its phosphatase activity. However this is a speculation and
there is no information to support such a possibility.
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Dominant phosphorylation sites: GSK-3β is one of the many kinases that phosphorylate
glycogen synthase and regulate its activity (explained in Roach et al., 2012). It has been proposed
that in rabbit muscle cells expressing glycogen synthase-1 the phosphorylation of site 2 (*Ser-8),
site 2a (*Ser-11), site 3a (*Ser-641) and site 3b (*Ser-645) play an important role in its regulation
(* amino acid numbers in relation to mouse glycogen synthase) (Skurat et al., 1994, 1995). The
phospho-GS antibody used in this study is specific to the pSer-641 and pSer-645 residues. In liver
glycogen synthase isoform 2 is present and the dominant phosphorylation site on glycogen
synthase-2 is site 2 (*Ser-8) (Ros et al., 2009). It could be possible that the phosphorylation status
of Ser-641 and Ser-645 might be playing a less important role in the regulation of glycogen
synthase-2. Hence it can be speculated that the use of GSK-3β inhibitors in NIH/3T3 cells seems
to have no effect on the phosphorylation status of glycogen synthase-2 (Fig 16). However the
effect of GSK-3β inhibitors on the pGS levels has to be investigated in a cell line representing
hepatic lineage. In this way the precise effect of GSK-3β inhibitors on the phosphorylation status
of glycogen synthase-2 can be analyzed.
Compartmentalization

of

GS:

Prats

et

al

showed

that

along

with

the

phosphorylation/dephosphorylation mechanism compartmentalization of glycogen synthase
seems to be playing an important role in its regulation (Prats et al., 2009). It could be possible that
the glycogen synthase isoforms in the NIH/3T3 cells could be compartmentalized and hence
differentially regulated by GSK-3β inhibitors.
Li+ mimics the actions of insulin and inhibits GSK-3β, which in turn has a positive effect on
glycogen metabolism (Cheng et al., 1983; Bosch et al., 1986; Choi et al., 2000).Whether the Be 2+
treatment induced dephosphorylation of glycogen synthase (GS) has a positive effect on the
activity of GS and glycogen metabolism has to be investigated further.
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The most common way to demonstrate the after effects of GSK-3β inhibition is by assessing
the stabilization and nuclear localization of the important GSK-3β substrate called as β-catenin.
Our data shows that Li+ treatment promotes nuclear localization of β-catenin in NIH/3T3 and
A172 cells. β-catenin is an important constituent of the Wnt signaling pathway. The Li + induced
nuclear localization of β-catenin is an expected result because Li+ mimcs the action of Wnt
ligands (Stambolic et al., 1996; Klein and Melton, 1996; Hedgepeth et al., 1997). Li + treatment
also regulates the glycogen metabolism pathway. Be2+ treatment induced a minimal nuclear
translocation of β-catenin in NIH/3T3 and A172 cells (Fig. 17&18). The analysis of the nuclear
localization of β-catenin in Be2+ or Li+ treated NIH/3T3 and A172 cells suggests that in
comparison to Li+ induced nuclear localization of β-catenin the effect of Be2+ is subtle. Insulin did
not elicit any major influence on the nuclear localization of β-catenin and the same has been
reported in other studies (Ding et al., 2000).
The inability of Be2+ to induce substantial nuclear localization of β-catenin while decreasing
the levels of phospho-glycogen synthase points to the fact that Be2+ could be a pathway specific
GSK-3β inhibitor. Analysis of the effect of Be2+ on axin, an important constituent of the β-catenin
destruction complex shows that Be2+ has little effect on the β-catenin destruction complex, unlike
Li+ (Fig. 21). With little effect on the stability of axin, Be2+ will not be able to destabilize βcatenin destruction complex. A stable and active β-catenin destruction complex marks β-catenin
for ubiquitin mediated proteosomal degradation thus deterring any substantial nuclear localization
of β-catenin. GSK-3β enzyme can be dived into two cellular fractions the “free GSK-3β”, which
is part of the insulin signaling pathway and the “bound GSK-3β” involved in the Wnt pathway.
Li+ seems to be behaving as a GSK-3β inhibitor in a more universal fashion, inhibiting both the
free GSK-3β and the β-catenin destruction complex bound GSK-3β fractions. The GSK-3β
associated with the β-catenin destruction complex is responsible for phosphorylating β-catenin
and marking it for ubiquitin mediated proteasomal degradation.
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We hypothesized that the lack of nuclear localization of β-catenin in the presence of
beryllium is because of its inability to regulate the “bound GSK-3β” which is part of the β-catenin
destruction complex. Axin is a member of the β-catenin destruction complex along with APC,
PP2A, GSK-3β and CK-1. Phosphorylation of axin by GSK-3β stabilizes it and plays a central
role in the regulation of β-catenin. Analysis of the effect of Li+ on axin stability shows that Li+treatment caused de stabilization of axin in A172 and NIH/3T3 cells (Fig 21a&b, panel 1).
However Be2+ seems to be having no effect on axin stability in A172 and NIH/3T3 cells (Fig 21a,
b&c). Lithium is known to de stabilize axin by interfering with GSK-3β mediated
phosphorylation of axin (Yamamoto et al., 1999). It can be concluded that Li+ is able to inhibit the
kinase activity of “bound GSK-3β” because of which it cannot phosphorylate axin. However Be2+
seems to be unable to interfere with the kinase activity of “bound GSK-3β” thus eliciting no
effect on axin’s stability. It can be hypothesized that the Be2+ induced decrease of pGS is because
of the Be2+ mediated inhibition of “free GSK-3β”. Conversely the inability of Be2+ to elicit the
nuclear localization of β-catenin could be because of its failure to access or inhibit the “bound
GSK-3β” thus leaving its kinase activity intact. The inability of Be2+ to regulate proteins like axin
and β-cartenin indicates that the Wnt pathway could be insulated from its inihibitory effects.
Various studies have demonstrated the possibility of a cross talk between p53 and β-catenin
and that the activation of p53 expression down regulates β-catenin (Damalas et al., 1999; Sadot et
al., 2001; Levina et al., 2004). In our study it was observed that Be2+ could not induce nuclear
localization of β-catenin; we thought it would be interesting to investigate the effect of p53
upregulation on the nuclear localization of β-catenin. Our results demonstrated that in cell lines
carrying wt p53 Be2+ treatment did not induce any nuclear localization of β-catenin (Fig. 16). Be2+
treatment causes up regulation of p53 expression (Lehnert et al., 2001; Coates et al., 2007;
Gorjala and Gary, 2010) and it could probably be one of the reasons for the lack of nuclear
localization of β-catenin. Down regulation/knock down of p53 resulted in clear nuclear
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localization of β-catenin (Fig. 22, 24, 27&28). De regulation of β-catenin plays a central role in
development of various cancers. Hence β-catenin is regulated by multiple, overlapping and
intricate mechanisms which are still not clearly understood; p53 mediated down regulation of βcatenin is one among them. It has been proposed that p53 communicates with the endogenous βcatenin using a micro RNA known as miRNA-34a (Kim et al., 2011; Siemens et al., 2013). Our
efforts to knock down miRNA-34a using specialized RNAi analog to establish the role of miR34a in p53 mediated blockade of nuclear localization of β-catenin was not successful (data not
shown).
Li+ induced decrease of phospho β-catenin in 293T cells (human embryonic kidney cells) has
been reported previously (Sadot et al., 2002). Our studies indicate that in A172 cells (human
glioblastoma) Li+ treatment at 10 or 20 mM concentration leads to an increase in phospho-βcatenin levels. (Fig.29). Be2+ treatment on the other hand has no effect on the phospho-β-catenin
(Fig. 29). Even though Be2+ and Li+ are both inhibitors of GSK-3β they seem to be playing
contrasting roles in relation to the phosphorylation status of β-catenin. Interestingly no change
was observed in the total β-catenin levels even when the phosphorylated form of endogenous βcatenin was up regulated. This observation suggests that the change is primarily in the
phosphorylation status of β-catenin. Recently it was shown that Wnt stimulation elicited
accumulation of phosphorylated form of β-catenin in HEK293T cells (Gerlach et al., 2014).
Lithium mimics the action of Wnts (Stambolic et al., 1996; Hedgepeth et al., 1997) and the Wnt
signaling induced accumulation of phospho-β-catenin in HEK293T cells gives credibility to the
ability of lithium to up regulate phosphorylated form of β-catenin.
It has been suggested that along with GSK-3β mediated phosphorylation there could be some
serine/threonine phosphatases which are involved in the regulation of β-catenin. Protein
phosphase 2A (PP2A) is an prominent member of the β-catenin destruction complex and plays an
important role in the regulation of Wnt/β-catenin signaling pathway (Willert et al., 1999; Seeling
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et al., 1999; Li et al., 2001; Yang et al., 2003; Yokoyama and Malbon, 2007). PP2A is made up of
three subunits designated as A, B and C which constitutes the holoenzyme. It has been reported
that the phosphorylation of PP2A inhibits its phosphatase activity, which in turn leads to an
increase in β-catenin phosphorylation (Bos et al., 2006). Interestingly lithium has been shown to
inhibit PP2A in certain cell types (Mora et al., 2002). It has been reported that lithium inhibits
PP2A by preventing methylation of subunit C and by causing the dissociation of subunit B from
the core enzyme (Chen et al., 2006). These studies points to the fact that lithium has the ability to
regulate the phosphatase activity of PP2A towards phospho-β-catenin. Another closely related
phosphatase called as protein phosphatase 1 (PP1) is an important constituent of the GSK-3β–
TIMAP–PP1 feedback loop, wherein it positively regulates GSK-3β via its phosphatase activity
(Jope, 2003; Li et al., 2007). The ability of Li+ to elicit an increase in the Ser-9 phosphorylation
of GSK-3β has been partly attributed to the perturbations it can cause in the GSK-3β–TIMAP–
PP1 feedback loop (Zhang et al., 2003). It is possible that only Li+ but not Be2+ is able to interfere
with the PP2A activity, because of which only Li+ could be facilitating accumulation of phosphoβ-catenin in A172 cells.
However the precise role of PP2A in the β-catenin destruction complex is not clear yet. It has
been reported that PP2A might be involved in de phosphorylation of APC (Ikeda et al., 2000).
The most important question whether PP2A can dephosphorylate the β-catenin associated with
the β-catenin destruction complex remains unanswered. It has been reported that PP2A can
dephosphorylate β-catenin in vitro (Su et al., 2008). Su et al also suggests that APC could be
protecting the phosphorylated N-terminal region of β-catenin by shielding it from PP2A. The
available data implies that the role of PP2A in regulation of β-catenin in the β-catenin destruction
complex is not clearly understood.
β-TrCP is a F-Box protein which is an important component of the ubiquitin ligase complex
(SCF) involved in regulation of β-catenin stability (Winston et al., 1999; Latres et al., 1999) and
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this ubiquitin ligase complex is associated with the β-catenin destruction complex (Hart et al.,
1999; Liu et al., 1999, Major et al., 2007). The GSK-3β mediated phosphorylation of Ser-33 and
Ser-37 present on the N-terminal region of β-catenin in the β-catenin destruction complex serves
as the recognition site for β-TrCP (reviewed in Kikuchi et al., 2006). The β-TrCP initiates the
binding of E2 ligase followed by poly-ubiquitination of β-catenin which ultimately leads to its
proteosomal degradation (reviewed in Kimelman and Xu, 2006). It has been suggested that APC
could be playing an important role in the β-TrCP mediated ubiquitination of β-catenin (Sadot et
al., 2002; Yang et al., 2006; Su et al., 2008). It has also been suggested that in the absence of
APC, phoshorylated form of β-catenin is rapidly de phosphorylated thus diminishing the
possibility of poly-ubiquitination (Su et al., 2008). These studies suggest that some members of
the β-catenin destruction complex could be helping the β-TrCP mediated ubiquitination of βcatenin. Hence the loss of a stable and functional β-catenin destruction complex could interfere
with the β-TrCP mediated ubiquitination thus preventing the proteosomal degradation of
phospho-β-catenin.
Lithium is a strong GSK-3β inhibitor and is known to inhibit GSK-3β’s ability to
phosphorylate its substrates. β-catenin is a well established and highly studied GSK-3β substrate
and the “accepted β-catenin dogma" is that the inhibition of GSK-3β should elicit a sharp
decrease in phospho-β-catenin levels. Surprisingly our results suggest that the “accepted βcatenin dogma” may not be always true. Lithium seems to be inhibiting the Wnt/β-catenin
signaling pathway by three different mechanisms. Lithium induces Ser-9 phosphorylation of
GSK-3β (Zhang et al., 2003), it induces destabilization of axin because of which the stability of
the β-catenin destruction complex could be affected (Fig. 21). Lithium also inhibits the activity of
PP2A (Chen et al., 2006; Mora et al., 2002). The above mentioned reasons could be responsible
for the lithium mediated up regulation of phosphorylated form of β-catenin. We are proposing a
hypothetical model to explain the “regulation of β-catenin/phospho-β-catenin” by the β-catenin
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destruction complex and the role of lithium as a “Wnt mimicking agent” (schematic diagram 6, next page)
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Schematic diagram 6: Hypothetical model explaining the increase of phospho-β-catenin in
the presence of lithium
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The lithium induced increase in the phospho-β-catenin levels of A172 cells was a surprising
observation (Fig. 29). Conventional knowledge about lithium’s role as GSK-3β inhibitor points to
the fact that it should lead to a decrease in the levels of phospho-β-catenin, as explained in Sadot
et al. A critical difference between our study and Sadot et al is their use of 293T cells (human
embryonic kidney cells containing the SV40 T antigen) and we have used A172 cells
(glioblasoma). Another important difference is the p53 status in A172 and 293T cells; T antigen
is known disrupt the activity of p53 protein (Ali and DeCaprio, 2001). We speculated that the
accumulation of phospho-β-catenin in A172 cells could be because of the presence of wt p53.
Hence we used the shRNA A172 p53 KO cells to analyze the effect of lithium on phospho-βcatenin. Our speculation that the presence of wt p53 in A172 cells could be causing accumulation
of phospho-β-catenin in lithium treated cells was incorrect. The effect of lithium on phospho-βcatenin did not change depending upon the functional status of p53. These observations are very
intriguing because Li+ induced inhibiton of GSK-3β should cause a decrease in the phospho-βcatenin. As observed p53 status seems to be eliciting no effect on the Li+ induced accumulation of
phospho-β-catenin. There is a remote possibility that the Li+ induced accumulation of phospho-βcatenin in A172 cells could be an exclusive cell type specific event. However it would be prudent
to examine the effect of Li+ on phospho-β-catenin in other cell types as well.
Several studies have shown that β-catenin plays a critical role in cancerous proliferation of
cells (Morin, 1999; Valenta et al., 2012). De regulation of β-catenin can happen due to many
reasons and the two most important being: 1. mutations in the β-catenin gene (CTNNb1) which
affects the important serine/threonine residues in the N-terminal region of the β-catenin. 2. Any
mutation or inhibition of the proteins like APC, axin, GSK-3β or PP2A, which are all constituents
of the β-catenin destruction complex. The mutated ser/thr residues on the amino terminal region
of β-catenin cannot provide the post translational phosphorylation signal for the ubiquitin
mediated proteasomal degradation of β-catenin. The stabilization and nuclear accumulation of β-
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catenin leads to activation of β-catenin-target genes some of which are involved in the
development of cancer (Thakur and Mishra, 2013). Activation of Wnt signaling and abnormal
nuclear localization of β-catenin results in development of tumoural phenotype in mesenchymal
stem cells (Herencia et al., 2012), development of colon cancer (Tetsu and McCormick, 1999)
and development of human colorectal carcinomas (Mann et al., 1999). Nuclear localization of βcatenin is associated with the local lymph node metastasis or distant metastasis in a variety of
cancers like colorectal (Cheng et al., 2011), breast (Robles-Frias et al., 2006), oesophageal (Hou
et al., 2011) and cervical (Noordhuis et al., 2011). Nuclear localization of β-catenin is associated
with malignant melanomas as well (Rimm et al., 1999) and abnormal repression of GSK-3β can
possibly lead to activation of oncogenes.
Inhibition of GSK-3 presents a peculiar problem and has its own implications. Down
regulation of GSK-3β activity could have a positive effect on the glycogen metabolism and tau
protein phosphorylation dynamics, which have direct implications in diabetes miletus type 2 and
alzheimer’s disease respectively. Conversely inhibition of GSK-3β could lead to activation of
proto oncogenes due the stabilization and nuclear localization of β-catenin.
A potent GSK-3β inhibitor is expected to bring about the desired effect along with the
stabilization and nuclear localization of β-catenin. As demonstrated in our study GSK-3β
inhibitors insulin, Li+ and SB216763 were successful in down regulating the phosphorylation of
GS and except for insulin the other two GSK-3β inhibitors (Li+ and SB216763) caused nuclear
localization of β-catenin as well. Li+ is already in use for anti-bipolar therapy. The IC50 value of
Li+ is ~ 2mM but the therapeutic concentration is ~1 mM (Malhi et al., 2013). The use of Li + at a
concentration lower than its IC50 for therapeutic purpose is to avoid complete or unrestricted
inactivation of GSK-3β. Our study indicates that Be2+ can act as a potent GSK-3β inhibitor at
intra cellular level. The inhibitory effect of Be2+ seems to be biased more towards the glycogen
synthesis pathway, while keeping the Wnt signaling fairly insulated from its inhibitory effects.
166

Insulin is a GSK-3β inhibitor, but the GSK-3β fraction which is part of the β-catenin destruction
complex seems to be “insulated” from the inhibitory action of insulin (Ding et al., 2003).
However the possibility of a cross talk between insulin and Wnt signaling pathway does exists
and it has been reported that insulin can stimulate β-catenin pathway (Desbois-Mouthon et al.,
2001). Hence it is necessary to use the word “insulated” in relation to GSK-3β inhibition with
caution.
This preliminary study highlights the unique properties of Be2+ in terms of its differential
regulatory effect on the pathways in which GSK-3β plays a central role. This unique property of
Be2+ could conceivably be exploited for therapeutic purpose. Before commenting on the
therapeutic potential of Be2+ it is imperative to ascertain the mechanism behind the Be2+ induced
inhibition of GSK-3β. How is Be2+ modulating the inhibition of GSK-3β by “direct mechanism”
and what is the effect of Be2+ on the “scaffolding proteins” that are part of the β-catenin
destruction complex are some of the un answered questions.
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CHAPTER 6

Beryllium could be involved in the regulation of BTG2, DDB2 and FAM III B gene
products
Introduction:
Our lab demonstrated that beryllium can induce an increase in the expression of important
cell cycle regulators p53 and p21 (Coates et al., 2007; Gorjala and Gary, 2010, Mudireddy et al.,
2014). There is very limited information available about the effect of beryllium on mammalian
cells at molecular level. There could be many other important genes/gene products that might be
regulated by Be2+. Microarray is a powerful technique that can help in analyzing the expression of
genes under different conditions. From the microarray data available in our lab, it was observed
that apart from p21 there are other genes, which respond to beryllium treatment. BTG2, DDB2
and FAM III B genes were selected for this study and the expression of these genes after Be 2+
treatment was analyzed using RT PCR.

Materials and methods
Cell culture
A172 cells were cultured in RPMI 1640 HEPES (cat#23400-021, Gibco) supplemented with
10% fetal bovine serum (FBS) and 1x antibiotic-mycotic.
Beryllium treatment
BeSO4.4H2O (lot&filling code: 413015/1 22001, Fluka) was used to prepare a stock solution.
Beryllium stock solution was diluted to obtain required concentration.
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Cells used in this study were obtained after trypsinizing a batch of cell culture dishes. A
common pool of cells was generated which was then used for the experiment. The cells
designated as control were cultured in normal RPMI 1640 or 10 µM BeSO4 for 24 hr.
Real time PCR
After the treatment of A172 with the inhibitors or ionizing radiation, total mRNA was
extracted using Rneasy Mini Kit and QIA-shredder (Qiagen cat #74104 and 79654). The RNA
concentration was measured using nano drop UV-vis spectrophotometer. Total mRNA was
reverse transcribed to generate copies of cDNA. Real time PCR was performed on same quantity
of cDNA sample using QuantiTect SYBR green PCR kit (Qiagen cat #205311) and QuantiTect
SYBR green PCR kit (Qiagen cat # 204143). The following primer sets were used in the study
QT00095431, QT00079247, QT00062090, QT00240247 for human GAPDH, human p21
(CDKN1A) and human BTG2 respectively (QuantiTect Primer assay). .
The thermal cycling program was set in the following way for amplification and detection –
Step 1: Initial denaturation step at 95 C for 15 minutes
Step 2: Annealing at 55 C for duration of 30 seconds.
Step 3: The primer extension step was set at 72 C for 30 seconds
The step 1, 2 and 3 can be considered as a thermal cycle and the BioRad thermal cycler was
programmed to repeat this cycle 40 times.
Final step: The thermal cycle program was terminated after performing a final denaturation step
at 95 C for 1 minute followed by a final extension performed at 72 C for 1 minute
For the melt curve analysis the starting point was set at 55 C for 10 seconds with a step by
increase of 0.5 C after cycle 2 (of the total 40 cycles).
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For data analysis – RT PCR data was normalized against actin. The upregulation or down
regulation of the gene expression under the effect of inhibitors or ionizing radiation was
calculated as % of control.
IR treatment
For ionizing radiation, the Cabinet X-Ray system, model Rx-650, by Faxitron X-ray corp was
used. Accordingly A172 cells were exposed to 5 Gy or 10 Gy ionizing radiation.
Statistical analysis:
GraphPad Prism v6.0c (Mac OS) was used for analyzing the data. One-way ANOVA with
Tukey’s multiple comparisons test was used to obtain P values comparing each group with all the
other groups (P <0.05 considered as significant). The log transformed values were used for the
analysis.

Results
Be2+ at concentrations, as low as 10 µM caused a marked increase in the mRNA levels of the
important cell cycle regulator p21 in A172 cells (Fig. 33). Li+ treatment too caused an increase in
the mRNA levels of p21. However exposing the cells to ionizing radiation (X-rays) did not elicit
any increase in the mRNA levels of p21.
Be2+ caused a significant decrease in the mRNA levels of FAM III B in A172 cells (Fig. 34).
Li+ and ionizing radiation (X-ray) treatment as well caused a decrease in the mRNA levels of
FAM II B. However the function of FAM III B gene is not known.
DDB2 gene encodes the DNA damage binding protein 2 and it is is involved in DNA damage
repair. (Keeney et al., 1993; Wakasugi et al., 2002; Liu et al., 2000). Be 2+ has no significant effect
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on the mRNA levels of DDB2 in A172 cells. Li+ treatment and exposure of A172 cells to X-ray
did not have any significant effect on the DDB2 mRNA levels (Fig. 35).
B-cell translocation gene 2 (BTG2) is a member of the BTG gene family and encodes the
BTG2 protein. BTG2 is a p53 dependent protein and is an important component of the cellular
response to DNA damage (Rouault et al., 1996; Puisieux and Magaud, 1999; Winkler, 2010). In
the presence of Be2+ there is little increase in the mRNA levels of BTG2, which is comparable to
the increase/change induced by ionizing radtaion (X-ray) treatment (Fig. 36). Li+ treatment caused
significant increase in the mRNA levels of BTG2 gene in A172 cells.
The is no significant change in the actin mRNA levels in the presence of Be2+ or after
treatment with ionizing radiation (Fig. 37). Li+ treatment seems to be down regulating the actin
mRNA levels to an extent.
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Fig. 33 Beryllium at 10 µM concentration caused an increase in p21. A172 cells were treated
with 0, 10 µM BeSO4, 10 mM LiCl for 24 hr or 5 Gy X-ray or 10 Gy X-ray. A significant
increase in the p21 mRNA is observed in the 10 µM BeSO4 samples. Statistically significant
differences are indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistically
non significant values are mentioned as ns.
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Fig. 34 Beryllium at 10 µM concentration caused a significant decrease in FAM III B
mRNA. A172 cells were treated with 0, 10 µM BeSO4, 10 mM LiCl for 24 hr or 5 Gy X-ray or
10 Gy X-ray. Data presented as mean +/- standard deviation. Statistically significant differences
are indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Fig. 35 Beryllium at 10 µM concentration had no significant effect on the DDB2 mRNA.
A172 cells were treated with 0, 10 µM BeSO4, 10 mM LiCl for 24 hr or 5 Gy X-ray or 10 Gy Xray. Data presented as mean +/- standard deviation. Statistically significant differences are
indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistically non significant
values are mentioned as ns.
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Fig. 36 Beryllium at 10 µM concentration had no significant effect on the BTG2 mRNA.
A172 cells were treated with 0, 10 µM BeSO4, 10 mM LiCl for 24 hr or 5 Gy X-ray or 10 Gy Xray. Data presented as mean +/- standard deviation. Statistically significant differences are
indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistically non significant
values are mentioned as ns.
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Fig. 37 Beryllium at 10 µM concentration had no significant effect on the actin mRNA
levels. A172 cells were treated with 0, 10 µM BeSO4, 10 mM LiCl for 24 hr or 5 Gy X-ray or 10
Gy X-ray. Data presented as mean +/- standard deviation. Statistically significant differences are
indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistically non significant
values are mentioned as ns.
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Discussion
Limited information is available about the effects of beryllium at molecular level. The effect
of beryllium on the cell cycle regulators like p53 and p21 has been documented well in our lab.
Here we tried to investigate the effect of Be2+ on other genes/gene products.
Be2+ affects a sharp decrease in the mRNA levels of the FAM III B gene. No information is
available about the function of FAM III B gene. In our lab it was observed that beryllium
treatment either induces an increase in expression of target genes or has no effect. The significant
decrease in the expression of FAM III B gene is an interesting observation, which has to be
investigated further.
One of the physiological affects associated with Be2+ treatment is the up regulation of cell
cycle regulators. DDB2 is a protein associated with DNA damage and the mRNA levels are
increasing in the presence of Li+ only but not Be2+ or ionizing radiation. It indicates that Be2+ may
not be able to induce any DNA damage in A172 cells. BTG2 protein is associated with cell cycle
regulation. Beryllium induces cellular senescence (Coates et al., 2007; Gorjala and Gary, 2010)
and the up regulation of BTG2 could be one of the reasons behind Be2+ induced senescence.
It is important to analyze the effect of Be2+ on the above mentioned genes at the transcript
level. It will be worthwhile to investigate whether Be2+ can induce any post translational
modification or if it has any effect on the stability of the above mentioned gene products.
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CHAPTER 7

RESEARCH SUMMARY AND FUTURE DIRECTIONS
Summary
1. The DRC survey shows that not all cell lines are tolerant to beryllium. The breast cancer cell
lines MCF-7 and T-47D were found to be tolerant to high concentrations of BeSO4. It was
also observed that neuronal cell lines are responsive to optimum concentrations of BeSO4.
2. Beryllium inhibits the in vitro kinase activity of pure recombinant GSK-3β much more
potently compared to lithium - another potent inhibitor of GSK-3β. These results indicate a
direct interaction between Be2+ and GSK-3β.
3. Beryllium is less toxic to cells at physiologically relevant concentrations compared to lithium.
4. The effect of beryllium on the Ser-9 phosphorylation of GSK-3β seems to be cell type
specific. Beryllium did not induce an increase in the pSer9-GSK-3β in A172, HFL and
U87MG cells. However an increase in the pSer9-GSK-3β was observed in NIH/3T3 and
Caki-1 cells.
5. For the very first time our results demonstrate the effect of beryllium on the proteins that are
downstream of GSK-3β. A beryllium induced decrease in the phosphorylation status of
glycogen synthase (GS) was observed in NIH/3T3 cells. The inhibitory effect of beryllium on
the kinase activity of GSK-3β is confirmed by the decrease in the phospho-GS levels.
6. A very interesting aspect of this study has been the effect of beryllium on β-catenin, another
important target protein of GSK-3β. Beryllium seems to be differentially regulating glycogen
synthase and β-catenin. Lack of nuclear localization of β-catenin in NIH/3T3 and A172 cells
in the presence Be2+ indicates that the Wnt/β-catenin pathway could be insulated from its
effects.
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7. Beryllium seems to be having no effect on the stability of axin, an important member of the
β-catenin destruction complex. The inability of beryllium to de-stabilize the β-catenin
destruction complex could be the possible reason behind its differential regulation of
glycogen synthase and β-catenin.
8. We have observed in our study that the presence of active and functional p53 plays an
important role in the regulation of β-catenin. Loss of functional p53 caused an increase in the
nuclear localization of β-catenin in A172, A172 E6 and U87MGE6 cells.
9. Beryllium was not able to modulate any change in the phosphorylation status of β-catenin.
We observed that lithium seems to be inducing an increase in the phospho-β-catenin levels
and beryllium cannot. This was a very surprising observation since lithium is a strong GSK3β inhibitor and is expected to induce decrease in the phosphorylated form of β-catenin.
These results also indicate that beryllium could possibly be having no effect on the Wnt/βcatenin pathway. We have proposed a hypothetical model to explain the lithium induced up
regulation of β-catenin.

FUTURE DIRECTIONS
1. In order to analyze the effect of Be2+ on other cellular kinases, we investigated its effects on
the kinase activity of pure recombinant protein kinase A (PKA) enzyme. Our studies
(documented in CHAPTER 4) shows that Be2+ is down regulating the activity of pure
recombinant PKA (Fig. 3a). The specificity of beryllium against the activity of other closely
associated kinases like Akt/PKB has to be investigated thoroughly. Akt (also called protein
kinase B) phosphorylates GSK-3β and is involved in the insulin signaling pathway
(Sutherland et al., 1993; Shaw, et al., 1997; Cross et al., 1994, 1995; Stambolic and
Woodgett, 1994). Apart from Akt/PKB another good candidate to analyze the effect of
beryllium on other kinases would be the cyclin dependent kinases (CDK). The role of CDKs
along with GSK-3β especially CDK-5 has been established in the tau hyperphosphoryaltion
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(Plattner et al., 2006; Garcia-Perez et al., 1998). It will be interesting to investigate the
inhibitory effect of beryllium on kinases closely associated with GSK-3β, in order to
comment on the specificity of Be2+.
2. The inhibitory Ser-9 phosphorylation plays a significant role in regulation of GSK-3β. We
observed that beryllium modulates an increase in the Ser-9 phosphorylation of GSK-3β
depending on the cell type. It would be logical to investigate whether beryllium induces any
other post translational modification of GSK-3β. Phosphorylation of Tyr-216 along with the
Ser-9 seems to play an important role in regulating GSK-3β (Diehl et al., 1998; Meijer et al.,
2004; Bijur and Jope, 2003; Park et al., 2013). It could be possible that the effect of
beryllium on the Tyr-216 if any might be consistent across all cell types. Hence it would be
worthwhile to investigate the effect of beryllium on Tyr-216 phoshorylation of GSK-3β.
3. Li+ mimics insulin and has a positive effect on glycogen metabolism (Cheng et al., 1983;
Bosch et al., 1986; Choi et al., 2000). Beryllium too inhibits GSK-3β and induces a decrease
in the inactive phosphorylated form of GS (Fig. 16). However whether the beryllium
induced decrease in the phospho-GS form translates into any positive effect on glycogen
metabolism or glucose transport has to be investigated further. We have analyzed the effect
of Be2+ on the phospho-GS levels in murine embryo fibroblasts only and it would be
worthwhile to extend these studies in cell lines representing liver and muscle lineages. Since
muscle and liver are major sites of glycogen metabolism.
4. A major concern that arises due to lithium induced inactivation of GSK-3β is the nuclear
accumulation of β-catenin. The adverse effect of accumulated nuclear β-catenin is the
activation of the β-catenin/TCF/LEF target genes, some of which are proto-oncogenes (Dale,
1998; Brantjes et al., 2002). We observed that beryllium seems to be inducing minimal
nuclear localization of β-catenin in NIH/3T3 and A172 cells (Fig. 17). However the effect of
beryllium on the TCF/LEF target genes which are further down stream of β-catenin, needs to
be investigated. The effect of beryllium on the the β-catenin/TCF/LEF targets has to be
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investigated to re assure the fact that the beryllium induced inhibition of GSK-3β will not
lead to activation of oncogenes. Some of the important β-catenin/TCF/LEF targets that can
be investigated are CDK-1, matrix metalloproteinase-7, c-jun and fra-1 (Shtutman et al.,
1999; Brabletz et al., 1999; Mann et al., 1999).
5. GSK-3β is an important member of the β-catenin destruction complex along with APC
(Adenomatous Polyposis Coli), axin, casein kinase 1 (CK1), protein phosphatase 2A (PP2A)
and E3-ubiquitin ligase β-TrCP (Zeng et al., 1997; Behrens et al., 1998; Hart et al., 1998,
Ikeda et al., 1998; Itoh et al., 1998; Salic et al., 2000; Kikuchi, 1999). We have analyzed the
effect of beryllium on the stability of axin and it was observed that unlike lithium, beryllium
was not able to destabilize axin (Fig. 21). APC is another important member of the β-catenin
destruction complex and a bonafide substrate of GSK-3β (Ikeda et al., 2000; Ferrarese et al.,
2007). It will be interesting to investigate the role of beryllium in regulating the
phosphorylation/stability of APC and the overall effect it has on the stability of the β-catenin
destruction complex. A comprehensive understanding of the effect of beryllium on the
important members of the β-catenin destruction complex could provide answers behind the
inability of beryllium to induce clear nuclear localization of β-catenin.
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CHAPTER 8

Alternate hypothesis – possible mechanism for Be2+ transport into the cells
Bivalent metal cations such as Mg2+ and Ca2+ play important roles as co factors of
proteins/enzymes along with other cations like Zn2+. The concentrations of these cations have to
be very tightly regulated because the intra and extra cellular concentrations of these ions are
critical for cellular signaling. There are specific mechanisms by which these ions are transported
in and out of the cells. There are other metal ions like iron that are also important for cellular
functions but we will limit our discussion to the Mg2+ and Ca2+. Beryllium is a group IIa metal
cation with an ionic radii of 34 pm and is a potential GSK-3β inhibitor at intracellular level
(unpublished data). For a metal ion or an inhibitor to function as a biologically active agent it is
necessary that the inhibitor has to be internalized by the cell so that it can interact with the target
protein. In our lab it was observed that A172 (human glioblastoma) and RKO (human colon
carcinoma) cells were able to successfully internalize Be2+ from the surrounding media (Gorjala
and Gary, 2010). The important question is what is the mechanism by which beryllium is
transported into the cell.
It could be possible that the cellular machinery associated with Ca2+ or Mg2+ transport might
be playing an important role in the intracellular transport of beryllium as well.
Calcium ion:
Ca2+ is a divalent metal cation that is involved in the regulation of different cellular functions
and is also an important intracellular messenger (Carfoli, 2003; Petersen et al., 2005; Berridge,
2005). The intra cellular concentration of Ca2+ is approximately 100 nM whereas the extracellular
concentration is around 2 mM (Clapham, 2007). The intracellular and extracellular concentrations

182

of Ca2+ are very tightly regulated and the intra cellular Ca2+ ions are stored in the endoplasmic
reticulum, mitochondria and golgi complex (explained in Bootman, 2012). The Ca 2+ homeostasis
is maintained with the help of multiple transporters such as voltage gated channels, Na +/Ca2+
exchanger (NCX), plasma membrane Ca2+ ATPase (PMCA), Na+/Ca2+ - K+ exchanger (NCKX)
and sarcoendoplasmic reticular Ca2+ ATPase (SERCA) (Clapham, 2007; Bootman, 2012).
The EF hand domain is the most common motif associated with the Ca2+ binding proteins
(Nakayama and Kretsinger, 1994). Calmodulin is one of the most well studied Ca2+ binding
proteins consisting of the EF hand motif (Stevens, 1983; Chin and means, 2000). Various proteins
have calmodulin binding sites where it acts as an adaptor recruiting Ca2+ to the target proteins that
lack the Ca2+ binding ability (Chin and Means, 2000).
Calmodulin is classified as a Ca2+ binding protein and it can be expected that its binding is
fairly specific towards Ca2+. It has been observed that calmodulin has auxillary binding sites for
other divalent cations like Zn2+ and Mn2+ (Milos et al., 1989). However in an independent study
by Ozawa et al it was reported that calmodulin can bind to cations with ionic radii larger than
Ca2+, such as Ba2+ and Pb2+ but not smaller ions like Mg2+, Zn2+ or Cu2+ (Ozawa et al., 1999). It
might be possible that calmodulin binds to certain divalent cations like Be2+ apart from Ca2+ and
that Be2+ might interfere with the functions of calmodulin.
Apart from calmodulin it could be possible that certain Ca2+ ion exchanger complex might be
playing a potential role in the transport of Be2+ into the cells. It was observed that a Na+/Ca2+ -Li
exchanger (NCLX) called as FLJ22233 can transport Li+ into the cells and affect Ca2+ efflux
(Patly et al., 2004). Even though Li+ is a monovalent cation it is being transported by a transporter
associated with Ca2+. It can be speculated that as in the case of Li+, ‘ion exchangers’ associated
with Ca2+ transport could be involved in transport of Be2+.
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Additionally it can be conjectured that there might be an unidentified ‘ion exchanger’ that
could be involved in the transport of Be2+.
Magnesium ion:
Magnesium is a divalent cation with ionic radii of 133 pm. Mg2+ is an important cofactor for
various metabolically important enzymes and GSK-3β is one among them. The intracellular
concentration of Mg2+ ions vary from 17 to 20 mM (Romani, 2007). Mg2+ plays an important role
in the regulation of proteins and in maintaining the integrity of nucleic acids and phospholipids
(Romani and Maguire, 2002).
There are different Mg2+ ion transporters/channels associated with prokaryotes and prominent
among them are the CorA super family consisting of CorA, ALR1/ALR2, Mrs2/AtMrs2, Lpe10
(Hmiel et al., 1986, 1989; Moomaw and Maguire, 2008). Another Mg2+ transporter associated
with prokaryotes is the Mgt family consisting of MgtA and MgtB (Smith et al., 1995, 1998;
Snavely et al., 1991; Moomaw and Maguire, 2008).
Some of the Mg2+ transporters of eukaryotic origin belong to the TRPM family consisting of
TRPM6, TRPM7 (LTRPC7, TRP-PLIK) (Alexander et al., 2008; Chubanov et al., 2005;
Schlingmann et al., 2002; Schmitz et al., 2002)
The CorA transporter is known to transport Co2+ and Ni2+ apart from Mg2+ ions (Gibson et al.,
1991). However the Mg2+ ion transporters are quite selective towards Mg2+ ions, which are mostly
hexacoordinated (Maguire and Cowan, 2002) and Be2+ ions on the other hand are tetra
coordinated with solvent ligands (Pittet et al., 1990). It could be possible that the transporters
associated with Mg2+ might selectively exclude the tertacoordinated Be2+ ions.
However the argument that Ca2+ and Mg2+ transporters could be involved in the transport of
Be2+ is speculative and has to be supported with experimental evidence.
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Table 8. Ionic radii of metal ions
Atomic number Name

Atomic radii (pm) Ionic radii (pm)

3

Lithium

152

78

4

Beryllium

113

34

11

Sodium

186

98

12

Magnessium 160

79

19

Potassium

227

133

20

Calcium

197

106

(Data taken from John Emsley, The Elements, 3rd edition. Oxford: Clarendon Press, 1998)
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Supplementary Figure I
Individual immunoflorescence images corresponding to the Fig. 17a from Chapter 5.
NIH/3T3 control/untreated cells (arrows indicate nuclear β-catenin)

Supplementary figure Ia: Untreated NIH/3T3 cells
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NIH/3T3 cells treated with 20 mM LiCl (profound nuclear localization of β-catenin)

Supplementary figure Ib: NIH/3T3 cells treated with 20 mM LiCl for 24 hr.

187

NIH/3T3 cells treated with 20 µM SB216763 (profound nuclear localization of β-catenin)

Supplementary figure Ic: NIH/3T3 cells treated with 20 µM SB216763 for 24 hr
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NIH/3T3 cells treated with 100 µM BeSO4 (minimal nuclear localization of β-catenin)

Supplementary figure Id: NIH/3T3 cells treated with 100 µM BeSO4 for 24 hr
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NIH/3T3 cells induced with 100 nM Insulin

Supplementary figure Ie: NIH/3T3 cells induced with 100 nM insulin for 30 – 60 min post
serum starvation
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Supplementary figure II
Individual immunoflorescence images corresponding to the fig. 17b from Chapter 5.
A172 control/untreated cells (arrows indicate nuclear β-catenin)

Supplementary figure IIa: A172 cells untreated
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A172 cells treated with 20 mM LiCl (arrows indicate profound nuclear localization of βcatenin)

Supplementary figure IIb: A172 cells treated with 20 mM LiCl for 24 hr
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A172 cells treated with 100 µM BeSO4 (arrows indicate minimal nuclear localization of βcatenin)

Supplementary figure IIc: A172 cells treated with 100 µM BeSO4 for 24 hr
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A172 cells treated with 20 µM SB216763 (arrows indicate prominent nuclear localization of
β-catenin)

Supplementary figure IId: A172 cells treated with 20 µM SB216763 for 24 hr

194

Supplementary Figure III
Individual immunoflorescence images corresponding to the fig. 17c from Chapter 5.
A172 P1B control/untreated cells (arrows indicate nuclear β-catenin)

Supplementary figure IIIa: A172 P1B cells untreated
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A172 P1B cells treated with 20 mM LiCl (arrows indicate prominent nuclear localization of
β-catenin)

Supplementary figure IIIb: A172 P1B cells treated with 20 mM LiCl for 24 hr
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A172 P1B cells treated with 100 µM BeSO4 (arrows indicate minimal nuclear localization of
β-catenin)

Supplementary figure IIIc: A172 P1B cells treated with 100 µM BeSO4 for 24 hr
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APPENDIX I
Statistical analysis
Table 9. In vitro kinase activity of purified recombinant GSK-3β
Inhibitor

Relative
specific
activity
(GSK-3β)

P – value

Significantly
different

Control

1.00

-

(unpaired
test)
-

0.3 µM Be2+

0.97

P >0.05

No

1 µM Be2+

0.62

P < 0.005

Yes

3 µM Be2+

0.47

P < 0.005

Yes

10 µM Be2+

0.13

P < 0.0005

Yes

30 µM Be2+

0.11

P < 0.0005

Yes

100 µM Be2+

0.02

P < 0.0005

Yes

300 µM Be2+

0.04

P < 0.0005

Yes

Control

1.00

-

-

1 mM Li+

0.91

P >0.05

No

3 mM Li+

0.75

P < 0.005

Yes

10 mM Li+

0.51

P < 0.05

Yes

30 mM Li+

0.23

P < 0.0001

Yes

100 mM Li+

0.01

P < 0.0001

Yes

300 mM Li+

-0.03

P < 0.0001

Yes

t-

Table 9. Two tailed unpaired t-test was used to compare the in vitro GSK-3β activity of the
samples treated with inhibitors against their corresponding control. (Data from same experiment)

198

Table 10. In vitro kinase activity of pure recombinant PKA
Inhibitor

Relative
specific
activity
(PKA)

P – value

Significantly
different
(unpaired
test)
-

Control

1.00

-

0.3 µM Be2+

0.67

P >0.05

No

1 µM Be2+

0.63

P < 0.005

Yes

3 µM Be2+

0.70

P < 0.05

Yes

10 µM Be2+

0.69

P < 0.05

Yes

30 µM Be2+

0.40

P < 0.0001

Yes

100 µM Be2+

0.32

P < 0.0001

Yes

300 µM Be2+

0.31

P < 0.0001

Yes

Control

1.00

-

-

1 mM Li+

0.77

P < 0.05

Yes

3 mM Li+

0.88

P >0.05

No

10 mM Li+

0.85

P >0.05

No

30 mM Li+

0..99

P >0.05

No

100 mM Li+

0.73

P < 0.05

Yes

300 mM Li+

0.31

P < 0.0001

Yes

t-

Table 10. Two tailed unpaired t-test was used to compare the in vitro PKA activity of the samples
treated with inhibitors against their corresponding control. (Data from same experiment)
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Table 11 Validation of the z-lyte assay using PKA inhibitor H89
Inhibitor
(H89)

Relative
specific
activity
(GSK-3β)

P – value

Significantly
different

Relative
specific
activity
(unpaired t- (PKA)
test)
1.00

P – value

(unpaired ttest)
-

0 µM

1.00

0.1 µM

1.00

P >0.05

No

0.57

P < 0.0005

Yes

0.3 µM

1.03

P >0.05

No

0.32

P < 0.0001

Yes

1 µM

0.99

P >0.05

No

0.125

P < 0.0001

Yes

3 µM

0.99

P >0.05

No

0.05

P < 0.0001

Yes

10 µM

0.94

P >0.05

No

0.01

P < 0.0001

Yes

-

-

Significantly
different

Table 11. Two tailed unpaired t-test was used to compare the in vitro PKA activity of the samples
treated H89 against their corresponding control (data from same experiment). Two tailed
unpaired t-test was used to compare the in vitro GSK-3β activity of the samples treated H89
against their corresponding control (data from same experiment).
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Table 12. TR-FRET assay to quantify the pSer9-GSK-3β signal
Inhibitor

P – value

Control

Relative
TR-Fret
signal
(GSK-3β)
1.000

10 µM Be2+

1.002

P >0.05

ns

30 µM Be2+

0.908

P >0.05

ns

100 µM Be2+

1.037

P >0.05

ns

Control

1.00

-

-

10 mM Li+

1.27

P >0.05

ns

20 mM Li+

1.54

P <0.05

30 mM Li+

1.92

ns

-

Significantly
different
(unpaired- t test)
-

significant
ns

Table 12. Two tailed unpaired t-test was used to compare the TR-FRET signal of the inhibitors
treated cells with their corresponding control cells (data from same experiment).
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Table 13. Flow analysis of nuclear β-catenin in stable nuclei
Treatment

Duration

Mean Fluorescence / nuclei
(% of control +/- std dev)
100 (+/- 5)

control

24 hr

10 µM BeSO4

24 hr

110 (+/- 3)

30 µM BeSO4

24 hr

148 (+/- 5)

100 µM BeSO4

24 hr

151 (+/- 12)

10 mM LiCl

24 hr

150 (+/- 12)

20 mM LiCl

24 hr

188 (+/- 23)

30 mM LiCl

24 hr

180 (+/- 20)

Table 13 Mean fluorescence values corresponding to the nuclear β-catenin. Stable nuclei isolated
from A172 cells treated with inhibitors for 24 hr.

202

Table 14. Flow analysis of nuclear p53 in stable nuclei
Treatment
control

Duration

Mean Fluorescence / nuclei
(% of control +/- std dev)

24 hr

100 (+/- 3)

100 µM BeSO4

24 hr

124 (+/- 5)

20 mM LiCl

24 hr

148 (+/- 1)

Table 14 Mean fluorescence values corresponding to the nuclear p53. Stable nuclei isolated from
A172 cells treated with inhibitors for 24 hr.
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Appendix II

Physiologically relevant concentration of lithium is more cytotoxic to cells compared to
beryllium at 24 hr
Introduction
The IC50 value of lithium = 12 mM and the IC50 value of beryllium is ~2 µM. When A172
cells are cultured in BeSO4 or LiCl at concentrations close to their IC50 values, lithium was found
to be more cytotoxic. As observed in the viability test, Li+ at concentrations close to its IC50 was
more toxic to the viability of A172 cells (Fig. 4).

Experiment 1
A172 cells were cultured in the presence of BeSO4 and LiCl for 24, 48 or 72 hr. The effect of
the inhibitors on the viability of the cells was analyzed using a live cell protease based
fluorescence assay. The viability assay shows that Be2+ is less cytotoxic to A172 cells even at
concentrations way higher than its IC50. Be2+ at 100 µM is fairly tolerated by A172 cells even for
longer periods of time (Fig 1). There is no big difference in the number of dead cells between the
control and beryllium samples. Li+ treatment on the other hand seems to be causing an increase in
cytotoxicity especially at 48 or 72 hr.
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Fig. 1a Effect of BeSO4 and LiCl treatment on cells cytotoxicity at 24 hr. A172 cells were
treated with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 24 hr. Cell cytotoxicity
was assessed using a fluorogenic substrate that can be cleaved by a protease associated with dead
cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using one-way
ANOVA (P < 0.05 considered significant) by Tukey’s multiple comparison test. GraphPad Prism
trial version 6.0 for Mac OS X, GraphPad Software, La Jolla California USA,
www.graphpad.com was used. (ns = non significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤
0.001, **** = P ≤ 0.0001).
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Fig. 1b Effect of BeSO4 and LiCl treatment on cells cytotoxicity at 48 hr. A172 cells were
treated with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 48 hr. Cell cytotoxicity
was assessed using a fluorogenic substrate that can be cleaved by a protease associated with dead
cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using one-way
ANOVA (P < 0.05 considered significant) by Tukey’s multiple comparison test. GraphPad Prism
trial version 6.0 for Mac OS X, GraphPad Software, La Jolla California USA,
www.graphpad.com was used. (ns = non significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤
0.001, **** = P ≤ 0.0001).
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Fig. 1c Effect of BeSO4 and LiCl treatment on cells cytotoxicity at 72 hr. A172 cells were
treated with 0, 10, 20, 30, 100 µM BeSO4 or 10, 20, 30, 100 mM LiCl for 72 hr. Cell cytotoxicity
was assessed using a fluorogenic substrate that can be cleaved by a protease associated with dead
cells only. Mean intensities (+/- std. dev) are reported here. Data was analyzed using one-way
ANOVA (P < 0.05 considered significant) by Tukey’s multiple comparison test. GraphPad Prism
trial version 6.0 for Mac OS X, GraphPad Software, La Jolla California USA,
www.graphpad.com was used. (ns = non significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤
0.001, **** = P ≤ 0.0001).
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Experiment 2
A172 cells were treated with BeSO4 or LiCl for 24 hr. Bright field images of the A172 cells
were captured using Nikon Inverted Microscope Eclipse TE2000-U (dia-illuminator 100W).
When treated with 10-100 µM BesO4 for 24 hr no major morphological changes were observed in
A172 cells (Fig 2.1). When A172 cells are cultured in the presence of LiCl for 24 hr a marked
change in the morphological appearance of the cells was observed (Fig. 2.2).

Results
Images of the A172 cells cultured in the presence of BeSO4 for 24 hr, shows that LiCl is more
toxic to cells compared to BeSO4 at concentrations similar to their IC50 values. A172 cells seem to
be tolerating LiCl at a concentration of 10 mM (Fig 2.2b). When the LiCl concentration was
increased to 20 mM or 30 mM it induced high cytotoxicity in A172 cells (Fig. 2.2 c&d). LiCl at
100 mM concentration was extrememly toxic to A172 cells at 24 hr.
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Fig 2.1Be2+ doesn’t produce any extreme morphological changes in A172 cells at 24 hr. A172
cells were cultured in the presence of 0, 10, 20, 30 or 100 µM BeSO4 for 24 hr.
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Fig 2.2 Li+ treatment leads to extreme morphological changes in A172 cells at 24 hr. A172
cells were cultured in the presence of 0, 10, 20, 30 or 100 mM LiCl for 24 hr.
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Appendix III
Quatitative analysis of Ser-9 phsophorylation of GSK-3β in A172 cells cultured in the
presence of BeSO4 or LiCl at 48 hr

Introduction
Li+ caused an increase in the Ser-9 phosphorylation of GSK-3β in A172 cells at 24 hr.
However Be2+ did not induce any big change in the Ser-9 phosphorylation of GSK-3β. Here we
have analyzed the effect of BeSO4 or LiCl on the Ser-9 phosphorylation of GSK-3β of A172 cells
at 48 hr via flow cytometry.
Flow cytometry
Cells were treated with BeSO4 and LiCl for 48 hr. After the treatment period, cells were
collected by trypsinization, washed with PBS and fixed with 4% paraformal dehyde. Cells were
then permeabilized with methanol. Cells were blocked with starting block TBS (prod#37543,
Thermo Scientific), supplemented with Halt protease and phosphatase inhibitor cocktail (Pierce
cat#78442). Fixed and blocked cells were then incubated with pSer9-GSK-3β rabbit monoclonal
antibody (clone D85E12, cat#5558, Cell Signaling Technology) over night at 4 C, followed by
FITC conjugated goat anti-rabbit secondary antibody (cat#sc-2012, Santa Cruz Biotechnology) at
0.5 µg/1x106 cells. Cells were run on a BD FACSCalibur flow cytometer recording 20,000 events
per sample, and FITC channel fluorescence intensity was analyzed using CellQuest Pro Software.
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Results
At 48 hr beryllium did not induce any clear increase in the Ser-9 phosphorylation of GSK-3β
(Fig. 1a). Lithium treatment at 48 hr caused a concentration dependent increase in the Ser-9
phosphorylation of GSK-3β.

Conclusion
This study shows that even at longer exposure time i.e. 48 hr, beryllium has little effect on the
Ser-9 phosphorylation of GSK-3β.
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Fig. 1a Flow cytometric analysis of the Be2+ treatment effect on Ser-9 phosphorylation of
GSK-3β at 48 hr. A172 cells were treated with 0, 10, 30, 100 BeSO4 for 48 hr. The change in
the pSer-9 status of GSK-3β was assessed using a pSer9-GSK3β primary antibody and FITC
conjugated secondary antibody. Each flow cytometry histograms represents the mean
fluorescence per cell value obtained from independent replicates for each inhibitor used at
different concentrations.
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Fig. 1b Flowcytometric analysis of the Li+ treatment effect on Ser-9 phosphorylation of
GSK-3β at 48 hr. A172 cells were treated with 0, 10, 20, 30 mM LiCl for 48 hr. The change in
the pSer-9 status of GSK-3β was assessed using a pSer9-GSK3β primary antibody and FITC
conjugated secondary antibody. Each flow cytometry histograms represents the mean
fluorescence per cell value obtained from independent replicates for each inhibitor used at
different concentrations.
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Appendix IV

Measuring beryllium induced up regulation of p53 expression using nuclei flow analysis
Introduction
To confirm that effect of BeSO4 on nuclear β-catenin, flow-analysis of nuclei isolated from
A172 cells treated with BeSO4 or LiCl was used. Along with the β-catenin analysis, the p53
protein levels were also tested independently in the nuclei isolated from A172 cells treated with
BeSO4 or LiCl. The aim of this experiment was to validate the fact that nuclei flow analysis
method can be used to quantify protein expression.

Result
The flow analysis of nuclei isolated from A172 cells treated with BeSO4 or LiCl for 24 hr
indicate an increase in p53 levels. Beryllium treatment caused an increase in the p53 protein
levels in A172 and HFL cells (Gorjala and Gary, 2010; Mudireddy et al., 2014). The nuclei flowanalysis results confirm the beryllium induced upregulation of p53 expression.

Discussion
The flow analysis could be used to quantify the Be2+ induced upregulation of p53. The ability
of the flow analysis technique to successfully detect the increase in the p53 level, validates it as a
reliable quantitative method to detect the up regulation or down regulation of proteins.
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Fig. 1 Detection of increase in p53 level after beryllium treatment at 24 hr in A172 cells.
A172 cells were treated with 0, 100 µM BeSO4 or 20 mM LiCl for 24 hr. Stable nuclei were
extracted from the Be2+ or Li+ treated cells. The effect of Be2+ or Li+ on the nuclear localization of
p53 was assessed using a mouse mono clonal p53 primary antibody and an Alexa647 –
conjugated secondary antibody. For each treatment, mean fluorescence per cell was determined
from independent replicates and representative peak for each treatment is shown here.
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Appendix V

Validation of A172 cells over expressing wt GSK-3β, GSK-3β S9A and GSK-3β K85A
Introduction
Mammalian cells over expressing wt GSK-3β and its mutants can serve as valuable tools in
our study to characterize beryllium as a potent GSK-3β-inhibitor. Over expression of GSK-3β in
A172 cells will provide a system with abundant amont of substrate protein to analyze the effect of
inhibitors. A172 cells were transfected with the addgene plasmid#14753 – HA GSK-3β wt
pcDNA3, plasmid#14754 – HA GSK-3β S9A pcDNA3, plasmid#14755 – HA GSK-3β K85A
pcDNA3 as explained in the materials and methods section.
Results
Fig. 1 The total cell lysates extracted from these clones along with proper controls were probed
for the expression of “HA – tag” using a rabbit polyclonal anti HA antibody (Thermoscientific
#CAB3872).
P1B, P1C, P1D = A172 clones over expressing wt GSK-3β,
P2A, P2B, P2C = A172 clones over expressing GSK-3β S9A mutant
P3A, P3B = A172 over expressing GSK-3β K85A mutant
The detection of HA band in the transfected A172 cells validates the success of transfection,
since only A172 cells tranfected with the addgene clones will be expressing the HA-tag.
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Discussion
Fig. 1 Expression of HA-tag in the A172 cells transfected with the addgene clones is
observed indicating a successful integration and expression of the addgene plasmids in the host
cells. The clones demonstrating the maximum expression of the HA-tag were selected for further
analysis. The selected clones are:
A172 clones over expressing wt GSK-3β – P1B
A172 clones over expressing GSK-3β S9A mutant – P2B
A172 over expressing GSK-3β K85A mutant – P3B
The P1B clone (A172 clones over expressing wt GSK-3β) was used in the confocal imaging
experiment to demonstrate the effect of beryllium on the nuclear localization of β-catenin.
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Fig. 1 Western analysis of A172 clones expression wt GSK-3β and its variants. Total cell
lysates from the A172 clones expressing various variants of GSK-3β were assessed for the
expression of the “HA – tag” using a rabbit polyclonal anti HA antibody. The “date label” refers
to the day the samples were extracted. Untransfected A172 along with NIH/3T3 and Caki-1cells
serve the purpose of negative controls.
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Appendix VI

DRC analysis to investigate the effect of SB216763 on NIH/3T3, A172 and Caki-1 cells
Introduction
SB216763 is a strong GSK-3β inhibitor (Coughlan et al., 2000).

To determine the

concentration suited best for inducing optimum results in different cell lines a dose response
curve experiment was done using A172, NIH/3T3 and Caki-1 cells.

Materials and methods
Cell culture media
RPMI 1640 HEPES (cat#23400-021, Gibco) supplemented with 10% fetal bovine serum
(FBS) and 1x antibiotic-mycotic was used for culturing B 35, C6, Caki-1, IMR 32 and SF539 cell
lines. Only for NIH/3T3 cells, RPMI 1640 was supplemented with 10% bovine growth serum
(BGS) instead of FBS.
Dose response curve - cell counting
Cells were cultured in 60 mm CELLSTAR cell culture dishes (cat#664 160) at 37 C using a
5% CO2 incubator. Cells were dosed with culture media supplemented with appropriate
concentrations of BeSO4 and the dosing day was counted as Day 0. On the Day 2 the cells were
collected by trypsinization using 0.5 ml trypsin (0.05% Trypsin-EDTA). The cells were collected
by adding 2.5 ml of RPMI (2.5 ml RPMI + 0.5 ml trypsin = total 3 ml cell suspension). Cells
were counted using a cell counter and 0.5 ml of the total cell suspension from day 2 was added to
a new 60 mm culture dish. The cells were allowed to grow till day 4 and were trypsinized again,
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counted in a manner similar to day 3. 0.5 ml of cells from the total 3 ml cell suspension from day
4 was added to a new 60 mm dish. The process was repeated again on Day 6 with the exception
that the cells were discarded instead of re seeding.

Data analysis
The day 2, day 4 and day 6 cell counts were fitted onto a plot using non-linear regression.
The effect of BeSO4 on the different cell lines was represented as % of control on the y-axis and
the log values of BeSO4 concentration on the x-axis. GraphPad Prism v6.0c (windows) was used
for curve fitting.

Results
Caki-1 cells are the most sensitive to SB216763 compared to A172 and NIH/3T3. A
concentration of 10-30 µM seems to be tolerated well by A172 and NIH/3T3 cells. Caki-1 cells
are sensitive to SB216763 and seem to be tolerating a concentration of 10-20 µM.
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Fig. 1 Dose response curve of A172, NIH/3T3 and Caki-1 cells for SB216763. Caki-1, A172
and NIH/3T3 cells were cultured in the absence or presence of 1, 5, 10, 10 0r 100 µM SB216763
for 24 hr.
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Appendix VII

Quantification of phospho-GS bands from fig 15a
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Band

Treatment
1 20 µM SB216763 1
2 20 µM SB216763 2
100 nM Insulin 60 min
3 1
100 nM Insulin 60 min
4 2
100 nM Insulin 30 min
5 1
100 nM Insulin 30 min
6 2
100 nM Insulin 15 min
7 1
100 nM Insulin 15 min
8 2
9 20 mM LiCl 1
10 20 mM LiCl 2
11 100 µM BeSO4 1
12 100 µM BeSO4 2
13 30 µM BeSO4 1
14 30 µM BeSO4 2
15 20 mM KCL 1
16 20 mM KCL 2
17 Control 1
18 Control 2

Band
Intensity
background
substracted

% of control

10600 23.55555556
10700 23.77777778
36200 80.44444444
39500 87.77777778
40700 90.44444444
52500 116.6666667
38100 84.66666667
36100
19500
19800
28000
27800
39300
34400
48200
50200
42000
48000
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80.22222222
43.33333333
44
62.22222222
61.77777778
87.33333333
76.44444444
107.1111111
111.5555556
93.33333333
106.6666667

Appendix VIII

Quantification of pGS bands from fig 16
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Band
1
2
3
4
5
6
7
8
9

Band
10
11
12
13
14
15
16
17
18

Treatment
20 mM KCL 1
Control 1
30 uM Be 1
100 uM Be 2
20 mM Li 1
100 nM Insulin 1
SB216763 1
10 uM Rott 1
100 uM CaCl2 1

Band
intensities
background
substracted
27000
23200
15200
13500
25300
13100
10500
23200
30700

% of
controls
116.63067
100.215983
65.6587473
58.3153348
109.287257
56.587473
45.3563715
100.215983
132.613391

Treatment
20 mM KCL 2
Control 2
30 uM Be 2
100 uM Be 2
20 mM Li 2
100 nM Insulin 2
SB216763 2
10 uM Rott 2
100 uM CaCl2 2

Band
intensities
background
substracted
25200
23100
14100
11900
18600
19100
11300
24500
18600

% of
controls
108.855292
99.7840173
60.9071274
51.4038877
80.3455724
82.5053996
48.812095
105.831533
80.3455724
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Appendix IX
Expression of glycogen synthase isoforms in NIH/3T3 cells
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Appendix X
Validation of FRET-based kinase assay
To validate the FRET-based kinase assay, purified recombinant GSK-3β and purified
recombinant PKA (protein kinase A) proteins were treated with H-89. The aim of this experiment
was to demonstrate that the FRET-based kinase assay is a robust technique and is inherently
competent to exclude false positives. H-89 is a specific PKA inhibitor (Marunaka et al., 2003)
and it should not have any effect on the kinase activity of the purified GSK-3β protein. As
observed in (Fig. 2c) H-89 treatment has no effect on the kinase activity of GSK-3β, whereas it
leads to a decrease in the activity of PKA enzyme only.
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Fig 1. H-89 inhibits the in vitro kinase activity of PKA but not GSK-3β. Pure recombinant
GSK-3β (filled bars) and PKA (pattern bars) proteins were used in the FRET-based kinase assay
and the enzyme activity was measured in the absence (control) or in the presence of 0.1, 0.3, 1, 3
or 10 µM H-89. Activity is expressed as the rate of formation of phosphorylated peptide substrate
(mean +/- SD). Data was analyzed using one-way ANOVA (P < 0.05 considered significant
compared to control) by Tukey’s multiple comparison test. GraphPad Prism version 5.0 for
windows, GraphPad Software, La Jolla California USA, www.graphpad.com was used. (ns = non
significant compared to control, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤
0.0001).
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